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Abstract 
This thesis discusses some aspects of the use of ultraviolet rays to treat skin 
disease. The early history of dermatological phototherapy in Scotland is 
summarised as an introduction to the more recent developments described in 
a chapter on the Scottish phototherapy and photochemotherapy audit of 
1996/1997 (funded by the Clinical Resource and Audit Group, the Scottish 
Office). This audit revealed some aspects of the phototherapy service that 
could be improved, and identified areas of particular importance for future 
research. 
Following the audit, recommendations to guide those prescribing and 
administering phototherapy were produced. A major aim of the audit was to 
identify important aspects of phototherapy practice for which there was 
evidence on which to base recommendations, and where such evidence was 
not available, to identify areas for future research. Clinical audit cannot itself 
provide the evidence on which to base best practice, and this thesis contains 
original research designed to provide information on which we can answer 
three questions identified as important during the audit. 
Firstly, what type of UVB phototherapy lamp is most effective: the narrow-
band (311-313nm) TL-01 lamp, or the broad-band UVB lamp? Whereas the 
original studies designed to answer this question left some doubts, these 
studies being small, and having various other flaws, a meta-analysis 
conducted as part of this thesis gave a clear answer. TL-01 UVB is much more 
effective than broad-band UVB: 
The second included stUdy was a randomised, controlled study that has 
contributed to deciding the optimal treatment frequency for TL-01 UVB 
phototherapy of psoriasis. Although 5x weekly treatment cleared psoriasis 
slightly more quickly than 3x weekly treatment, the difference in speed of 
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clearance was too small to warrant the significantly greater frequency of acute 
erythema during treatment, and the greater number of exposures and dose 
required. 
The final question, answered by a randomised, controlled trial, in conjunction 
with a systematic review of the previous literature, was: for chronic plaque 
psoriasis, is TL-Ol UVB or psoralen-UV A photochemotherapy to be 
preferred? The study conducted for this thesis showed TL-Ol UVB to be more 
effective. Heterogeneity in findings of the studies addressing this question 
highlighted the importance of the particular treatment regimens selected for 
comparison, but the overall conclusion was that TL-Ol UVB is the first choice 
of these two therapies for patients presenting with moderately severe and 
severe chronic plaque psoriasis. 
A series of recommendations based on review of the published literature, 
When appropriate incorporating the findings of the studies described in this 
thesis, were produced. This thesis, as a whole, illustrates aspects of the 
synergistic roles of clinical audit, systematic literature review, and original 
clinical research in strengthening the evidence base supporting clinical 
practice in phototherapy. 
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Preface 
Over three thousand patients are treated, for a variety of skin diseases, with 
phototherapy in Scotland every year. This thesis includes clinical research and 
audit designed to improve the safety and effectiveness of this treatment. 
The thesis starts with a historical review of phototherapy to treat skin disease. 
This includes a discussion of adverse effects, particularly skin cancer. Chapter 
2 reports the survey of current phototherapy practice conducted during 1996 
and 1997, as part of the Scottish phototherapy and PUV A (psoralen-ultraviolet 
A) photochemotherapy audit. The discussion of the audit findings is followed 
by Chapters 3, 4 and 5 which describe research conducted to answer important 
clinical questions concerning ultraviolet B (UVB) phototherapy and PUV A for 
psoriasis. 
Chapter 3 is a meta-analysis of studies comparing narrow-band UVB with 
broad-band UVB for psoriasis. Chapter 4 is based on a study designed to 
ascertain the optimum frequency for narrow-band UVB phototherapy of 
chronic plaque psoriasis. Chapter 5 reports a study comparing the efficacy of 
PUV A with UVB as chronic plaque psoriasis treatments. These last two studies 
were designed to contribute to the evidence-base for guidelines designed to 
improve the Scottish phototherapy service. 
Chapter 6 includes recommendations for phototherapy and PUV A use, based 
on findings of the survey of current practice (Chapter 2) and a review of 
published studies. The quality of evidence for each recommendation is assessed. 
The concluding Chapters 7 and 8 discuss the contributions of both clinical audit 
and research towards i~proving the efficacy and safety of phototherapy and 
photochemotherapy. Some priority areas for future research are suggested. 
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Chapterl 
A history of phototherapy, with emphasis on its early use in Scotland; phototherapy 
and psoralen-UVA photochemotherapy (PUVA) for psoriasis; the realisation that 
PUV A is assodated with a significantly increased risk of skin cancer; and the 
introduction of narrow-band (TL-Ol fluorescent lamp) ultraviolet B. This forms the 
background to, and explains the reasons for, the Scottish phototherapy and 
photochemotherapy audit described in Chapter 2. 
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Introduction and definitions 
Phototherapy, the therapeutic use of non-ionising electromagnetic radiation, 
includes treatment with several ultraviolet B (UVB), ultraviolet A (UV A), and 
visible light lamps. The term can also be used more broadly to include 
psoralen photochemotherapy, involving the administration of one of several 
available psoralens, followed by ultraviolet (usually UV A) irradiation. 
Every year, more than 3000 Scottish patients receive a course of phototherapy 
for skin disease. Phototherapy is effective for controlling the common, chronic 
diseases psoriasis and atopic dermatitis. Patients with many other, less 
common, conditions also benefit. It is important that phototherapy is used 
appropriately. If it is not and, for example, an ultraviolet B (UVB) treatment 
regimen that is not optimally effective is used, the consequences are serious. 
Not only may individual patients needlessly continue to suffer from their 
disease, but also resources, otherwise available to treat others, are wasted. 
Additionally, how we use these treatments can influence the risk of adverse 
effects, including skin cancer. 
A short history of ultraviolet phototherapy in Scotland 
In 1895, Finsen first treated lupus vulgaris with artificial lamps, emitting 
predominantly UV -B wavelengths. Sunlight exposure had been prescribed for 
multifarious ailments since ancient times (RoIlier 1923; Humphries 1926a) but 
the development and use of more reliable, artificial sources became possible 
following the introduction of publ!c electricity supplies (Hedley 1896). 
Reliable lamps made it possible to experiment in the treatment of a diversity 
of diseases with lamps with differing characteristics (such as wavelengths 
emitted), and to compare the effects of different phototherapy regimens. 
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By 1902, localised treatment with the Finsen carbon-arc lamp was a 
recognised treatment for lupus vulgaris. Some Scottish patients requested 
referral to the Finsen Institute in Copenhagen, although (unlike the Danish 
patients whose treatment was government-funded) they had to pay (Clark 
1901).1 A year later Dr MacIntosh, Medical Electrician at the Western 
Infirmary in Glasgow, reported his experience of treating lupus vulgaris with 
a carbon arc lamp, obtained through funds donated by local industry in 
recognition of the centennial celebrations (MacKintosh 1902). Over the next 25 
years artificial ultraviolet radiation was increasingly used for this and other 
indications, and a variety of lamps (different types of carbon-arc and mercury 
vapour lamp) became available in the major Scottish cities. In the absence of a 
national health service, there was little co-ordination in the introduction of 
phototherapy equipment. A variety of different lamps were used, some 
designed for phototherapy, and others initially used for other purposes such 
as street lighting (Percival 1982).2 
Early phototherapy lamps 
Lamps powered by mains electric current could then, as now, be divided into 
three main types: 1) incandescent lamps with a continuous solid connection 
between the electrodes, such as tungsten filament bulbs, 2) arc lamps in which 
1 "Your letter duly received, and I shall with pleasure tell you alii can about Finsen's, 
and the treatment here, ... 
" ... in August we go to a new institution, money having been provided by the 
government now that the cure has proved more than an experiment. ... ft (Extracts 
from a letter by a lupus vulgaris patient to her doctor in Dumfries.) 
2 "Walker [then Professor of Dermatology in Edinburgh] and I then visited the Street 
Lighting Department [of Glasgow Corporation} and inspected some dismantled 
carbon arc street lamps, selected four which we thought were least dilapidated, 
agreed a price of £1 per lamp, arranged for them to be delivered to the Edinburgh 
Royal Infirmary .... " (Recollections of a visit to Glasgow to attend a SMA meeting and 
to purchase lamps - probably in 1923 or 1924. The lamps were in use by the end of 
1924.) 
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the unenclosed electrodes were separated, and 3) mercury vapour lamps in 
which the current passed through gaseous mercury held in a quartz chamber 
between two liquid mercury electrodes. For phototherapy, the latter two lamp 
types were used (Humphries 1926b; Rosewarne 1928a). Arc lamps differed 
according to the make-up of the carbons or irons used, and the length of the 
gap between electrodes. Arc lamps, particularly those with tungsten 
electrodes (Rosewarne 1928a; Burdon-Cooper et al. 1931), produced 
unpleasant fumes, but were possibly more effective than mercury vapour 
lamps, at least for lupus vulgaris (Aitken 1946). The fragile quartz cases of the 
early mercury vapour lamps tended to become dirty, and were expensive to 
replace when broken during cleaning. Most modern phototherapy sources are 
fluorescent lamps, which are mercury vapour lamps with a coating to the 
chamber which absorbs the radiation produced and re-emits it. The 
composition of this phosphor coating determines the wavelengths produced. 
Indications 
The report of a meeting of the Forfarshire Medical f\ssociation held in 1927, 
published in the British Medical Journal (Anonymous 1927b),3 gives an idea 
of the diversity of conditions then treated with phototherapy. In a book 
written a few years later, Robert Aitken, Lecturer in Dermatology and 
Physician in Charge of the Dermatological Light Departments at Edinburgh 
Royal Infirmary and Leith General Hospital, described his experience of 
3 Dr Milln, Medical Electrician, reported that phototherapy worked well in skin 
conditions, especially carbuncles and furunculosis, for which the "results of ultra-violet 
radiation were almost uncanny". However, he warned: "Claims were being made for 
ultra-violet rays in almost all diseases, but it would be well to see that this most 
beneficial form of treatment did not fall into disrepute through exaggerated 
statements." Dr J. Hunter, Dundee's Chief Tuberculosis Officer, favoured open 
carbon arc therapy. Dr J.B. MacDonald, of Dundee Eastern Hospital, described his 6 
months experience USing a mercury vapour lamp for marasmus and rickets. Dr John 
Kinnear described what is, to the best of my knowledge, the first recorded use of an 
artificial ultraviolet source for prophylactic treatment of a photodermatosis, a case of 
"summer eruption due to sunlight cured by small doses of ultra-violet rays." Dr AR. 
Moodie discussed ophthalmological uses. 
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phototherapy for many dermatological, and other, diseases (Aitken 1930a). 
Like others (Rasch 1926-27),4 he warned against over-reliance upon 
phototherapy, and the tendency to uncritically accept anecdotal evidence of 
its efficacy. 
Most agreed upon the value of phototherapy for lupus vulgaris (Hall 1925; 
Aitken 1930a), although there were differences of opinion regarding the most 
appropriate lamp (Sibley 1920; Sollux Company 1937). Many, including 
Whitfield (Whitfield 1907), regarded phototherapy as the treatment of choice, 
and preferable to X-rays.5 Other dermatological indications included 
psoriasis, childhood dermatitis - perhaps particularly of flexural pattern 
(Cassie 1927) - pityriasis rosea, vitiligo and alopecia areata. A manual by a 
lamp-manufacturing company (Sollux Company 1937) lists multiple 
indications: including, amongst the other non-dermatological ones, 
agranulocytosis, common cold, diphtheria carriage, neurasthenia, miners' 
nystagmus, poliomyelitis and whooping cough. Aitken's handbook provides 
a more critical review, and he was particularly sceptical about its role in 
treating vitiligo, and also warned that, for alopecia areata, "to speak of it as a 
specific remedy is to show a lack of knowledge and experience of the disease" 
(Aitken 1930a).6 
Phototherapy with carbon arc and mercury vapour lamps was used 
successfully to treat psoriasis, although some, including Rosewarne 
(Rosewarne 1928b), favoured using it in conjunction with X-rays. Aitken 
4 "The reason that we see so many of the harmful effects [of light on skin] is partly due 
to a mistaken conception of light therapy, for many people think that as much light as 
possible is good for all people and all diseases." 
5 "Compared with the Finsen treatment, it may be said that it [X-ray therapy] is much 
less constantly successful, and when the eradication of the disease is secured, there 
is almost always left a peculiar, polished atrophy of the skin, often accompanied by 
the development of telangiectasis. The danger of causing necrotic changes and 
inflammation is much greater than with the Finsen method .... n 
6 Aitken on alopecia areata: "The disease is very capricious, and the last remedy - and 
the last doctor - always get the credit for the cure." 
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conducted a controlled trial (Aitken 1930a),7 which confirmed the efficacy of 
twice-weekly carbon arc lamp treatment in some patients. Not all responded, 
however, and thick plaque disease proved particularly resistant. 
Early concern about possible carcinogenicity 
The possibility that phototherapy would increase the risk of future skin 
cancer development was considered in the 1920s. However, not all took this 
possibility seriously. A speaker at a talk at the Royal Society of Medicine in 
London stated that "the bogy of carcinoma as a sequel to ultra-violet 
treatment had been laid to rest by Dr Reyn and Dr Sequeira, both of whom 
stated that they had never seen such a case" (Anonymous 1927a). 
Not everyone accepted this anecdotal evidence of safety and, in Edinburgh, 
Aitken was concerned by animal studies which showed mercury vapour lamp 
irradiation to be carcinogenic (Findlay 1928), and a case of multiple solar 
keratoses apparently induced by mercury vapour lamp treatment prescribed 
by an unqualified practitioner in Australia (Colquhoun 1927). He believed 
that lupus vulgaris patients might be at particular risk, because of the 
prolonged courses of treatments, usually administered daily, required. He 
favoured carbon arc lamps over mercury vapour lamps not only because of . 
possible greater efficacy, but also because of his greater concern about the 
risks of adverse effects with mercury-vapour lamps (Aitken 1930b). With the 
choice of an appropriate II carbon" (which might be impregnated with iron, 
tungsten or other metal), carbon-arc lamps generally emitted relatively less of 
the shorter (ultraviolet C and UVB) wavelengths. 
7 "I have tested the effect of the radiations in several cases, smearing the one side of 
the body with ointment so as to prevent the rays acting on that side, the other side 
being left without any such protection. There was no doubt that the side receiving the 
radiations twice a week, with ordinary treatment on other days, paled more rapidly 
than the side receiving ordinary treatment only." 
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Phototherapy no longer the treatment of choice for lupus vulgaris 
The introduction of calciferol treatment, followed by systemic antimicrobial 
chemotherapy for tuberculosis, led to the abandonment of phototherapy as 
the treatment of choice for lupus vulgaris. Also, tuberculosis, perhaps 
particularly of the skin, was becoming less common (Paul 1964). By the mid-
1940s, there was a decline in academic medical interest in UVB phototherapy 
in Europe, reflected in a down-turn in the number of publications concerning 
its use for any indication. Phototherapy was still used, but increasingly 
administered by non-medically trained physical therapists, often working in 
isolation from those prescribing the treatment. At least one Scottish university 
hospital dermatology department phototherapy unit was closed some time 
between 1953 and 1966 (Percival 1982). 
Increased interest in phototherapy for psoriasis 
Ultraviolet B phototherapy was used for psoriasis in Europe since shortly 
after its widespread introduction, primarily for lupus vulgaris. However it 
was generally regarded as not particularly effective and, for this indication, 
many favoured radiotherapy if psoriasis required treatment other than tar or 
chrysarobine8• In the United States of America, where the introduction of 
UVB phototherapy was not driven by the needs of the many severely disabled 
lupus vulgaris patients in Europe, phototherapy was only introduced two 
decades after its wide availability in Europe. However, early interest in using 
UVB for psoriasis appears to have been greater in the USA. In particular, 
Alderson (Alderson 1923) was more enthusiastic than most of his European 
contemporaries about phototherapy (using a mercury vapour lamp) for this 
indication. In particular, he noted that his experience was that "recurrences 
are delayed longer" than after X-ray treatment. Goeckerman (Goeckerman 
8 This was developed from Goa powder, and contained the active principal dithranol. 
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1931), who used adjunctive coal tar (in place of the salicylic acid ointment 
used by Alderson), also endorsed phototherapy for psoriasis. Combined tar 
and UVB therapy were widely used, and it was not until the 1970s (Petrozzi 
et al. 1978; Ie Vine et al. 1979; Eells et al. 1984) that the first controlled studies 
were conducted, and it was recognised that the tar component of 
Goeckerman's regimen was unnecessary for effective treatment. 
Despite the more cautious reports on phototherapy for this indication from 
the United Kingdom, psoriasis became the main condition treated following 
the decline of the lupus vulgaris problem. It was not generally regarded as an 
especially effective treatment, and was often used in combination with other 
treatments, including X-rays and topical dithranol. In a report of his 
experience of setting up a psoriasis treatment centre in Leeds, Ingram (Ingram 
1953) described a
e 
regimen, involving dithranol application and UVB, he 
considered effective. Later, a combination therapy based on Ingram's regimen 
was studied more carefully. 
In an observer-masked, randomised controlled trial Bowers and colleagues at 
the Gloucester Royal Infirmary (Bowers et al. 1966) showed both dithranol 
and UVB separately to be more effective than controls presumed to have little, 
if any, therapeutic effect. The combination of these two effective treatments 
proved better than either alone. Tar baths, customarily prescribed as a 
preliminary to phototherapy, were not shown to offer any additional benefit. 
For the purposes of this study a suitable control for phototherapy had to be 
found. A glass filter preventing transmission of wavelengths longer than 320 
nanometres (nm) was used, and this preliminary study confirmed that the 
UVB of the broad-spectrum (UVB, -UV A and visible) output of all the 
phototherapy lamps then in use was the therapeutic portion. This was the 
first experimentally derived information on the therapeutic action spectrum 
for psoriasis. 
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The development of photochemotherapy 
Photochemotherapy involves the interaction between ultraviolet radiation, 
usually UV A, and a photosensitising chemical, usually a psoraIen (linear 
furocoumarin). The use of plants containing high psoralen concentrations, 
particularly Psora lea corylifolea (a Legume) and Ammi majus (an Umbillifer), 
for white patches on the skin (probably vitiligo) was described in ancient 
Indian and Egyptian texts (Mosher et al. 1991; Kopera 2000). This use of 
naturally occuring psoralens (which serve various functions in plants, 
including protection against leaf infections (Afek et al. 1995»,9 with sunlight 
as the ultraviolet source, continues in areas where refined psoralens and 
artificial ultraviolet sources are unavailable. 
In the 1940s, 8-methoxypsoralen (8-MOP) was isolated from Ammi majus by 
EI Mofty (EI Mofty 1948). This isolated psoralen was used, with the Sun as an 
ultraviolet source (EI Mofty 1948; Lerner et aI. 1953), and then with man-made 
ultraviolet sources (Parrish et al. 1976), to treat vitiligo. 
In 1974, 8-MOP-ultraviolet A photochemotherapy (8-MOP PUV A) was found 
to be an effective treatment for psoriasis. Parrish et al (parrish et al. 1974) 
showed, in a 21 patient paired comparison study, that 8-MOP PUV A was 
more effective than broad-band UVB at clearing chronic plaque psoriasis. 
Large multicentre studies in the United States of America (USA) (Melski et al. 
1977; Anon. 1979) and Europe (Henseler et al. 1981) found clearance rates to 
be far higher (85% to 88 %) than would be expected for untreated psoriasis, 
and similar to, or better than, clearance rates with other established therapies. 
9 Furocoumarins possess activity against various fungal pathogens, and some insect 
pests, of plants. The apparent paradox of increased psoralens in some damaged, 
unrooted plants (for which we would not expect any evolutionary advantage related to 
possession of endogenous anti-pathogenic substances) may be explained by the fact 
that psoralens can be break-down products of substances, such as marrnesin, that 
may possess even higher fungicidal activity in the healthy plant. 
11 
The 16-centre USA study showed in a randomised, controlled comparison 
that, in Fitzpatrick skin phototype I to III patients (Gupta et al. 1987), twice-
weekly was as effective as thrice-weekly treatment (Melski et al. 1977). Also, 
maintenance therapy was found to be of limited value. Maintenance PUV A 
frequencies of once weekly, once every fortnight, and once every 3 weeks 
were compared with no maintenance therapy. Even once weekly maintenance 
therapy did not prevent 50% of patients experiencing a flare of psoriasis 
within a year. The European multicentre study showed no benefit from 
routine maintenance therapy. This European regimen cleared psoriasis more 
quickly and with a mean cumulative UV A dose less than half of that recorded 
for the 16-centre USA study (Henseler et al .. 1981). Caution is required in 
comparing UV A doses recorded in different centres even within one country, 
as was shown by the Scottish phototherapy and PUV A audit (described in 
Chapter 2), but this raised the suggestion that the European regimen might 
prove safer. The main differences between these regimens were the different 
treatment frequencies (4x weekly in Europe and 2x weekly in the USA), and 
the fact that most patients treated in the European multicentre study were 
given an individualised, minimal phototoxic dose-based starting dose instead 
of the sun-reactive skin type-based regimen used in the USA. 
A UK study, which found a combination regimen of daily broad-band UVB, 
dithranol and tar to clear psoriasis more quickly than thrice weekly PUV A, 
with starting dose based on skin type, (Vella Briffa et al. 1978), showed PUV A 
maintenance therapy to be of value (Vella Briffa et al. 1981), although once-
weekly maintenance treatment was of no greater value than continuing 
treatment once every 3 weeks. Following this, many centres in the UK did use 
maintenance therapy. 
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Photochemotherapy and skin cancer 
A major concern with the use of PUV A is that it increases the risk of skin 
cancer development. Before its use to treat psoriasis, it was recognised to be 
mutagenic (IgaIi et aI. 1970; Arlett 1973), and carcinogenic to mouse skin 
(Griffin 1959). None of the early reports on PUV A use for vitiligo described 
long-term follow-up to determine whether or not these patients were at 
increased risk of developing skin cancers. A randomised, double-blinded 
controlled trial was conducted in a group of patients with skin cancers in 
Texas to determine whether daily administration of 20mg 8-methoxypsoraIen 
had a protective effect (MacDonald et aI. 1963). Neither this study, nor a 
replicate study conducted in Australia (Hopkins et al. 1963), showed any 
effect on skin cancer incidence. The low dose of psoralen used in these triaIs 
appeared to have some effects: in the Texas study 42/86 8-MOP patients 
described "sunburn" episodes compared to 27/87 control patients. Follow-up 
was short (with the main end-point being number of new lesions over 12 
months) and it is likely that any increased skin cancer risk might have been 
missed for this reason. Because of concern about the possibilty it would 
increase the risk of skin cancer development in humans, it was considered 
wise to carefully follow-up those treated with PUV A for psoriasis (Bridges 
1978). 
Follow-up of 1380 participants in the 16-centre USA study of PUV A for 
psoriasis showed a higher than expected incidence of squamous cell 
carcinoma of skin (Stem et al. 1984). Further follow-up showed a strong dose-
reponse relationship for induction of squamous cell carcinoma, and that many 
of these were arising on sites not much exposed to sunlight (Stern et aI. 1994). 
Other studies also found PUV A to be carcinogenic (Lobel et al. 1981; 
Bruynzeel et aI. 1991; Chuang et aI. 1992). Although the initial reports of other 
European authors (Henseler et aI. 1984; Tanew et al. 1986) raised the 
possibility that the risk might only be associated with particular regimens, it 
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is likely that follow-up in those studies that did not find a definite increased 
risk was not sufficiently long, and not enough high-exposure patients were 
included, to detect the increased risk, which was even more apparent on 
meta-analysis of all the English language studies involving at least 150 
patients and 5 years follow-up (Stem et al. 1998). 
The increased risk of squamous carcinoma of the skin associated, probably 
causally, with PUV A treatment is not now in doubt. The possibility that 
PUV A also increases the risk of other cutaneous cancers, including malignant 
melanoma, has been raised (Stern et al. 1997; Lunder et al. 1998), but a 
causative association remains less certain. 
Development of a new UVB source (TL-Ol fluorescent lamps) 
Despite concern about the risk of skin cancer with PUV A, and practical 
problems with its administration (which shall be discussed in Chapter 2), it 
was generally recognised as more effective than UVB (Kenicer et al. 1981; 
Williams 1991), and regarded as the second-line treatment of choice for 
psoriasis. A major change has occurred with the development of a new UVB 
phototherapy lamp. 
Narrow-band (TL-01) phototherapy (Figure 1.1) was introduced in 1984, after 
therapeutic action spectrum studies suggested that it ought to clear psoriasis 
more effectively than broad-band UVB (Parrish et al. 1981). Initial use 
demonstrated that it could clear psoriasis (see Figure 1.2 for example). Several 
studies published since its introduction concluded that TL-01 UV -B is indeed" 
more effective than broad-band UV-B, and its use has greatly increased, 
replacing broad-band UV -B in many centres throughout Europe (Bilsland et 
al. 1997). Chapter 3 of this thesis describes a meta-analysis of studies designed 
14 
to compare the efficacy of TL-01 UVB and broad-band UVB as treatments for 
psoriasis. '. 
Reasons for the Scottish phototherapy and PUVA audit 
In 1991 when the first national survey of PUV A use in Scotland was 
conducted, and recommendations produced, PUV A· was regarded as the 
second-line treatment of choice for moderately severe and severe psoriasis. 
Evidence of its association with skin cancer development was concerning. It 
was largely because of this concern that it was regarded as essential to assess 
how we were using this treatment. 
The next survey of the audit (conducted in 1996 and 1997, and described in 
the following chapter) was designed to assess whether or not the 
recommendations of 1991 had been implemented. This time, with the new 
TL-01 UVB source available and increasingly used, it was decided to survey 
UVB (in dermatology and physiotherapy departments) as well as PUV A 
usage. 
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Figure 1.1 Relative spectral emission from the narrow-band TL-Ol . lamp 
(right) and a o/pical traditional broad-band UVB phototherapy lamp. (From 
Green et al. 1988). 
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Figure 1.2 An example of a patient with psoriasis treated with the new 
TL-01 UVB phototherapy lamps. 
At start of treatment 
course 
After 20 treatments 
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Chapter 2 
The Scottish phototherapy and PUV A audit, funded by the Clinical Resource and 
Audit Group (CRAG) of the Scottish Office. 
This Chapter summarises the main findings of the 1991 survey of PUV A use in 
Scotland (conducted by Dr W. Perkins), and the resulting recommendations. This is 
followed by a more detailed report of the 1996 to 1997 survey of both phototherapy 
and PUV A use in physiotherapy and dermatology departments. 
The next phase of the audit cycle, the development of recommendations and their 
implementation will be discussed in Chapter 6, following one chapter describing a 
meta-analysis of previous studies comparing narrow-band and broad-band UVB for 
psoriasis, and two chapters describing studies conducted to fill gaps in our knowledge 
about how best to use phototherapy and PUV A noted during the survey. 
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The 1991 suroey of PUV A practice 
In 1991, Dr W. Perkins (then a trainee in dermatology in Glasgow) conducted 
a survey of PUV A use in Scotland. This first survey of practice, with resultant 
recommendations, was funded by the Oinical Resource and Audit Group 
(CRAG) of the Scottish Office department of health. The main findings and 
recommendations are summarised in Table 2.1. Members of the Scottish 
Dermatological Society discussed these recommendations. Following this 
initial phase of the Scottish phototherapy and PUV A audit, the Scottish PUV A 
users' group, consisting of consultants supervising PUV A and phototherapy 
in each centre, was established. 
Regular meetings of the Scottish PUV A users' group were held to help update 
all members regarding developments in PUV A and phototherapy, and to 
assist implementation of the 1991 audit recommendations. In 1995 an annual 
national course for nurse phototherapists was established in Dundee, and has 
been held every year since. This was followed in 1997 by the 
photodermatology update course for dermatologists, another development to 
assist those prescribing and supervising phototherapy in keeping up-to-date, 
and to encourage the exchange of views and ideas. 
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Table 2.1 
The 1991 Scottish PUV A Audit: main findings and recommendations of 
audit carried out by William Perkins 
Findings 
• Wide variation in UV A dosimetry (how meters used; how meters 
calibrated; which meters used) 
• Few centres offer 5-MOP or bath PUV A 
• UV A starting dose (for PUV A) only based on MPD in 3 centres 
• Several centres customarily use maintenance therapy for psoriasis 
• Increasing use of PUV A since 1975 
• Limited availability in some geographical areas/ out of government office 
hours 
• In only 9 of 20 centres, is UVB available at the same site as PUV A 
• Permanent PUV A records kept in department in only 8 centres 
Recommendations 
• Named Consultant to oversee service in each centre 
• Aim to extend availability 
• Aim to have UVB and PUV A available at same site 
• Records (PUV A & UVB) to be kept in departments with /I risk factors" and 
cumulative exposures recorded; to allow 
• Follow-up of patients regarded as at significantly increased risk of skin 
cancer as a result of treatment (patients with cumulative exposure to >150 
PUV A treatments or >1000Jcm-2 UV A during PUV A) 
• UV A metering throughout Scotland should be reviewed and standardised 
• A range of psoralens should, ideally, be available in each centre 
• Aim to base UV A starting dose on MPD 
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The 1996/1997 survey of phototherapy and PUVA practice 
Survey Methods 
• Information on unit structure, process and outcomes were collected from all Scottish 
dermatology department phototherapy units and from physiotherapy department-based 
units. Information for each centre was collated on a structured questionnaire. 
• UV A and TL-Ol UVB dosimetry between centres was compared - cubicle outputs were 
measured in the same way with the same meters in centres visited. 
• Data were analysed graphically with, when appropriate, the use of statistical tests to 
determine the probability of chance accounting for findings of differences between groups. 
All dermatology departments in Scotland were invited to participate. A list of 
physiotherapy deparhnental heads was obtained from The Chartered Society 
of Physiotherapy Scottish Board, and all were written to, to find out who 
provided a phototherapy service. 
Information on aspects of unit structure, process, and outcomes were 
collected by visiting ~ll dermatology deparhnent phototherapy units, and a 
sample of physiotherapy units. Questionnaires were sent to the remainder of 
the physiotherapy phototherapy units. Information was collected in 
dermatology units by interview with appropriate staff (nursing, medical, 
medical physics) and by review of phototherapy and PUV A notes. Ninewells 
Hospital UVB (National Light® 1400 meter, spectroradiometrically calibrated 
against a bank of TL-01 lamps) and UV A (Waldmann® meter, calibrated 
according to Scottish PUV A dosimetry guidelines) meters were used, as in 
Ninewells Hospital, to measure stand-up irradiation cubicle outputs - to be 
compared with outputs used in each centre, and so allow comparison of 
dosimetry between centres. 
At each visit, data were collected, and collated on a structured questionnaire 
form. It was important that it was a dermatologist (I had 3 years of post-
" ~ 
... ,"; 
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MRCP clinical training in dermatology, with particular experience in 
phototherapy and PUV A, when I started the audit) who personally visited 
each department. It is unlikely that a non-medically qualified audit officer 
would have been able to adapt the way information was collected in each 
centre sufficiently to learn as much from the phototherapy staff. Also, it is 
likely that the audit visits would have been met by some distrust if it was not 
clear that this was being done by someone whose interests were in patient 
care and clinical dermatology. Because of marked variation in how records 
were kept, and in the terminology used for different outcomes, a non-
dermatologist would not have been able to obtain useful information from the 
notes review component of the survey in many centres. Information on unit 
structure (siting, staffing, equipment), process (treatment indications, 
phototherapy and PUV A methodology, patient follow-up arrangements) and 
outcomes (respoIlSe to treatment and unwanted effects) was gathered. As 
outcomes, in particular, were recorded in different ways in different 
departments a coding system to grade outcomes, which could be applied in 
all centres, was used.1 
After collection, data were entered onto a computer spreadsheet (Microsoft® 
Excel Version 5.0) before transfer to a statistics and graphics package 
(Intercooled Stata for Windows Release 5.0, Stata Corporation 1997) for 
analysis. Data were analysed graphically (Crombie et a1. 1993), using box-
whisker plots to examine between centre differences in variables such as 
number of treatments per course of UVB or PUV A. When appropriate the 
Mann-Whitney U test or the Kruskal-Wallis test for equality of populations 
was used to determine the probability that chance accounted for differences 
Codes used when recording treatment course outcomes: 1) - clear! minimal residual 
activity! "much" or "greatly" improved! ">90% clear"; 2) - moderate improvement! 
"better" (but still disease, requiring other therapy); 3) - no better! slight improvement 
only; 4) - condition for which UVB or PUVA prescribed worse (whether or not because 
of therapy); 5) - outcome of course not ascertainable from phototherapy unit notes; 6) 
- did not attend to complete course. 
) 
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in values (for example, treatments per course for polymorphic light eruption) 
between centres (Altman 1991). 
Participating Centres 
All identified NHS hospital dermatology department phototherapy and 
PUV A units participated: 
Aberdeen Royal Infirmary & Woolmanhlll Hospitals, Aberdeen; 
Crosshouse Hospital, Ayrshire; Dumfries and Galloway District General 
Hospital; Inverclyde Royal Hospital, Greenock; Monklands Hospital, 
Airdrie; Ninewells Hospital and Medical School, Dundee; Perth Royal 
Infirmary, Perth; Queen Margaret Hospital, Dunfermline; Raigmore 
Hospital, Inverness; Royal Alexandra Hospital, Paisley; Royal Infirmary, 
Glasgow; Royal Infirmary, Edinburgh; Southern General Hospital, 
Glasgow; Stirling Royal Infirmary; Stobhill Hospital, Glasgow; 
Stonehouse Hospital, Lanarkshire; Stranraer Hospital; Victoria Hospital, 
Kircaldy; Victoria Infirmary, Glasgow; and Western Infirmary, Glasgow. 
Separate physiotherapy department phototherapy units in: 
Arbroath Infirmary; Blairgowrie; Borders General Hospital; Broadford; 
Dr Gray's Hospital, Elgin; Forfar Infirmary; Golspie; Haddington; 
Montrose Infirmary; Peterhead; Heathfield Hospital, Ayr; Raigmore 
Hospital, Inverness; St Johns Hospital, Howden; Stornoway; Stracathro 
District General Hospital, Brechin; Strathclyde Hospital, Motherwell; 
Thurso; Vale of Leven District General Hospital, Alexandria; and Wick. 
also took part. 
23 
Numbers were randomly allocated to each centre for the presentation of 
. results. This centre number (used in the graphs that follow later in this 
chapter) bears no relation to geographical location of centre or when it was 
visited, but the same number is used consistently for each centre. 
All but one of the dermatology department units (that treated less than 20 
patients each year and was only open when a clinic there is running) were 
visited. Records were available in all except two of the units visited. In one 
unit the records were kept in main hospital notes, so only a convenience 
sample of those notes most readily obtained by the unit secretary were 
reviewed. In another centre a random sample of 25% of the records was 
examined. For the other units an attempt was made to review all records, 
although in some it was not possible to examine those of patients currently 
attending. Table 2.2 shows the total number of notes and documented 
treatment courses reviewed. Unless stated otherwise, as where estimates 
extrapolated from notes reviewed are given, figures based on the notes 
review component of this survey relate to notes actually examined, therefore 
underestimating the total numbers of courses and patients treated. 
Eight physiotherapy departments were visited, and information was obtained 
from the other 10 listed above by letter, questionnaire, and telephone. Three 
other physiotherapy phototherapy departments were identified but did not 
respond to invitations to participate. 
Table 2.2 Notes review 
Notes reviewed: 
Documented 
treatment courses: 
PUV ABroad-band UVB 
2345 2561 
4531 3625 
24 
TL-Ol UVB 
3522 
5499 
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Results 
Dermatology department phototherapy & PUVA units: Structure 
• 22 centres had whole-body PUV A facilities and 21/22 compared with 8/15 in 1992 
provided UVB on the same site. 19 units offered TL-01 UVB. 
• Since 1992, 8 new units had opened, and 5 had extended their opening hours to make 
treatment accessible to more patients. There were still patients in geographically remote 
areas who could not benefit from these treatments. 
• Most dermatology department based PUVA/UVB units were within a dermatology 
outpatient department, treatment centre or ward. Two were in other wards but treatment 
was supervised by a dermatology nurse. 
• Only 3 dePartments still used a combined UVB and PUV A cubicle: all others had 
separate cubicles for each treatment to allow shorter treatment times, and to minimise 
the risk of administering the wrong treatment. 
• In 19 units treatment was administered by nursing staff. Level of staffing, and grade and 
experience of the nurse in charge, varied between units. 
• Increasing numbers of UVB courses were administered each year. The number of PUV A 
courses per year had declined since 1994. 
• In 1996, 1 in 1580 of the Scottish population completed a course of UVB and 1 in 8455 
completed a course of PUVA. There was marked regional variation in the use of UVB and 
PUV A - it is probable that the number of courses administered yearly by most centres will 
continue to increase. 
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Results 
Generaloveroiew 
Twenty-two centres now have whole-body PUV A facilities, compared to 
fifteen in 1992 (Figure 2.1). All but one (compared to only 8/15 in 1992) 
provided UVB phototherapy on the same site. In 1992 there were eight 
dermatology departments with whole-body, stand-up UVB phototherapy 
units. There were twenty-one units with such cabinets in 1997 (Figure 2.2), 
with therapy administered by dermatology nurses except in three that were 
physiotherapy-run but worked closely with dermatology departments. 
Nineteen of these units had narrow-band (TL-Ol) UVB lamps, and another 
two fitted them within the year after this survey. 
Patient accessibility of units 
This depends on a variety of factors: geographical situation of unit, opening 
hours, patient's occupation and the local public transport system. Although 
few patients were known by staff to spend more than 2 hours travelling for 
each treatment visit, there were exceptions (particularly those dependent on 
ambulance transport in some areas). Also, in areas remote from the "local" 
phototherapy unit, there were patients known to medical and nursing staff 
who would be expected to benefit from phototherapy but who could not be 
offered it because of their inability to get to the :unit. Some who cannot travel 
for treatment can be treated with inpatient phototherapy but this is not 
always practicable or appropriate. It is probable that there is more unmet 
need than those working in phototherapy and PUV A units are aware of. 
Patients may not seek attention because they are themselves aware that 
treatment cannot be offered locally. Although waiting list figures were not 
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specifically collected, some centres lacked the resources to provide treatment 
as rapidly as they would like: in one centre, in 1996, patients sometimes had 
to wait over 4 months after referral before starting UVB phototherapy. Other 
centres had a shorter (or non-existent) waiting list for UVB or PUV A, 
although patients might still have to wait many months from general 
practitioner referral before assessment in the outpatient clinic where UVB or 
PUV A could be prescribed. 
Opening hours 
Opening hours ranged from 3 hours twice a week to 16 hours seven days a 
week. Since the 1992 survey, five departments had extended their opening 
hours. The availability of treatment before and after office-working hours is of 
particular benefit to some employed patients who might otherwise have to 
take annual holiday or sick leave to attend. Such extension of opening hours 
is not, however, universally helpful. Whether or not it is appropriate depends 
on the area served. One unit, in an area with high unemployment, found little 
demand for early morning appointments when these were offered. 
Siting of dermatology department-based PUV N UVB units 
Ten units were within a dermatology outpatient department or treatment 
centre, 5 within a combined ward/ outpatient centre, 3 in a dermatology 
ward, and 2 in other wards (but with dermatology nurse supervision of 
treatments). 
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Figure 2.1 
• ~ 
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Figure 2.2 
UV8 Centres 
Units with stand-up UVB cubicles, 1997 • 
• 
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Equipment 
All but 3 departments used separate cubicles for UVB and PUV A, allowing 
greater numbers of patients to be treated than if a combined UVB/UV A unit 
were used, and minimising the risk of accidental administration of the wrong 
treatment. Eighteen departments offered hand and foot PUV A with separate 
UV A irradiation apparatus. Equipment in use in 1997 were Waldmann® 
cabinets (1000, 5000, 8001, 7001), Dixwell® cabinets, cabinets built by 
Ninewells Hospital Medical Physics department, Waldmann® PUV A 180 and 
200 hand and foot/ scalp units, and various locally-built localised UVB 
treatment units. MPD and MED testing apparatus include locally-built units 
and (for MPDs) a sunbed and Waldmann PUV A 180 units. One department 
occasionally used localised high-dose UV A, for pre-tibial myxoedema and 
morphoea, using a metal halide source. All the other UVB and UV A sources 
used in dermatology (but not physiotherapy) departments were fluorescent 
lamps. 
Staffing 
In 19 departments therapy was administered by nursing staff: with regular 
staffing ranging from a department with an enrolled nurse a few hours per 
week to one with at least 2 fully trained nurses, including a G-grade charge 
nurse, working primarily in phototherapy /PUV A 50 hours a week. The 
phototherapy /PUV A unit staffing was impossible to determine in many 
centres, especially those based in a ward, because of the varying proportions 
of time devoted to other duties in between treating UVB and PUV A patients. 
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Trends in the use of PUV A and UVB phototherapy 
Increasing numbers of UVB courses were being administered each year, and 
over the previous 3 years there appeared to have been a trend towards fewer 
courses of PUV A being administered (Figure 2.3). Some caution must be 
taken in looking at these figures as, until recently, many centres kept more 
detailed records of PUV A than of UVB treatment. Nevertheless, the trends 
shown in this figure could not be explained by changes in documentation 
alone. Figure 2.4 shows the number of courses of UVB and PUV A for 
psoriasis at four centres that did keep comprehensive combined UVB and 
PUV A records over the preceding 3 years. 
These trends towards greater use of UVB and less use of PUV A were 
apparent in 13 of the 16 units for which the relevant information was 
recorded. 
Figure 2.3 Documented courses of UVB and PUVA 
per year (all conditions; all centres) 
2000 o UVB (fL-01 and broad-band) 
L-
III 
a> 
>-
L-
a> 
a. 
-0 
a> 
...... 
a> 
C:i 
E 
0 
u 
(/) 
a> 
(/) 
L-
::J 
0 
u 
o PUVA 
1986198719881989199019911 99219931994 19951996 
year 
Figure 2.4 Documented courses of UVB and PUVA for 
psoriasis per year (4 centres with combined UVB and 
PUVA notes) 
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In 1996, 1 in 1580 of the Scottish population completed a course of ultraviolet 
B (TL-Ol or broad-band) and 1 in 8455 completed a course of PUV A.1 In 1992, 
1 in 2825 completed a course of UVB and 1 in 7908 a course of PUV A. The 
proportion of the population receiving a course of UVB or PUV A varies from 
region to region. Estimated proportions for two regions (selected as regions in 
which most UVB and PUV A courses are given in a limited number of centres 
with good records) are shown in Table 2.3. 
A far higher proportion of the population in Region A finished a course of 
UVB or PUV A each year than in Region B. There had been relatively little 
change in these proportions over the prior 5 years in Region A. In Region B, 
however, the proportion of the population receiving phototherapy and PUV A 
rapidly increased. Psoriasis, the main indication for phototherapy and PUV A, 
affects about 2% of the population (Williams 1997). If we estimate that 1 in 10 
psoriasis patients are moderately or severely affected we arrive at a 
prevalence of 1 in 500 of the population with moderately severe or severe 
psoriasis who might benefit from phototherapy. Perhaps in Region A many of 
these psoriasis patients received UVB or PUV A, whereas in Region Bother 
therapies (such as outpatient centre topical treatment, oral cytotoxics, and 
hospital admission) were presumably used for more patients. Patients who 
have received a successful course of phototherapy tend thereafter to be 
reluctant to accept messy topical treatments or ward admission. This may be 
one of the factors causing the increased use of phototherapy in many centres. 
These figures are extrapolated from data collected during this survey - including 
estimated numbers for centres with incomplete records, inaccessible records or 
where only a sample of records were reviewed. Population figures used were taken 
from Scottish Health Statistics 1992 and Scottish Health Statistics 1996 (ISO, NHS 
Scotland). 
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Table 2.3 Proportion of the population receiving a course of UVB or 
PUV A in 2 Scottish regions in 1992 and in 1996.2 
The estimated proportion of the population with psoriasis receiving each of 
these treatments is shown in brackets. 
UVB PUVA 
1992 1996 
REGION A. 
REGIONB. 
1/659 (1/37) 1/582 (1/24) 
1/6118 (1/150) 1/2125 (1/52) 
1992 
1/2057 (1/56) 
1/24471 (1/583) 
1996 
1/2824 (1/98) 
1/12275 (1/433) 
2 Assumptions made in making these estimates: that each individual patient receives 
no more than 1 course per year (leading to a, probably small, over-estimation of 
numbers of patients treated) and that people are only treated in their own region of 
residence. 
Figures in brackets refer to proportion of psoriasis population (assumed to be 2% of 
general population) treated - only courses documented to be for psoriasis as primary 
indication considered in these calculations. 
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National trends in PUV A and UVB use for a selection of conditions 
• Psoriasis remained the major indication for UVB and PUV A, but increasing numbers 
of UVB courses were given for other conditions, particularly atopic dermatitis and 
polymorphic light eruption. 
• For most conditions there was a trend towards increased use of UVB and a decline in 
the use of PUV A. Palma-plantar pustulosis was an exception, with a decline in UVB use 
after a peak in the number of courses for this indication in 1993, reflecting the 
impression that for this condition PUV A may be more effective. 
Psoriasis 
Psoriasis was the main indication for these treatments. As expected a graph of 
courses per year for psoriasis alone (Figure 2.5) was similar to Figure 2.3 
(courses for all indications combined). 
Atopic dennatitis 
Ultraviolet B phototherapy was increasingly used for this indication (Figure 
2.6), although the numbers of patients treated were still few compared to 
those treated for psoriasis. Thirteen centres used phototherapy for atopic 
dermatitis and, although one department accounted for half the patients 
treated, 6 departments treated over 10 patients in 1996. Of 632 UVB courses 
for atopic dermatitis between 1992 and 1996, 396 were with narrow-band (TL-
01) UVB and 236 with broad-band UVB lamps. In one centre, 15 patients were 
treated with UV A I (340-400nm ultraviolet A) monotherapy. 
Figure 2.5 Documented courses of UVB and PUVA 
for psoriasis per year (all centres) 
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Figure 2.6 Documented courses of UVB and PUVA 
for atopic dermatitis per year (all centres) 
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There is open study evidence for the efficacy of TL-01 UVB, broad-band UVB 
and PUV A for atopic dermatitis (Morison et al. 1978; Falk 1985; Atherton et al. 
1988; Ekler et al. 1988; Jekler 1990; George et al. 1993a; Collins et al. 1995; 
Hudson-Peacock et al. 1996). Although a controlled comparative study has 
not been done many have the impression that TL-01 UVB is more effective, 
and less likely to "flare" dermatitis, than broad-band phototherapy. Because 
of concerns about adverse effects (particularly considering that many atopic 
dermatitis patients requiring treatment are children), and in the absence of 
any evidence that it possessed any advantages over UVB phototherapy, 
PUV A was rarely used. Recently, since this survey was conducted, a 
controlled study showed TL-01 UVB and PUV A to be similarly effective (Der-
Petrossian et al. 2000). 
Polymorphic light eruption (PLE) 
Increasing numbers were treated with UVB, mainly TL-01 UVB, for this 
indication (Figure 2.7). This suggests that those prescribing prophylactic 
treatment for polymorphic light eruption were aware of the published 
evidence that TL-Ol UVB is as effective as PUV A (Bilsland et al. 1993), 
whereas broad-band UVB is less effective than PUV A (Addo et al. 1987; 
Murphy et al. 1987). 
Palmo-plantar pustulosis 
For this condition (Figure 2.8) the trend was towards increasing numbers of 
courses of PUV A each year. Although 5 centres had used UVB for this 
/ 
Figure 2.7 Documented courses of UVB and PUVA 
for polymorphic light eruption per year (all 
centres) 
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Figure 2.8 Documented courses of UVB and 
PUVA for palmo-plantar pustulosis per year 
(all centres) 
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condition, 4 using TL-01 lamps, the decline in the number of courses after a 
peak in 1993 may have been related to the impression that many of these 
patients do better with other treatments, such as PUV A. 
Mycosis fungo ides 
Broad-band UVB is effective for early patch stage mycosis fungoides (Milstein 
et al. 1982; Piccinno et al. 1990; Ramsay et al. 1992; Resnik et al. 1993), 
although PUV A may be more effective for plaque stage disease (Piccinno et 
al. 1990; Ramsay et al. 1992). Five departments had tried TL-01 UVB for this 
indication, including its use for patients who would previously have been 
offered PUV A. As yet, no comparative studies have been conducted, but TL-
01 UVB does appear highly effective for patch stage mycosis fungoides (Oark 
et al. 2000), although PUV A appears to be more effective for plaque stage 
disease. 
PUVA and UVB (Process and Outcomes) 
PUVA methodology 
• Since the 1991 audit, PUV A methodology had become more uniform across Scotland. 
• All departments provided written and oral information to patients and sought written 
consent to treatment. 
• Oral8-methoxypsoralen (8-MOP) and 5-methoxypsoralen (5-MOP) were available in all 
units. Bath PUV A was used only occasionally, if available at all: only 4 departments 
administered >10 courses of whole-body bath PUVA during 1995 and 1996. Of these 4 
centres, 2 used trimethoxypsoralen (TMP) and 2 used 8-methoxypsoralen (8-MOP) for 
bathPUVA. 
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• Pre-treatment checks in all centres included a drug history and examination of normally 
exposed skin. Liver function tests and lupus serology were checked if indicated by the 
patient's history. 
• Duration of recommended wearing of eye protection varies from 12 to 24 hours. Checking 
of protective spectacles varied from none (but advice to use only approved spectacles and 
UV-absorbent coatings) to checking that transmission of cubicle UV A through spectacles 
to a UV A meter was negligible to checking spectacles with a spectrophotometer. 
• Dosimetry has become much more uniform since the development of the Scottish PUVA 
Dosimetry Guidelines following the last 1992 survey of practice. 
• The UVA starting dose is now usually based on minimal photo toxic dose (MPD) 
determination in 10 units, compared to just 3 in 1991. The standard treatment frequency, 
for indications except polymorphic light eruption (often treated 3x weekly), was 2x 
weekly in all units. Incremental regimens varied but most were based on a geometric 
incremental regimen, with each dose a percentage of the previous dose. Use of topical and 
systemic adjunctive therapies varied. All used adjunctive retinoids (Re-PUVA) at least 
occasionally. 
• Significant between-centre variation in numbers of treatments per course remained. This 
might in part have been because of differences in patient selection for treatment, but 
remaining differences in treatment methodology were important. 
Indications 
Psoriasis remained the primary indication for PUV A (Figure 2.9). It was used 
for severe or moderately severe psoriasis not adequately controlled by topical 
therapies. In centres with access to TL-Ol UVB this was usually used first, 
with PUV A only prescribed if TL-Ol UVB proved disappointing or provided 
an unacceptably short duration of remission. Of the other frequent indications 
for PUV A, the only conditions f~r which increasing numbers of PUV A 
courses are prescribed each year are palmo-plantar pustulosis and palma-
plantar psoriasis. Other conditions treated with PUV A are listed, in 
alphabetical order, in Table 2.4. 
Figure 2.9 PUVA courses 1992 to 1996 (n= 3225) - the 5 most frequent 
indications for PUVA. Percentage of courses for each 
indication is shown. 
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Table 2.4 PUV A courses - outcomes of courses - numbers (percentages) 
Condition Clear/ Moderate No change/ Worse 
MRA improvement minimal 
improvement 
Acquired perforating 1 (100) - - -
dermatosis 
Actinic prurigo 3 (60) 1 (20) - -
Alopecia areata 8 (20) 16 (40) 11(27.5) 1 (2.5) 
Angiolymphoid - 1 (100) - -
hyperplasia with 
eosinophilia 
Annular erythemas - 1 (33.3) 2 (66.7) -
Aquagenic pruritus - - - 1 (100) 
Atopic dermatitis 44 (25) 59 (33.5) 17 (9.7) 5 (2.8) 
Cholinergic urticaria 1 (100) - - -
Chronic idiopathic 4 (33.3) 4 (33.3) 1 (8.3) 
urticaria 
Chronic superficial 16 (53.3) 3 (10) 193.3) -
dermatitis 
Diffuse cutaneous 1 (100) - - -
reticulohistiocytosis 
Discoid eczema - 3 (100) - -
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Outcome DNA 
not (did not 
recorded attend) 
- -
1 (20) -
2 (5) 2 (5) 
- -
- -
- -
33 (18.8) 18(10.2), 
- -
1 (8.3) 2 (16.7) 
8 (26.7) 2 (6.7) 
- -
- -
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Condition Clear/ Moderate No change/ Worse Outcome DNA 
MRA improvement minimal not (did not 
improvement recorded attend) 
Epidermolysis bullosa - 1 (100) - - - -
Follicular mucinosis 2 (40) 3 (60) - - - -
Granuloma annulare 2 (25) 2 (25) 1 (12.5) - 3 (37.5) -
Hidradenitis - 1 (100) - - - -
suppuritiva 
Ichthyoses - - - - 3 (75) 1 (25) 
Idiopathic pruritus 1 (11.1) 3 (33.3) 2 (22.2) 2 (22.2) - 1 (11.1) 
Idiopathic solar 1 (12.5) 1 (12.5) 2 (25) - 4 (50) -
urticaria 
Insect bite reactions - 1 (100) - - - -
Jessner's lymphocytic - 2 (66.7) 1 (33.3) - - -
infiltrate 
Lichen amyloidosus - - - - - 1 (100) 
Lichen nitidus 1 (100) - - - - -
Lichen planus 13(44.8) 6 (20.7) 5 (17.2) - 4 (13.8) 1 (3.5) 
Lichen simplex - 2 (66.7) - - - 1 (33.3) 
Linear IgA disease 2 (100) - - - - -
Lymphomatoid 2 (40) - 1 (20) - 1 (20) 1 (20) 
papulosis 
Mastocytoses 4 (22.2) 1 (5.6) 2 (11.1) - 10 (55.6) 1 (5.6) 
Mycosis fungoides 47 (46.1) 26 (25.5) 5 (4.9) 1 (1) 17 (16.7) 6 (5.9) 
Necrobiosis lipoidica - 3 (30) 4 (40) - 1 (10) 2 (20) 
Palmar hyperhidrosis - - 1 (100) - - -
Papuloerythroderma of - - - - 1 (100) -
Ofuji 
Perifolliculitis capitis - - 1 (100) - - -
abscedens et suffodiens 
Photosensitivity 1 (50) - - 1 (50) - -
dermatitis/ actinic 
reticuloid syndrome 
Pityriasis lichenoides 8 (61.5) 3 (23.1) - - 2 (15.4) -
chronica 
Polymorphic light 64 (19.3) 45 (13.6) 12 (3.6) 4 (1.21) 200 (60.4) 6 (1.8) 
eruption 
Sezary's syndrome - - - - 1 (100) -
Undefined eczemas 14 (41.2) 5_(14.7) 2 (5.9) 1 (2.9) 5 (14.7) 7 (20.6) 
Palmar/plantar 20 (37) 11 (20.4) 10 (18.5) 3 (5.6) 8 (14.8) 2 (3.7) 
dermatitis 
Palmo-plantar 54 (20.9) 81 (31.4) 34 (13.2) 6 (2.3) 64 (24.8) 19 (7.4) 
l'ustulosis/ psoriasis 
P~tyriasis rubra pilaris 1 (25) - 1 (25) 1 (25) 1 (25) -
Pretibialmyxoedema - - 1 (100) - - -
Prurigo nod ularis 7 (22.6) 15 (48.4) 5 (16.1) - 3 (9.7) 1 (3.2) 
Psoriasiform dermatitis 1 (33.3) - - 2 (66.7) - -
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Condition Clear/ Moderate No change/ Worse Outcome DNA 
MRA improvement minimal not (did not 
improvement recorded attend) 
Psoriasis 1598 (48.9) 455 (13.9) 171 (5.23) 47 (1.4) 791 (24.2) 208 (6.4) 
Scleroderma - 1 (33.3) 2 (66.7) - - -
Vitiligo 1 (4.55) 6 (27.3) 11(501 - - 4 (18.2) 
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Consent to treatment and patient information 
The referral process for PUV A varied from centre to .centre. Usually, the 
patient was seen in the outpatient clinic and PUV A prescribed, either on a 
specific referral form (including documentation of previous treatments and 
any relative contraindications), as used in 6 centres, or by letter or telephone 
call to the nurse in charge of administering PUV A. In 4 departments patients 
were referred from the outpatients' clinic to another dermatologist in the 
phototherapy unit who further assessed the patient before prescribing PUV A. 
All departments provided written as well as oral information about PUV A 
and sought written consent. Information sheets about PUV A described what 
is involved in administering the treatment, mentioned the most frequent 
acute adverse effects, and explained the need for protective eye-wear after 
psoralen administration. Some emphasised the need to avoid pregnancy 
because psoralens are mutagenic (Lambert et al. 1978; McEvoy et al. 1987), 
although they may not be teratogenic (Stern et al. 1991; Gunnarskog et al. 
1993). Three of the information sheets viewed contained specific mention of 
increased risk of skin cancer as a chronic adverse effect. Only two 
departments' information sheets explicitly listed PUV A pain amongst the 
possible adverse effects. 
Ps ora lens 
Psoralens may be administered orally or topically, for whole-body treatment 
orfor localised (usually hands/ feet or scalp) treatment. Oral psoralens were 
most often used for both whole body and local treatment (Figure 2.10). Oral 
8-methoxypsoralen (8-MOP) and 5-methoxypsoralen (5-MOP) were available 
in all PUV A units. In all centres, 8-MOP was the first-choice psoralen, with 5-
MOP used if 8-MOP caused unacceptable gastro-intestinal adverse effects. In 
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some centres, 5-MOP was also prescribed, apparently successfully, as an 
alternative psoralen for those who developed PUV A pain during 8-MOP-
UV A therapy. The oral psoralen dose was based on patient weight (0.6 mg/ 
Kg for 8-MOP and 1.2 mg/Kg for 5-MOP) in all but one centre which had 
adopted a surface-area-based psoralen dosing scheme. In practice, similar 
doses are used for most patients whichever system is used: but low-weight 
patients may be under-dosed if body-weight alone is used. Some centres 
avoid this by never prescribing less than 40mg of 8-MOP regardless of body 
weight. Minimal phototoxic dose determination ensures that whatever dosing 
schedule is favoured, there is an adequate psoralen skin concentration to 
interact with UV A. 
For whole-body topical PUV A, the psoralens are applied in bath-water. Only 
4 centres gave more than 10 courses of whole-body bath PUV A during the 
previous 2 years (1995, 1996) - two used trimethoxypsoralen (TMP) and two 
8-MOP. 
Bath PUV A is indicated for patients unable to tolerate oral psoralens (usually 
because of nausea), those already on multiple oral medications or with 
hepatic or renal impairment, those with no phototoxic response detectable 
after 2 or more oral psoralen doses prior to minimal phototoxic dose (MPD) 
testing, and (particularly when TMP is used - as it requires low UV A doses, 
leading to short treatment times) claustrophobic patients (Halpern et al. 2000). 
There is a hope that bath-PUV A may tum out to be less photocarcinogenic 
than oral PUV A. Epidemiological data from Scandinavia suggests that TMP 
bath PUV A may be safer than oral 8-MOP PUV A (Berne et al. 1984; Lindelof 
et al. 1992; Hannukselaet al. 1996). However, the latest report from Finland, 
which showed no more skin cancers than expected in a matched population 
in 527 TMP-treated patients followed-up for a mean of 10 years, could have 
Figure 2.10 Method of psoralen administration 1992-1996 
Whole body 
2923 courses 
topical psora len Local application 
426 courses 
( 13 centres) 
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missed up to a seven-fold increased risk because of the, still small, cohort size 
and relatively short duration of follow-up. There is no evidence that topical 8-
MOP, or 5-MOP (Calzavara-Pinton et al. 1997) PUV A is any less, or more, 
photocarcinogenic than when the psoralen is administered orally. It cannot be 
assumed that bath 8-MOP PUV A will be safer than oral PUV A, despite the 
lower UV A doses required to produce the same phototoxic and therapeutic 
effects (Figure 2.11). Although TMP-bath PUV A may eventually tum out to be 
safer, if this occurs the explanation might relate to the particular psoralen 
used, rather than the mode of administration. Mouse studies have shown 
topicaI8-MOP+UV A to be as carcinogenic as oraI8-MOP+UV A (Griffin et al. 
1958) and, in another study, lifelong topical TMP-PUV A caused no mouse 
skin cancers· (Hannuksela et al. 1986)whereas topical8-MOP PUV A did. 
When following-up patients regarded as at risk of skin cancer as a result of 
PUV A, cumulative treatments may be a more important risk factor than 
cumulative dose. This is because a high UV A dose given in relatively few 
treatments may be safer than the same dose spread over more treatments 
(Gibbs et al. 1985), . and because of variation in UV A dosimetry leading to 
difficulty in meaningful comparison of dose Ocm-2) reported from different 
centres (Diffey et al. 1986). Given the lower cumulative UV A doses to achieve 
the same phototoxic, therapeutic (and, possibly, photocarcinogenic) effects if 
psoralens are applied topically, it\ is particularly important that the 
cumulative number of treatments, and not just cumulative UV A dose, is 
regarded as a risk factor when following-up bath PUV A patients. 
Figure 2.11 UVA dose per course for whole-body PUVA for psoriasis (1992 -
1996). The central lines represent median dose, the boxes enclose the 
interquartile range (lOR). The whiskers enclose the adjacent values (1 1/ 2 x lOR) 
and more extreme outlying values are represented as circles . 
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Only 36 of a total of 132 recorded localised PUV A courses administered in 
1996, predominantly for hands and/or feet, were documented to involve 
topical psoralen application. Frequently-used preparations included: 8-MOP 
emulsion 0.15% applied for 15 to 30 minutes before UV A irradiation, 8-MOP 
bath lotion made up in a 0.0003% solution applied as a soak for 10 to 20 
minutes, and TMP bath solution made up with 1mg TMP in 3 litres applied as 
10 minute soak. One centre was assessing an 8-MOP gel. No centre was yet 
using the newly available preparation, 0.005% aqueous gel of psoralen (the 
parent compound), which appears promising as a treatment for palmoplantar 
psoriasis (de Rie et al. 1995). 
Pre-treatment checks 
In all centres, patients were asked about possible relative contraindications, 
and examined for any skin malignancies or premalignant lesions. A drug 
history was also taken in all departments. A total body skin examination was 
. routine in some departments. In others, pressure on clinic time allowed 
routine examination of normally exposed sites only. 
Liver function tests (LFTs) were always carried out if there was a history to 
suggest possible liver disease. Other departments still checked LFTs routinely 
for all PUV A patients. Hepatic injury is an uncommon side effect of PUV A 
(Bjellurup et al. 1979; Pariser et al. 1980; Freeman 1984), and has occurred as 
an idiosyncratic effect of topical 8-MOP lotion (park et al. 1994) as well as 
with oral psoralens. It is generally accepted that, if baseline LFTs are normal, 
there is no need for routine monitoring of LFTs (British Photodermatology 
Group 1993). There is no clear evidence in favour of unselective pre-treatment 
screening for liver biochemistry abnormalities in all PUV A patients, but if a 
PUV A patient does develop liver dysfunction, it could be helpful to have 
baseline results. 
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All centres checked antinuclear factor antibodies (ANAs) for patients with a 
history of photosensitivity, or who developed a photosensitivity problem 
(commonly polymorphic light eruption) during treatment. Just over half 
followed the British Photodermatology Group recommendation that anti-Ro 
antibodies also be checked in these patients (British Photo dermatology Group 
1993). Some centres routinely requested ANA tests for all patients prior to 
starting PUV A. Therewas a suggestion that PUV A might induce antinuclear 
antibodies, but it has since been shown that this is not a complication of 
PUV A for psoriasis (Picascia et al. 1987; Calzavara-Pinton et al. 1994b), and no 
Scottish departments routinely monitor ANAs during treatment. 
Only two departments routinely requested a pre-treatment pregnancy test for 
female patients ... The others relied on warning of the potential risks, and 
giving advice on contraception. If pregnancy occurs during a course of PUV A 
this treatment is stopped but, as pregnancy outcomes following psoralen 
exposure have been reassuringly normal (Stem et al. 1991; Gunnarskog et al. 
1993), no department would advise pregnancy termination in this situation. 
Eye protection 
The usual eye protection during treatment was with "UVC-303 treatment 
goggles", provided by Arthrodax Surgical Ltd., also used during UVB 
treatment. There was some variation in the advice given after psoralen 
administration. All advised UV A protective spectacles for at least 12 to 24 
hours following oral psoralen ingestion. Two departments distinguished 
between those regarded as at low risk, advised to wear protection for 12 
hours, and those at higher pre-existing risk of cataract (children and atopic 
dermatitis patients) who were advised to wear protection for all waking 
hours up to 24 hours after taking psoralens. Advice to bath PUV A patients 
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was variable: some regarding this as unnecessary and others, cautiously, 
advising eye protection for 24 hours, on the grounds that topical application 
can lead to significant plasma (and presumably lens) psoralen levels (Gomez 
et al. 1995). Since this survey, most departments have adopted the guidelines 
of a British Photodermatology Group workshop (Halpern et al. 2000), and no 
longer recommend eye protection routinely to bath PUV A patients. 
Any increased risk of cataract in humans as a result of PUV A appears to be 
low (Cox et al. 1987; Stem 1994), despite concern about a possible risk based 
on theoretical and animal study grounds. Even in a cohort of patients known 
not to comply with eye protection advice no excess in cataract incidence was 
noted (Calzavara-Pinton et al. 1994a). Nevertheless, while the true risk 
remains uncertain, protective spectacles fulfilling recommended transmission 
criteria should b.e advised (Moseley et al. 1988; Diffey 1996). If the patient 
wishes to wear his or her own sunglasses these must be checked, ideally with 
a spectrophotometer although reasonable alternatives have been suggested 
(Diffey 1996). This is especially important because inadequate UV A 
absorption by sunglasses is potentially a greater hazard than no protection at 
all, due to pupillary dilatation resulting from visible light-shielding (Deleu et 
al. 1990). Eye protection of aphakic patients to prevent retinal damage is 
essential. Fortunately most cataract extractions now are followed by insertion 
of a UV -absorbing anterior chamber prosthetic lens implant. 
UVA administration 
Dosimetry 
Implementation of the Scottish PUV A Dosimetry Guidelines, following the 
1991 PUV A audit, succeeded in making UV A dosimetry throughout the 
country more uniform: so that a Jcm-2 of UV A in one· department means 
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approximately the same as a Jcm-2 in another department. Figure 2.12 
illustrates this, with the, still non-standardised, UVB dosimetry for 
comparison. 
Until similar guidelines are established elsewhere we will have to continue to 
be cautious in our interpretation of Jcm-2 quoted in the literature from other 
countries, but uniform dosimetry in Scotland is a start and, practically, 
already allows safer transfer of patients between units during a course of 
PUVA. 
Starting dose 
This is ideally based on determination of the minimal phototoxic dose (MPD) 
for each patient. This ensures that sufficient psoralen is present in the skin at 
the time of irradiation - taking into account individual variation in drug 
metabolism and any drug interactions. It is also a safety check, ensuring that 
the starting dose does not cause an acute phototoxic II bum" . Also, there is 
evidence from a Scottish population (Collins et al. 1996b), that use of an MPD-
based starting dose allows clearance of psoriasis with a lower cumulative 
number of exposures than with a skin-type based starting dose. 
Ten units in Scotland routinely used an MPD-based starting dose for most 
patients, and 4 determined the MPD for some patients (those with a 
photodermatosis or those who are starting a first PUV A course). This is 
encouraging as in 1991 only 3 centres determined MPDs. Figure 2.13 shows 
that more treatments were required for a successful course of PUV A in 
centres which did not routinely base starting UV A doses on MPD 
measurement, compared to those that did. This is not controlled trial data and 
there are many possible explanations for the finding but, we do have evidence 
that basing starting dose on the individual's MPD leads to significantly fewer 
Figure 2.12 UVA dosimetry 
1 Jcm-2 in each of 14 units converted to "Ninewells Joules" 
TL-01 dosimetry shown for comparison 
Differences in values in shaded area possibly accounted for by 
measurement error alone 
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Figure 2.13 PUVA treatments per course for psoriasis documented as 
leading to clearancel MRA (1992-1996). Centres with starting dose 
routinely based on MPD or not. 
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treatments required to achieve clearance (Collins et al. 1996b) and this was 
likely to be an important factor. 
Treahnentfrequency 
The standard PUV A treatment frequency for psoriasis in Scotland was 2x 
weekly in all centres. This differed from the situation in the UK as a whole in 
1991, when most centres used 3x weekly PUV A (Farr et al. 1991). One reason 
for using PUV A only 2x weekly (instead of 3 or 4x weekly as has been 
customary in parts of continental Europe) is that PUV A erythema does not 
reach maximum intensity until at least 72 hours after UV A irradiation. Open 
study evidence supports the use of 2x weekly PUV A for a UK psoriasis 
patient population (Sakuntabhai et al. 1993). An "aggressive" 3x weekly 
regimen, with weekly MPD determination (Carabott et al. 1989), caused 
uncomfortable erythema episodes too frequently to be appropriate for a 
Scottish population (Green et al. 1993). Two centres occasionally used a 1x 
weekly regimen (Cox 1995) for selected patients who would find it difficult, or 
impossible, to attend more frequently. For polymorphic light eruption, 3x 
weekly treatment is traditional, although some patients are treated 2x a week. 
The optimal treatment frequency for PLE has not yet been determined. Other 
conditions are usually treated 2x weekly, as for psoriasis. 
Dose increments 
The centres that routinely based the UV A starting dose on each individual 
patient's MPD, then used increments based on a percentage of previous dose: 
usually 40% increments reducing to 20% or 10% later during the course, 
depending upon erythemal response. Other centres had a variety of arbitrary 
incremental regimens .. 
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Adjunctive therapy 
. Many centres sometimes used adjunctive tar, dithranol, or calcipotrioI. The 
use of adjunctive retinoids varied greatly between centres. Systemic retinoids 
combined with PUVA (Re-PUVA) have been shown to minimise the UVA 
dose required to clear psoriasis (which is expected to reduce the risk of long-
term adverse effects), and retinoids may, themselves, exert anti-neoplastic 
effects (Bertram et aI. 1985; Eccles 1985). One centre, which until recently 
tended to use maintenance therapy more frequently than others, frequently 
had more than half the patients attending for PUV A on etretinate or acitretin. 
Because of its shorter biological half-life, isotretinoin was occasionally used as 
an adjunct (and PUV A sparing therapy) when a retinoid was required for a 
young woman. 
Fewer than 20 patients were documented to have had methotrexate, 
cyclosporin, hydroxyurea or azathioprine in conjunction with PUV A. One 
department had tried psoralen-UVB treatment for one, previously treatment 
resistant, psoriasis patient. 
Stopping treatment 
Treatment for psoriasis is usually stopped on achievement of clearance or 
"minimal residual activity", The decision to stop a course of treatment was 
made in different ways in different centres: 
1) some had a protocol allowing the staff administering therapy to stop, with 
or without clinic follow-up, treatment if clearance was achieved before 20 
treatments, 
2) in others a doctor reviewed every patient before discharge, and 
3) some units had the patient reviewed in clinic after a set number of 
treatments (often 20) or weeks (often 6). This has the disadvantage of 
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meaning that some patients are given unnecessary extra exposures, after 
clearance, because the decision to stop treatment is not made until this 
review. 
For other conditions, in all centres, the patient was usually reviewed by a 
doctor before discharge. For polymorphic light eruption (PLE) 15 treatments 
were usually prescribed. Polymorphic light eruption is provoked during 
about half of all prophylactic treatment courses administered in Dundee (Man 
et al. 1999). In some departments, however, patients had unusually prolonged 
"desensitisation" courses, with treatment apparently continued until they 
stopped having PLE provoked during treatment. In other centres, it was 
customary to "give up" and stop treatment early if a patient experienced a 
few episodes of provoked PLE. 
Between-centre differences 
Use of maintenance PUV A for psoriasis has declined over the years since 1977 
(Figure 2.14). Another explanation for falling numbers of treatments per 
course may be that, as treatment regimens have been improved, the number 
of treatments to attain clearance has fallen. To compare treatments per course 
between centres, it is important to ensure that changes in PUV A use over time 
and different mixes of conditions treated are not confounding variables. 
Figure 2.14 Whole-body PUVA treatments per course for 
psoriasis for which data available. Median is central line; box 
encloses interquartile range. 
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Psoriasis 
No Scottish centres now routinely use maintenance PUV A for psoriasis. 
Maintenance treatment was used for mycosis fungoides and, occasionally, for 
vitiligo or alopecia areata. Figure 2.15 shows the between-centre variation in 
number of treatments per course for psoriasis. Possible reasons for centres 
giving unusually large numbers or low numbers of treatments per course are 
listed: 
Unusually prolonged, multiple treatment courses 
• Sub-optimal treatment regimens. 
• Patient selection: an unusually high proportion of particularly severely 
affected, and relatively treatment-resistant, patients referred for PUV A. 
• No clear policy on when a course should stop, or a protocol that 
encourages extra treatments after clearance or MRA is achieved (such as a 
"standard" 20 treatments before a decision on stopping or continuing 
treatment is made). 
Unusually short, few treatment, courses 
• Many patients failing to attend 
- difficulties in travelling to centre (geography, local public 
transport). 
- a perception by patients and/ or staff that treatment is ineffective (a 
self-fulfilling prophecy if patients stop treatment early). 
• Other therapies, such as UVB and hospital admission, not readily 
available so patients with relatively mild,"and easy to clear, psoriasis are 
referred for PUV A. 
Figure 2.15 Whole-body PUVA treatments per course for 
psoriasis (1992 - 1996) in each centre for which data 
available. Median is central line; box encloses interquartile 
range. 
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UVB phototherapy methodology 
• Whilst psoriasis remained the major indication for UVB, increasing numbers of UVB 
courses were administered for other conditions, particularly atopic dermatitis and 
polymorphic light eruption. Most UVB courses administered in Scotland between 1992 
and 1997 were narrow-band TL-01 UVB. 
• 12 departments provided written as well as oral information to patients and requested 
written consent to treatment. Baseline lupus serology was checked prior to a first course 
of UVB in patients with a known photodermatosis, in every centre. 
• UVB dosimetry varied widely between centres, making between-centre comparisons of 
"uncorrected" doses meaningless. 
• The UVB starting dose was routinely based on minimal erythemal dose (MED) 
determination in 5 centres. The method of MED determination varied. 
• Treatment frequency varied from 2x weekly to daily. Routinely used treatment 
frequencies were 2x, 3x and 5x weekly. 
• All units encouraged use of appropriate emollients during a treatment course. About 
half of UVB courses also involved other adjunctive topical treatment. All units using 
TL-Ol occasionally used systemic retinoids with UVB (Re-TL-01). 
• There was wide variation between centres in numbers of treatments and dose per 
course for psoriasis. Similarly, although TL-01 UVB was an effective tr~aln'lent for 
psoriasis in all cen,tres using it, there were variations in outcomes between centres 
suggesting that, with improvements in methodology, some units could treat their 
patients more effectively. 
Indications 
Most courses of UVB, whether narrow-band TL-Ol (Figure 2.16) or broad-
band (Figure 2.17), administered in Scotland were for psoriasis or atopic 
dermatitis. TL-Ol UVB was more often used for PLE than broad-band 
UVB. Both UVB sources were still used for acne: the indication for 1 % of 
Figure 2.16 Narrow-band (TL-01) courses 1992 to 1996 (n= 4243) 
- the 5 most frequent indications for TL-01 UVB. 
Percentage of courses for each indication is shown. 
chronic urticaria (1 .5%) 
(1 %) 
Figure 2.17 Broad-band UVB courses 1992 to 1996 (n= 2601) -
the 5 most frequent indications for broad-band UVB. 
Percentage of courses for each indication is shown. 
pityriasis lichenoides (1 .2%) 
~-- PLE (0.7%) 
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courses. A significant proportion of TL-01 courses were for chronic urticaria. 
Both sources were used for a wide variety of other indications (Tables 2.5 and 
2.6) but the proportion of courses for these /I other conditions" was greater 
with TL-01. The number of yearly courses of TL-01 administered each year for 
atopic dermatitis, PLE and other conditions, as well as for psoriasis, was 
rapidly increasing (Figure 2.18). 
As with PUV A, the method of use of TL-01 varies according to the treatment 
indication with, for example, a course leading to clearance or minimal 
residual activity for atopic dermatitis generally requiring more UVB 
exposures than for psoriasis (Figure 2.19). 
Pre-treatment checks 
In 12/19 departments a UVB patient information sheet was given to patients, 
either when the treatment was prescribed or when it started. These 
departments usually sought patients' written consent to phototherapy 
whereas the others had consent forms for PUV A, but not for UVB. Although 
UVB is safer than PUV A, a written consent form is a useful focus for the 
discussion about the aims of treatment, and potential side effects, with the 
patient: and ensures all patients are given an opportunity to ask questions. 
Most patients treated for a photodermatosis, or who developed one (usually 
PLE) during a course of treatment, had baseline antinuclear antibody (ANA) 
and anti-Ro and La antibodies checked. Unless specifically indicated for an 
individual patient, these tests were not, in any unit, repeated for subsequent 
courses. Some centres had a problem with the apparently over-sensitive ANA 
assay used by one regional immunopathology service. 
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Table 2.5 Conditions treated with broad-band UVB - outcomes of courses 
- numbers (percentages) 
Condition Clear/ Moderate No change/ Worse Outcome DNA 
MRA improvement minimal not (did not 
improvement recorded attend) 
Acne vulgaris - 8 (24.2} 8 (24.2) 1 (3) 9 (27.3) 7 (21.2) 
Actinjc prurigo 1(33.3) - 1 (33.3) - 1 (33.3) -
Alopecia areata - - 1 (50) - 1 (50) -
Aquagenic pruritus 2 (50) 1 (25) 1 (25) - - -
Atopic dermatitis 50 (18.5) 87 (32.1) 27 (10) 5 (1.9) 71 (26.2) 31 (11.4) 
Cholinergic urticaria - - - - 1 (100) -
Chronic idiopathic urticaria - 2(100} - - - -
Chronic superficial 7 (50) 6 (42.9) - - 1 (7.1) -
dermatitis 
Darier's disease - - 1 (100) - - -
Discoid eczema 4 (44.4) 3 (33.3) - - 1 (11.1) 1 (11.1) 
Epidermolysis bullosa - 1 (50) 1 (50) - - -
Erythrokeratoderma - 5 (100) - - - -
variabilis 
Hidradenitis suppuritiva - 2 (100) - - - -
Idiopathic pruritus 2 (13.3) 7 (46.7) 3 (20) - 23 (13.3) 1 (6.7) 
Insect bite reactions 2(100) - - - - -
Keratosis l'ilaris - 2 (40) - - - 3 (60) 
Lichenplanus 2J50J - 1(25) - - 1 (25) 
Lichen simplex chronicus - - - 1 (50) 1 (50) -
Lymphomatoid papulosis - - - - 1 (100) -
Mastocytoses - 3 (50) 1 (16.7) - 1 (16.7) 1 (16.7) 
Milia - - 1 (100) - - -
Mycosis fungoides - - - - 1 (100) -
Necrobiosis lipoidica - 1 (25) - - 1 (25) 2 (50) 
Palmo-plantar pustulosis/ - . - 1 (100) - - -
psoriasis 
Papuloerythroderma of - 2 (100) - - - -
Ofuji 
Pityriasis alba - 1 (100) - - - -
Pityriasis lichenoides 19 (48.7) 5 (12.8) 3 (7.7) 1 (2.6) 9 (23.1) 2 (5.13) 
chronica 
Pityriasis lichenoides 1 (50) - - - - 1 (50) 
varioliformis et acuta 
Pityriasis rosea 
- 1 (25) - - 1 (25) 2 (50) 
Pityrosgorum folliculitis - - - - 1 (50) 1 (50) 
Polymorphic light eruption 50 (54.4) 7 (7.6) 2(2.2) 3 (3.3) 23 (25) 7 (7.6) 
Prurigo nodularis 2 (20) 2 (20) - - 6(60) -
Pruritus of Hodgkin's 1 (50) - - - - 1 (50) 
lymphoma 
Pruritus of liver disease 
- - 1 (50) - - 1 (50) 
Pruritus of renal failure 1 (11.1) 3 (33.3) - - - 5 (55.6) 
Psoriasis 153 (34.9) 431 (14.3) 122 (4) 9 (0.3) 1131 (37.5) 274 (9.1) 
64 
Condition Clear/ Moderate No change/ Worse Outcome DNA 
MRA improvement minimal not (did not 
improvement recorded attend) 
Symptomatic - 1 (50) - - - 1 (50) 
dermogra phism 
Undefined eczemas 2 (25) 2 (25) 1 (12.5) 1 (12.5) 2 (25) -
Urticarial vasculitis 1 (50) 1 (50) - - - -
Table 2.6 Conditions treated with TL-Ol UVB courses - outcomes of 
courses - numbers (percentages) 
Condition Clear/ Moderate No change/ Worse Outcome not DNA 
MRA improvement minimal recorded (did not 
improvement attend) 
Acne 8 (18.2) 13 (29.6) 14 (31.8) 2(4.6) 1(2.3) 6 (13.6) 
Acne agminata - - 1 (100) - - -
Acquired 1 (33.3) - 2 (66.7) - - -
perforating 
dermatosis 
Actinic prurigo 11 (39.3) 1 (3.6) - - 16 (57.1) -
Alopecia areata 1 (14.3) 1 (14.3) - - 1 (14.3) 4 (57.1) 
Angiolymphoid - - 1 (100) - - -
hyperplasia 
Annular erythema 1 (50) - - - - 1 (50) 
Atopic dermatitis 330 (58.6) 112_(19.9) 30 (5.3) 11 (2) 24 (4.3) 56 (10) 
Cholinergic 1 (33) - 2 (66.7) - - -
urticaria 
Chronic fatigue - - - - - 1 (100) 
Chronic idiopathic 31 (38.8) 22 (27.5) 17 (21.3) 2 (2.5) 2 (2.5) 6 (7.5) 
urticaria 
Chronic superficial 6 (66.7) 2 (22.2) - - - 1 (11.1) 
dermatitis 
Cold urticaria 1 (100) - - - - -
Discoid eczema 11 (78.6) 2 (14.3) - - - 1 (7.1) 
Drug induced 1 (100) - - - - -
photosensitivity 
Erythrokeratoderm 1 (100) - - - - -
a variabilis 
Erythropoietic 11 (50) - - - 9 (40.9) 2 (9.1) 
protoporphyria 
"Follicular 1 (50) - - - - 1 (50) 
dermatitis" 
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Condition Clear/ Moderate No change/ Worse Outcome not DNA 
MRA improvement minimal recorded (did not 
improvement attend) 
Granuloma 4 (50) 3 (37.5) 1 (12.5) - - -
annulare 
Heat urticaria - 1 (100) - - - -
Hydroa 7 (46.7) 1 (6.7) - - 7 (46.7) -
vacciniforme 
Ichthyoses 5 (71.4) 2 (28.6) - - - -
Idiopathic solar 2 (12.5) 1 (6.25) - - 11 (68.8) 2 (12.5) 
urticaria 
Insect bite reactions 1 (11.1) 8 (88.9) - - - -
Jessner's lympho- - 1 (50) 1 (50) - - -
cytic infiltrate 
Juvenile plantar - 1 (100) - - - -
dermatosis 
Juvenile Spring- 1 (33.3) 2 (66.7) - - - -
time eruption 
Keratosis pilaris 4 (50) 1 (12.5) 2 (25) - - 1 (12.5) 
Kimura's disease 1 (100) - - - - -
Lichen nitidus 1 (100) - - - - -
Lichen planus 6 (37.5) 4 (25) 3 (18.8) - 2 (12.5) 1 (6.3) 
Lichen simplex - 2 (100) - - - -
Mastocytoses 1 (16.7) 1 (16.7) 1 (16.7) - 3 (50) -
Mycosis fungoides 13 (72.2) 2 (11.1) - - 1 (5.6) 2 (11.1) 
Necrobiosis - - 2 (100) - - -
lipoidica 
Palmoplantar 21 (42.9) 5 (10.2) 14 (28.6) 1 (2) 4 (8.2) 4 (8.2) 
dermatitis 
Palmoplantar 13 (21.7) 19 (31.7) 13 (21.7) 1 (1.7) 9 (15) 5 (8.3) 
pustulosis/ 
palmoplantar 
psoriasis 
Photosensi tivity 2 (16.7) 2 (16.7) 2 (16.7) - 6 (50) -
dermatitis/ actinic 
reticuloid 
syndrome 
Pityriasis 46 (68.7) 7 (10.5) 1 (1.5) - 4 (6) 9 (13.4) 
lichenoides 
chronica 
Pityriasis rosea 3 (33.3) 2 (22.2) 1 (11.1) - - 3 (33.3) 
Pityriasis rubra - - 1 (33.3) - 2 (66.7) -
pilaris 
Pityrosporum 3 (37.5) 2 (25) 9912.5) - 2 (25) -
folliculitis 
Polymorphic light 164 (35) 8 (1.7) 9 (1.9) 2 (0.4) 269 (57.4) 17 (3.6) 
eruption 
Porphyrias (not 1 (50) - - - 1 (50) -
EPP) 
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Condition Clear/ Moderate No change/ Worse Outcome not DNA 
MRA improvement minimal recorded (did not 
improvement attend) 
Prurigo nod ularis 12 (37.5) S (lS.6) 9 (28.1) 1 (3.1) 3 (9.4) 2 (6.3) 
Pruritus 16 (34.8) 9 (19.6) 12 (26.1) 3 (6.5) 3 (6.5) 3 (6.5) 
(idiopathic) 
Pruritus (liver 1 (100) - - - - -
disease) 
Pruritus (renal 6 (66.7) - 2 (22.2) - 1 (11.1) -
disease) 
"Psoriasiform 13 (6S) 1 (S) 2 (10) - 1 (S) 3 (IS) 
dermatitis" 
Psoriasis 2661 (70.7) 30S (8.1) 104 (2.8) 38(i) 314(8.3) 343 (9.1) 
Scleroderma - - 1 (100) - - -
Seborrhoeic 3 (60) 1 (20) - - - 1 (20) 
dermatitis 
Subcomeal 1 (100) - - - - -
pustular dermatosis 
Symptomatic 2 (SO) 1 (2S) - - 1 (2S) -
dermographism 
Undefined eczemas 4 (66.7) 1 (16.7) - - - 1 (16.7) 
Urticarial vasculitis - - 2 (100) - - -
• I 
Figure 2.18 Courses of TL-01 UVB per year; all centres; since 1986 
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UVB administration 
Dosimetry 
TL-01 UVB dosimetry varied widely between centres (Figure 2.20). Reasons 
for this included: 
1) Different meters, calibrated in different ways 
2) Different methods of using the UVB meter, including 
- various direct methods, in which the, carefully protected, person 
performing the reading measures outputs while in the cubicle. 
- various indirect methods, such as using a meter clamped in the 
centre of the cubicle, or taking readings from individual lamps and using 
mathematical manipulations to provide a whole-cubicle output measure. 
Such variation in what a mJcm-2 of UVB represents in different centres matters 
because: 
1) It makes transfer of patients between centres during treatment difficult to 
arrange safely. This is important as many patients start treatment as an 
inpatient in one unit and continue treatment as an outpatient closer to 
home. Those working in certain individual centres know a few other 
centres where doses are comparable, because of metering by a single 
medical physics department. Ideally, doses should be comparable 
throughout the country. 
2) While 25 mJcm-2 in Centre X is the same as 170 mJcm-2 in Centre Y, to take 
the most extreme example, there are potential problems of over- or under-
treatment if a regimen from one centre is adopted by another if MED-
testing is not performed. 
3) While such variation in dosimetry exists, even in one relatively small 
country with a cohesive dermatology community, the UVB doses in quoted 
in publications must be interpreted cautiously. 
) 
" 
Figure 2.20 UVB lTL-01) dosimetry 
100 mJcm-2 in each of 12 units converted to "Ninewells millijoules" 
UVA dosimetry shown for comparison 
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Starting dose 
The starting dose of UVB (TL-01) was routinely based on the individual 
patient's minimal erythemal dose (MED) in 5 out of 17 centres for which this 
information could be obtained. 
Skin phototype is not a reliable proxy for an individual's erythema response 
to UVB (Rampen et al. 1988). An MED-based starting dose has the advantages 
that: 
1) It prevents patients suffering an erythemal episode following the first 
treatment. 
2) It also excludes an unexpected photodermatosis, for example, MED 
measurement in a patient with psoriasis showed he also had previously 
unsuspected solar urticaria, and a patient with atopic dermatitis was only 
found to be severely photosensitive, with chronic actinic dermatitis, when 
his MED was determined. If MEDs are not routinely determined such 
patients are at risk of disastrous consequences if treated using a "standard" 
dose in a whole-body UVB cubicle. 
3) It takes into account any drug causing increased photosensitivity with 
TL-01 radiation (Cameron et al. 2000a). 
4) It avoids setting the starting dose excessively low for the majority (and so 
impairing treatment effectiveness for them) in order to avoid "burning" in 
a minority. 
In the different centres where the MED was routinely measured, this was 
done in a variety of ways. Irradiation equipment was either a treatment 
cubicle, or separate lamp or lamps. Most used a template with squares that 
-could be closed off to administer the MED doses. It is essential that, 
whichever system is used, the radiometry is the same for the MED irradiation 
apparatus as for the treatment cubicle. 
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Ideally, considering the sigmoid shape of the TL-01-erythema dose response 
curve (Diffey et al. 1991), a geometric series of doses (with each dose being a 
percentage, usually 140%, of the preceding dose) should be used (British 
Photodermatology Group 1992), rather than the simple arithmetic series used 
in some departments. Use of an arithmetic series may result in significant 
under-estimation of some patients' MEDs, and so compromise the 
effectiveness of therapy. 
Figure 2.21 illustrates the trend to more treatments being required to attain 
clearance or minimal residual activity in centres not determining the MED. Of 
course, differences other than policy on MED determination may be 
important confounding variables. For example, in some centres not checking 
each patient's MED, UVB may be perceived as less effective (compared to, for 
example, PUV A) so many UVB patients may be relatively mildly affected 
(perhaps with guttate psoriasis) leading to an under-estimate of the number 
of "extra" treatments needed because MEDs cannot be determined. 
TreahnentjTequency 
In all except one department (which could only offer treatment twice weekly) 
the "standard" treatment frequency was 3x weekly. However, individual 
patients were treated as infrequently as once weekly (only one patient), and 
as often as 7x weekly. Five to seven times weekly regimens were most often 
prescribed for inpatients. The optimum treatment frequency for TL-01 UVB 
for psoriasis (let alone other conditions) is still unknown. For the majority, 3x 
is preferable to 5x weekly treatment, as shown by the study described in 
Chapter 3 (Dawe et al. 1998). Five times a week treatment clears psoriasis only 
slightly more quickly than 3x weekly treatment: for most patients the extra 
erythema episodes, greater number of exposures, and higher UVB dose are 
not worthwhile when clearance only one week quicker can be anticipated. We 
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do not know whether 2x weekly treatment is as effective as 3x weekly 
treatment, and whether treatment frequency is a factor contributing to the 
possible differences between centres shown in Figure 2.22. A randomised, 
observer-blinded trial nearing completion in Dundee compares 2x and 3x 
weekly TL-Ol UVB (Cameron et al. 2000b). 
Figure 2.21 TL-01 UVB treatments per course for 
psoriasis documented as leading to clearancel MRA in 
1996. Treatment in centres basing starting dose on MED or 
not. 
50 
~ 40 ... 
;::I 
0 
u 
... 30 11) Q.. 
~ 
11) 20 ~ 
i!:! 
E-< 10 
0 
(n= 363) 
MED not 
determined 
(n= 536) 
P = 0.023 (Mann-Whitney 
test) 
Difference in medians: 1 
treatment (95% C.I. 0 tn 2) 
1--------1---median (all centres) 
MED routine 
Figure 2.22 TL-01 UVB treatments per course for 
- psoriasis documented as leading to clearancel MRA in 
1996. Treatment given 2x or 3xJ week_ 
(n =20) (n= 879) 
. 
50 I 
~ P = 0.051 (Mann-Whitney 40 test) 
8 Difference in medians: 3 
~ 30 treatments (95% C.I. 0 to 5) Q.. --~-----rJl 1:: 11) ___ median (all centres) ~ 20 
~ 10 
0 
2x1week 3x1week 
treatment treatment 
73 
74 
Dose increments 
Most of the original studies, confirming the efficacy of TL-01 phototherapy for 
psoriasis, used 40% dose increments, reducing to 20% or lower depending on 
each individual patient's erythemal response. Recently it has been shown, in a 
Scottish patient population, that a lower incremental regimen with 20% 
reducing to 10% increments is as effective and leads to significantly fewer 
episodes of well-demarcated erythema (Wainwright et al. 1998). The fact that 
lower increments are appropriate for UVB phototherapy than for PUV A fits 
with the shallower erythema-dose response curve for PUV A compared to 
UVB (Cox et al. 1989). 
The most appropriate incremental regimens for atopic dermatitis, and other 
conditions, still have to be determined. Most treatment units aim to use the 
same regimen as used for psoriasis for atopic dermatitis but, in practice, 
because of erythemal episodes and flare-ups of dermatitis, patients often do 
not tolerate the same increments, and have to be held at the same dose for 
several treatments during a course. 
Adjunctive therapy 
All departments encouraged the use of emollients during a course of 
phototherapy. The majority had no restrictions on emollients except that 
preparations that act as a sunscreen (Lebwohl et al. 1995), and those which 
might contain photosensitising perfumes, were discouraged. Some asked 
patients not to apply an emollient shortly prior to treatment although, as long 
as appropriate preparations, such as 50:50 white soft paraffin/ liquid paraffin 
or aqueous cream, are used this advice may be unnecessary. Consistency is 
most important: no problems should arise if the same emollient is used at the 
same time prior to each treatment of a course. f I 
----------------------------~==== 
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In theory, an appropriate emollient might increase effectiveness of psoriasis 
treatment by reducing refraction of radiation by scale, and so increase the 
UVB dose reaching psoriasis plaques, while not affecting that reaching 
neighbouring normal skin. However, when the clinical effect of using coconut 
oil prior to irradiation was studied it did not lead to more effective psoriasis 
clearance (George et al. 1993b). The preliminary results of a more recent 
study suggested that the application of groundnut oil prior to each TL-01 
exposure might lead to more rapid initial psoriasis clearing. This study did 
not, however, examine the effect, if any, on time and exposures to clearance 
(Hung et al. 1997). Whether or not adjunctive emollients enhance the 
effectiveness of phototherapy, their use makes most psoriasis patients more 
comfortable while attending for treatment, and it is essential that those with 
atopic dermatitis continue frequent emollient use while attending for 
phototherapy. 
Data on use of concomitant topical therapy were sparse in most phototherapy 
notes, but approximately half of courses involved some form of adjunctive 
topical therapy other than emollients: tar preparations, dithranol, 
corticosteroids, or calcipotriol. 
There is no benefit in using adjunctive tar preparations with broad-band UVB 
if a "maximal suberythemogenic" regimen is used (Ie Vine et al. 1979). We do 
not know how concomitant tar therapy affects the effectiveness of TL-01 
phototherapy. Similarly, data is lacking on the effects of adjunctive dithranol, 
corticosteroids, and calcipotriol. A study examining the effect of dithranol 
showed a trend towards benefit from adding dithranol but the study was 
small and these results may have occurred by chance (Storbeck et al. 1993). 
Also the TL-01 regimen used may have been sub-optimal as an unusually low 
starting dose and dose increments were chosen. Calcipotriol plus TL-01 UVB 
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is more effective than calcipotriol alone (Kerscher et al. 1993), but whether it 
is any more effective than TL-01 alone remains undetermined. 
Most centres sometimes used systemic retinoids in combination with TL-01 
UVB (Re-TL-01). Acitretin was the retinoid most frequently used. This 
combination has been shown to reduce exposures and dose to clearance, but 
does not lengthen duration of remission if the retinoid is stopped on 
completion of the UVB course (Green et al. 1992). Fewer than 10 patients in 
Scotland were documented to have received combinations of UVB and 
methotrexate, cyclosporin, azathioprine, or hydroxyurea. There is a concern 
that such combinations may have a synergistic carcinogenic effect similar to 
that with combinations of PUV A and systemic immunosuppressive drugs 
. 
(Fitzsimmons et al. 1983; Bos et al. 1989; van de Kerkhof et al. 1997). 
Stopping treatment 
The comments regarding stopping treatment with PUV A (see Page 55-56) also 
apply here. Although maintenance treatment with broad-band UVB allows 
some patients with psoriasis to remain clear for longer than if it is not used 
(Stern et al. 1986), the extra exposures (with accompanying inconvenience, 
reduction in availability of treatment to others, and probable increased skin 
cancer risk) make it inappropriate for all but the exceptional, difficult-to-
manage patient for whom it may be the least risky of the available 
alternatives. The efficacy of maintenance TL-01 has not been assessed, 
although it has been used for a few patients in Scotland. Sixty-seven recorded 
TL-Ol courses extended beyond 50 treatments. 
It is easy to decide when to stop a course when complete clearance is 
achieved. It is more difficult if a few small, thin plaques remain on shins or 
sacrum (minimal residual activity or "MRA"): generally practice follows' that 
77 
described in the literature, and 4 to 6 1/ extra" treatments are given after MRA 
is reached if clearance is not achieved. The rationale for this is that: 
1) if all courses were stopped at MRA, complete clearance would rarely be 
achieved, and 
2) the extra exposures may help in clearing invisible (Farber et al. 1985; 
Kligman 1991), subclinical psoriasis from apparently normal skin and so 
reduce the risk of rapid relapse. This hypothesis has not yet been tested. 
As with PUV A, some centres have a standard course, often of 20 exposures, 
which has the disadvantage of encouraging over-treatment of some, and 
risking under-treatment of other, patients. 
Between-centre differences 
Figure 2.23 shows the wide variation in number of treatments per course for 
psoriasis. As shown in Figure 2.24, similar differences were still evident if we 
examined only courses completed in 1996 (in case of changes in practice 
within cen.tres during the preceding 5 years). Some of the explanations for 
differences between centres discussed under PUV A (Pages 56-58) apply 
equally to UVB. 
Centre 17 used unusually high numbers of exposures for some patients, but 
(see Figure 2.25) tended to use a lower cumulative UVB dose per course. A 
possible explanation is that the treatment regimen used there was relatively 
ineffective because unusually low doses were used, and that this resulted in 
the need for longer courses to achieve improvement, and a few patients 
required maintenance therapy because they were not completely cleared 
during the initial course. 
Some centres showed the reverse: those with unusually high cumulative UVB 
doses per course compared to number of treatments might be expected to 
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have more patients developing undesirable erythema episodes. This would 
appear to be true for some, but not for all: the exact regimen used, and patient 
selection for treatment, are important. 
There was similar variation between centres in how TL-Ol phototherapy was 
used for atopic dermatitis and for polymorphic light eruption, as illustrated in 
the graphs showing the range of numbers of treatments per course for those 
centres for which this data was available (Figures 2.26 and 2.27). 
Figure 2.23 Whole-body UVB (TL-01) treatments per 
course for psoriasis (1992 -1996) in each centre for which 
data available. Median is central line; box encloses 
interquartile range. 
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Figure 2.24 Whole-body UVB (TL-01) treatments per course for 
psoriasis (1996 only) in each centre for which data available. 
Median is central line; box encloses interquartile range. 
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Figure 2.25 TL-01 UVB dose per course for PSORIASIS ; 
1992 to 1996. Doses all converted to Ninewells Hospital 
mJcrrr2 to allow between-centre comparisons 
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Figure 2.26 Whole-body UVB (TL-01) treatments per course 
for atopic dermatitis (1992 - 1996) in each centre for which 
data available. Median is central line; box encloses 
interquartile range. 
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Figure 2.27 UVB (TL-01) treatments per course for 
polymorphic light eruption (1992 - 1996) in each centre for 
which data available. Median is central line; box encloses 
interquartile range. 
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Cumulative UVB exposures 
Total cumulative TL-Ol exposures for individual patients were being 
documented by all centres so, in years to come, we will have a far better 
record of TL-01 UVB use than we had for broad-band UVB. TL-01 UVB has 
not been available in the centre (Centre 17) in Figure 2.28 with the most high-
exposure patients for as long as it has been in several others. This figure 
illustrates the effects of different ways of using UVB: this particular centre 
tended to give more prolonged courses, and frequently repeated courses, to a 
significant minority of their patients. This may reflect local referral habits: 
perhaps some of these patients would, in another centre, have received 
methotrexate or cydosporin, and the use of prolonged or frequent courses of 
UVB for some such patients may well be preferable. 
How effectively UVB is used may also have an impact on duration of 
remission, and therefore how frequently courses have to be repeated. 
Treatment outcomes 
As for PUV A, meaningful direct between-centre comparisons cannot be made 
because of different patient populations referred for treatment, and wide 
variation in the completeness of records. In some departments, if no record of 
outcome was made this appeared to denote a successful course of UVB, but 
this did not apply in other centres. 
In general TL-01 UVB, as used in everyday practice, is highly effective (Figure 
2.29) for psoriasis. Table 2.6 lists outcome data for other conditions treated 
with TL-01 (and Table 2.5 shows the data for broad-band UVB). 
Figure 2.28 Total cumulative whole-body TL-01 UVB 
treatments per patient for psoriasis in each of 11 centres for 
which data available. Median is central line; box encloses 
interquartile range. 
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Reducing the risk of chronic adverse effects (PUVA and UVB) 
• Methods used to reduce the risk of chronic adverse effects, particularly non-melanoma 
skin cancer, included shielding sites not requiring treatment, as well as improving 
treatment regimens to minimise the number of exposures required to attain clearance. 
Retinoid-PUVA and retinoid-TL-Ol UVB combinations were used for selected patients. 
• All centres attempted follow-up of patients regarded as at especially increased risk, but 
only 2 used a computerised database to aid reliable recall of all patients with defined risk 
factors. 
Precautions before and during therapy 
In order to minimise the risk of chronic adverse effects, particularly non-
melanoma skin cancer, all centres recommended for occasional patients that 
only those sites requiring treatment be treated. Many psoriasis patients do not 
require many treatments to face, and were asked to wear a face-shield (Dawe 
et al. 1996) during treatments. To protect hands not requiring treatment 
gloves were advised. In 1997, other forms of facial photoprotection were still 
used, and included paper-bags, pillow-cases, and topical sunscreens. Some 
patients resist advice to avoid treatment to face, perhaps because the side 
effect of a tan is welcome, but most accept it if the rationale is explained. 
There appeared to be a trend in several centres towards the routine covering 
of unaffected sites during treatment, rather than advising it only for patients 
perceived as at high risk of skin cancer. 
Use of systemic retinoid-PUV A (Re-PUV A) and retinoid-TL-01 UVB (Re-
TL-01) combinations for patients requiring repeated courses, and who tolerate 
retinoid side effects, may reduce cumulative exposures and radiation dose, 
and so reduce long-term risks whether or not the retinoids exert a clinically 
significant anti-neoplastic effect. 
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Follow-up of "at risk" patients 
As the number of patients treated with UVB increases, and PUV A continues 
to be required for many patients (although the proportion who require PUV A 
is falling), some method of identifying" at risk" patients so that they can be 
kept under review is essential. In most departments, follow-up remains 
somewhat haphazard with each individual consultant having different 
methods, or no method, of following up patients regarded as "at risk". Only 
two departments visited had a reliable phototherapy unit database system for 
identifying all those fulfilling selected criteria of "at risk" status, and calling 
them back for annual total skin examination. 
Computer database systems designed to assist follow-up of "at risk" 
phototherapy patients, the "Metasa" system used in Dundee (Russell et al. 
1996), and a database based on Microsoft® "Access" being developed in 
Glasgow and available free to members of the Scottish Dermatological 
Society, should help, and are almost essential for departments treating large 
numbers. 
Some economic considerations 
Estimation of treatment costs is difficult (Sander et al. 1993). Much of the data 
required for accurate calculation of costs is not routinely collected, and it is 
difficult to separate the costs of UVB and PUV A from other costs in a 
dermatology or physiotherapy phototherapy unit. It is important to consider 
-
information on treatment outcomes along with cost per course of treatment 
(Arikian et al. 1994): a centre with inadequate equipment and relatively 
untrained staff might have a low cost per individual treatment yet a high cost 
per effective treatment course. 
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Patient selection for phototherapy and patterns of use of other, alternative 
therapies, vary from centre to centre so an attempt to directly compare 
phototherapy treatment costs between centres is likely to be unhelpful and, if 
carelessly interpreted, harmful. The administration of phototherapy and 
PUV A involves medical staff time (including initial assessment and 
prescription of treatment, assessment of patients with complications during 
treatment, and follow-up) and secretarial time if general practitioners are to 
be kept informed and good records, essential for follow-up, are to be kept. 
Medical physics involvement is also essential to ensure satisfactory 
dosimetry. These costs have not been included in the calculations below3 
because reliable information on number of hours of medical, secretarial, and 
medical physics input into each course of treatment could not be readily 
obtained. An attempt was made to estimate treatment costs in 1996 for three 
centres with particularly detailed documentation on treatment course 
outcomes (Table 2.7). 
It is reassuring to note that these figures are not markedly different from 
previous estimates of treatment costs - PUV A for 1 year at £560 and UVB and 
tar-baths (not necessary with an optimal TL-01 UVB regimen) at £2.22 for a 6 
week course. (Cork 1993) 
3 Cost per course of UVB or UVA phototherapy ("COST") = (S + 0 + L) + yearly number of 
therapy courses 
S= yearly nursing staff salary costs (each phototherapy nurse's salary multiplied by 
. the proportion of working hours devoted to phototherapy or PUVA) 
0= "overhead" costs - hospital management's cost per m-2 for lighting, heating and 
cleaning 
L= estimated cost per year for replacement lamps + cost for UVB and UVA cubicles' 
(at current prices, and assuming 15 years between replacements) 
UVB course cost = COST x (number of UVB courses in year + total number UVB and UVA 
courses) 
PUVA course cost = [COST x (number of UVA courses in year + total number UVB and 
UVA courses)] + £120 per course to cover oral psoralens and protective spectacles 
Cost per effective course (for psoriasis): PUVA course cost or UVB course cost 
. (as appropriate) x (number of courses for psoriasis that year + number of courses 
for psoriasis in that centre leading to clearancel MRA) 
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These absolute figures should be interpreted with caution, particularly 
considering the costs omitted from the calculations used. However, 
consideration of the factors leading to the cost differences here may be useful. 
As could be anticipated, costs in a large teaching hospital unit with a high 
throughput of phototherapy patients (Centre X) were lower than those for a 
smaller unit, treating fewer patients (Centre Y). We should, however, keep in 
mind that these apparently higher costs in a small unit ignore: 1) patient 
travel expenses and costs resulting from time away from work if patients had 
to travel further to a larger unit, and 2) the fact that the alternative treatments 
available to most Centre Y patients would be either inpatient treatment or 
more toxic (and expensive) systemic therapy rather than travel to a larger 
unit. 
Centre Z showed a particularly high cost per effective course of PUV A. There 
are many possible explanations: perhaps most important is that few patients 
were treated with PUV A in this unit and those who were referred for PUV A 
tended to have especially severe disease for which other therapies, including 
UVB, had proved disappointing. 
Another point for consideration is the markedly higher cost per effective 
course compared to cost for any UVB course in Centre Y. Although factors 
such as patient selection are relevant, use of phototherapy in this unit may not 
have been as effective as in some other units. Improvement in the 
phototherapy regimen used would involve more resources, for equipment as 
well as staff education, but it is possible that such resources used now could, 
in time, free up NBS resour~es for other uses, and allow more patients to .' 
benefit from phototherapy, so avoiding the need for messier and more time-
consuming or toxic treatments. 
When discussing cost implications it is important to consider cost savings 
through the effective use of phototherapy and PUV A: 
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1) Direct savings - avoidance of the costs of alternative inpatient topical 
treatments and systemic therapies; and 
2) Indirect savings:" reduction in working hours lost through effective control 
of handicapping conditions such as psoriasis and at<?pic dermatitis. 
A more comprehensive economic assessment of UVB phototherapy and 
PUV A than was within the scope of this survey would be of interest. 
Table 2.7 
Cost per course 
PUVA 
Centre x. £53 £173 
Centre Y. £108 £228 
Centre z. £56 £176 
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Cost per effective course 
for psoriasis 
PUVA 
£60 £203 
£174 £384 
£65 £317 
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Physiotherapy department phototherapy units 
• 21 NHS physiotherapy departments provide phototherapy. In all but 4 of these 
departments there has been a decline in the number of phototherapy courses administered 
each year over the past few years. 
• 19 departments have outdated phototherapy equipment. 
• Although some physiotherapists remain enthusiastic about their role in phototherapy 
many feel that, because of their other commitments and a decline in referrals for 
physiotherapy phototherapy, they cannot keep sufficiently up to date with new 
developments in phototherapy. 
• Except in geographically remote areas most phototherapy is now administered by 
phototherapy nurses working in dermatology department-run phototherapy units rather 
than by physiotherapists. 
There are 21 National Health Service physiotherapy depamnent-run 
phototherapy units. In all but 4 of these (3 of which worked closely with the 
local dermatology department) there was a decline in the number of 
phototherapy courses administered each year. Exact numbers cannot be given 
because they could only be obtained for a few centres. Physiotherapy 
phototherapy records tended to be kept in the main hospital notes, or with 
other physiotherapy records, and so unobtainable for this survey. 
One physiotherapy department provided a PUV A, as well as phototherapy, 
service and another had equipment for PUV A but had not yet started to 
administer it. 
Conditions treated 
Conditions treated, in order of frequency according to estimates of numbers 
. treated given by phys~otherapists, and those notes which were examined, 
were: 
Psoriasis (particularly guttate psoriasis) 
Acne vulgaris 
Atopic dermatitis 
Polymorphic light eruption 
Alopecia areata 
Legukers 
Pityriasis lichenoides chronica 
Physical urticarias (mainly symptomatic dermographism) 
Aquagenic pruritus 
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Some, physiotherapists expressed frustration at being asked to treat alopecia 
areata with UVB (as they perceived the treatment to be ineffective). Others 
commented on their concern that phototherapy for acne, as customarily 
administered by many physiotherapists, involves giving starting UVB doses 2 
to 3-times the minimal erythemal dose and so causing discomfort for, in many 
patients, limited benefit. 
Equipment 
The phototherapy equipment in most physiotherapy departments was 
outdated (Figure 2.30). The Theraktin tunnels in use were fitted with 4 broad-
band (TL-12) lamps and 2 infra-red lamps. The Hanau original was a quartz 
lamp point source that emits a broad spectrum of UVC, UVB and UV A 
wavelengths. The Kromayer mercury lamp was often used without filters as a 
UVC -II germicidal" source. The Alpine sunlamp was a high pressure mercury 
vapour arc-lamp. 
Only 3 physiotherapy departments had modern stand-up irradiation cubicles 
(to allow whole body treatment, with short treatment times), and only two of 
these were fitted with narrow-band (TL-Ol) UVB lamps. 
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Phototherapy methodology 
The majority of physiotherapists were familiar with minimal erythemal dose 
determination. Half routinely, and 80% sometimes, used a MED-based UVB 
starting dose. For psoriasis, 2x or 3x weekly UVB was usual. All the 
physiotherapy phototherapy units limited routine courses to less than 25 
treatments, with treatment stopped on clearance or after a set number of 
treatments. Follow-up was usually in the referring doctor's clinic, with no 
physiotherapy department arrangements to ensure long-term follow-up of 
#high-exposure" patients. 
General impressions - physiotherapy phototherapy units 
Some physiotherapists remained enthusiastic about their role in 
phototherapy, but many expressed the opinion that they have so many other 
duties, which comprise a much greater proportion of their workload, that 
they cannot keep adequately up to date with developments in phototherapy. 
In most areas, the exceptions being in places remote from the #local" 
dermatology unit, most phototherapy is now administered by phototherapy 
nurses in dermatology unit-run departments, leading to few referrals to the 
remaining physiotherapy phototherapy units. As phototherapy is 
increasingly used, often with other treatments prescribed by dermatologists 
and administered by dermatology nurses, this decline in physiotherapy 
phototherapy will probably continue. The problem of providing a modem, 
optimally effective and safe phototherapy service to those who live far from 
their closest dermatology department awaits a solution. In some regions the 
solution may be a carefully supervised home phototherapy service run by a 
dermatology unit. 
Figure 2.30 Physiotherapy phototherapy unit equipment 
Two departments 
havePUVA 
facilities - currently 
in use in one 
----- -------Hanau G 
Kromayer lamp (3) original (1) 
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Concluding comment, Chapter 2 
Following the 1991 audit, there have been great improvements in the PUV A 
service in Scotland. In particular, PUV A use is now more selective, aided by 
the availability in most centres now of UVB phototherapy as a more 
convenient and safer alternative. Various improvements could still be made: 
not all centres yet base the UV A starting dose on minimal phototoxic dose 
assessment, for example. However, the major deficiency in the PUV A service, 
is the lack of a reliable system in all centres to identify and follow-up patients 
at risk of skin cancer development as a consequence of therapy. 
As regards UVB phototherapy, the 1996/1997 survey has of necessity been 
largely descriptive. Although, in Chapter 6, recommendations for UVB 
phototherapy are given, many of these are based on limited evidence, as there 
remain many aspects of UVB phototherapy methodology that require proper 
study, with well designed clinical trials. Original research designed to expand 
the evidence base on which we can make recommendations is contained in 
the following three chapters of this thesis. 
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Chapter 3 
A new development discussed in Chapter 1 was the introduction of narrow-band 
(TL-01) UVB phototherapy. One of the findings of the survey phase of the Scottish 
phototherapy and PUVA audit (described in Chapter 2) was that, since 1991, broad-
band UVB lamps have been replaced by TL-01 lamps in almost all dermatology 
phototherapy units. This chapter consists of a meta-analysis of the published 
controlled studies comparing this new therapy with broad-band UVB for chronic 
plaque psoriasis, the most frequent indication for UVB phototherapy. 
Summary of meta-analysis of studies comparing narrow-band (TL-Ol) with broad-
band ultraviolet B for psoriasis 
Since narrow-band (TL-Ol lamp) UVB phototherapy was introduced in 1984, 13 small 
comparative studies have reported that it is a superior psoriasis treatment to broad-
band UVB. It is now widely used, but it has not replaced broad-band UVB 
everywhere. Should those centres still using broad-band UVB change? To answer 
this we need to know not just that TL-Ol is more effective, but how much more 
effective it is. 
A literature search (electronic database and manual, including search terms in 
English and German) revealed 20 published (2 as abstract only) clinical studies 
addressing the relative efficacy of TL-Ol compared with broad-band UVB. Fourteen 
were controlled or quasi-controlled (2 with historical controls) studies. Six open 
studies were excluded. The controlled studies included 9 with a within-patient, 
paired design. Five studies were randomised or quasi-randomised (randomised by 
birth date, or method not described). . 
The main comparable end-points (observer assessed "better treatment" on pairwise 
comparison, complete clearance, remission at 1 year) varied. The odds ratio, with 
95% confidence interval, for achievement of a better outcome with TIrOl than with 
broad-band UVB was calculated for each of the 13 studies including sufficient data to 
allow this. Using a fixed effects model, the combined odds ratio favouring TL-Olfor 
all these studies (comprising data from 455 subjects) was 9.1 (95% 4.3 to 19.4). 
Sensitivity analysis included re-analysis with a random effects model, and separate 
analyses of selected studies judged to be of better methodological quality (within-
patient paired studies and randomised studies) and those just examining an end-
point of particular interest (odds of achieving clearance versus not clearing). The 
findings of all analyses were similar, suggesting that, despite the heterogeneity in 
study design and comparable end-points, the overall conclusion that TL-Ol is 
significantly more effective than broad-band UVB is robust. 
H in a population treated with broad-band UVB we expect a good outcome in 60%, 
and we conservatively take the lower end of the summary odds ratio (4.3) as 
reflecting the "true" figure, the number needed to treat to see one extra good 
outcome is just 5. This magnitude of greater benefit with TIrOl suggests that, unless 
we believe it is safer (for which there is no evidence), the use of broad-band UVB for 
psoriasis is no longer appropriate. . 
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A meta-analysis of controlled studies comparing the efficacy of PUVA and 
TL-Ol UVB for psoriasis 
Every dermatology department phototherapy unit in Scotland offers narrow-
band (TL-01) UVB phototherapy. At the time of visiting the departments for 
the survey described in the last chapter, one department still also used broad-
band UVB. That department had one TL-01 UVB cubicle, and two broad-band 
UVB cubicles. 
Most UVB courses in Scotland are administered using TL-Ollamps. However, 
broad-band UVB is still used in one dermatology phototherapy unit, and 
most physiotherapy phototherapy units, in Scotland. In other countries, 
broad-band UVB remains frequently used, and in some regions is the only 
form of UVB available. It is therefore important to know whether TL-01 UVB 
is more effective than broad-band UVB, and if it is to know how much more 
effective. Is narrow-band UVB sufficiently more effective than broad-band 
UVB that we should recommend a change of lamps and treatment regimens 
to the centres where broad-band UVB is still used? 
Meta-analysis methodology 
Search strategy 
Articles comparing narrow-band (TL-Ol) UVB and broad UVB to treat 
psoriasis were identified as those previously known to us, those identified in 
a review of narrow-band UVB (Bilsland et al. 1997), and by search of 
EMBASE® (Elsevier Science, Amsterdam) and MEDLINE® (National Library 
of Medicine, Bethesda) using Ovid search software, version 7.8 (Ovid 
Technologies Inc, 1988). Search terms (subject headings and key-words) 
included "psoriasis" AND ["phototherapy" OR "ultraviolet radiation" (in 
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EMBASE®) OR "ultraviolet rays" (in MEDLINE®). To narrow the search, key-
word search terms combined with these previous terms included: "narrow-
band" OR "TL-Ol" OR "311nm" OR "311-313nm" OR "312nm" OR 
"Schmalspektrum". Some publications described more than one separate 
study. 
Study inclusion criteria 
All controlled studies comparing TL-01 UVB with broad-band UVB sources to 
treat psoriasis, and reported in sufficient detail to allow calculation of an odds 
ratio for an important comparable end-point, were included. Studies 
concerning TL-01 UVB for psoriasis that were excluded were: 1) open studies, 
2) studies comparing different adjuncts to TL-01 phototherapy, and 3) studies 
designed to compare different ways of administering TL-01 therapy. We 
chose not to use any arbitrary quality rating scales, because of concern that 
this could itself be a source of bias (Detsky et al. 1992), and instead 
documented important features of study design to allow these to be openly 
taken into account when interpreting the findings. 
For this meta-analysis all controlled trials, whether randomised or not, were 
included. Systematic reviews comparing treatments published by the 
Cochrane collaboration usually exclude studies that are not identified as 
randomised controlled trials. This is because most studies that do not use 
random allocation to decide who gets which treatment are more likely to be 
affected by treatment allocation bias. 
When different study subjects receive each treatment, avoidance of such bias, 
which can lead to spurious results caused by systematic differences between 
the subjects who get treatment A and those who receive treatment B, is 
essential. In the comparison of phototherapy treatment regimens for psoriasis 
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it is possible to compare two treatments at the same time within the same 
subjects. With this type of study, the risk of allocation bias influencing study 
results is less than in studies involving between (rather than within) subject 
comparisons. Therefore, although in paired, within-subject comparison 
studies, randomisation can usefully aid observer masking to treatment 
allocation (and lack of observer masking is a potential source of bias in 
assessment of treatment effects) it is not as essential as in the more frequent 
between-subject comparison studies considered by the Cochrane 
collaboration in their insistence on randomised controlled studies. 
Analysis 
For each study, the most readily comparable end-point of treatment, 
assessable on an intention-to-treat basis, was identified. To calculate odds 
ratios (ORs) and 95% confidence intervals for the paired (within-patient and 
-
cross-over) studies, the methods of Morris and Gardner, (Morris & Gardner 
1989) with reference to standard tables for the binomial distribution, (Lentner 
1982b) were used. Standard formulae were used to calculate these for the 
unpaired studies (Armitage et al. 1994). To permit odds ratio calculation for 
studies with no events in a cell of the 2x2 contingency table used for analysis, 
a small sample correction was made by adding 0.5 to each cell. The data were 
examined and, in the absence of significant heterogeneity, a fixed effects 
model odds ratio meta-analysis conducted and forest plot drawn using the 
macro written by Sharp and Sterne (Sharp & Sterne 1997) for "Stata" statistical 
software (Intercooled Stata, Release 6.0, College Station, Texas;' 1999). 
Sensitivity analysis was performed by repeating analysis using a random 
effects model, and by separate analyses examining just those studies in which 
the comparable end-point was clearance or minimal residual psoriasis versus 
not cleared, and also examining just those judged to be of greatest 
. methodological quality (half-body paired studies, randomised, and masked 
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studies). To aid interpretation of the clinical importance of odds ratios shown 
on the forest plot, corresponding numbers needed to treat (NNTs) were 
indirectly calculated from the odds ratios (Sackett et al. 2000). 
Results of broad-band UVB versus TL-Ol UVB meta-analysis 
Fourteen controlled studies comparing TL-Ol and broad-band UVB 
phototherapy for psoriasis, reported in 10 papers (van Weelden et al. 1984, 
van Weelden et al. 1988; Green et al. 1988; Larko 1989; Karvonen et al. 1989; 
Barth et al. 1990; Picot et al. 1992a; Storbeck et al. 1993; Hofmann et al. 1997; 
Coven et al. 1997; Walters et al. 1999), were identified (Table 3.1). All but one 
of these studies were included. This one (Hofmann et al. 1997) was excluded 
because of insufficient data provided to calculate an odds ratio for clearance 
or similar end-point. This was an 11 patient, randomised, within-patient 
paired comparison of TL-01 and broad-band UVB, both with adjunctive coal 
tar solution. Although initial clearing (during first 3 weeks) was faster with 
TL-Ol in 2 patients, complete clearing was achieved equally quickly with both 
treatments, and there was no detectable difference in remission duration .. 
For two half-body paired studies, reported in an abstract only (van Weelden 
et al. 1984), odds ratios were based on extrapolated numbers of subjects 
clearing with TL-01 and with broad-band UVB. These extrapolations were 
based on assuming that the probability reported as "P<0.05" in favour of 
TL-Ol was in fact P=0.05, so may have under-estimated the true odds ratio in 
favour of TL-01. 
Six reports of TL-01 for psoriasis were excluded because they were not 
controlled studies (Picot et al. 1992b; Alora et al. 1997; Wishart 1998; de Rie et 
al. 1998; Gupta et al. 1999; Carrozza et al. 2000). A further eleven controlled 
studies were identified, but were not comparisons of TL-Ol and broad-band 
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UVB: 5 were studies of adjunctive therapies (George et al. 1993b; Kerscher et 
al. 1993; Calzavara-Pinton 1998; Brands et al. 1999; Behrens et al. 2000), three 
compared TL-01 with PUV A (Van Weelden et al. 1990; Green et al. 1992; 
Tanew et al. 1999; Gordon et al. 1999), and three compared different TL-01 
administration regimens (Dawe et al. 1998; Hofer et al. 1998; Wainwright et al. 
1998). 
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Table 3.1 Controlled studies comparing TL-01 with broad-band UVB phototherapy for psoriasis 
Number of subjects 
Study Controls Randomized? Masking? Pattern of Adjunctive Main comparable 
(1st author & psoriasis therapy TL-01 Broad-band end-point 
year) 
Van Weelden, Crossover No No Not stated Not recorded 8 8 "better treatment" as 
1984 (historical assessed by observer 
controls) 
Van Weelden, Within patient Not stated Not stated Not stated Not recorded 9 9 "better treatment" as 
1984 paired assessed by observer 
Van Weelden, Within patient Yes (method Observer- "Widespread" Salicylic acid 10 10 "better treatment" as 
1988 paired unclear) masked ointment assessed by observer 
after 10 treatments 
Green,1988 Historical controls No No Chronic plaque Emollients 52 25 Remission at 1 year 
and "extensive" 
(>20% body 
surface) guttate 
Larko,1989 Within patient No Not stated "Extensive" None 29 29 Patient preference 
paired (average 57% body 
surface) 
Karvonen, Within patient No Not stated Chronic plaque Dithranol 20 20 "better treatment" as 
1989 paired assessed by observer 
Karvonen, Contemporary, Yes (by birth-date) Not stated Chronic plaque Dithranol 17 23 "good result" after 12 
1989 unpaired treatments 
Picot, 1989a Contemporary, Yes (method Double- Chronic plaque Salicylic acid 15 15 Patient preference 
unpaired unclear) masked and guttate ointment after 20 treatments 
Barth,199O Within patient No Not stated Exanthematic Salicylic acid 22 22 Complete clearance 
paired (guttate) ointment-
Storbeck,1993 Within patient Yes (method Observer- Chronic plaque Salicylic acid/ 10 10 One side better 
paired unclear) masked emollients 
Storbeck,1993 Within patient Yes (method Observer- Chronic plaque Dithranol 13 13 One side better 
paired unclear) masked 
Coven,1997 Within patient No No Chronic plaque Coal tar 22 22 "better treatment" as 
paired (below waist) assessed by observer 
after 20 treatments 
Walters, 1999 Within patient No Observer- Chronic plaque Emollients 11 , 11 Oearance by 18 , , 
paired masked , treatments , 
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The fourteen controlled (13 included in combined analysis, 1 not) studies are 
summarised in Table 3.1. It should be noted that although I have considered 
the first van Weelden, 1984 study (one of two studies reported in the one 
abstract) to be controlled, the controls were historical, but were the same 
patients. The control group used in study by Green et al (Green et al. 1988), in 
the early stages of investigation of TL-01 for psoriasis, was a population of 
unmatched patients who previously attended the same unit. 
Nine studies were of a within-patient paired (comparing TL-01 to one body-
half with broad-band UVB to the other half) design. Such a design lends 
power to the study, allowing for careful controlling of any potential 
confounding factors. Lack of randomisation (a potential flaw with 7 of these 
paired studies) is likely to matter less than in unpaired studies. Some studies 
looked at several outcomes but some, for example number of treatments to 
clearance, could not be compared across all studies. 
All the studies showed Tl-01 to be more effective than broad-band UVB 
(Figure 3.1), although the 95% confidence interval for all but three included 
the possibility that there might be no difference or that broad-band UVB 
might be slightly better. It should be noted that the method of calculating 
confidence intervals used for paired studies was a conservative method based 
only on the sample size of discordant pairs (patients better on one side than 
another). While this is intuitively appropriate for those studies in which the 
end-point was direct comparison of sides and decision about which was 
better, it seems less appropriate for the studies with end-point of clearance 
assessed independently. 
Despite the differences in study design and end-points, it is clear that every 
study points towards TL-01 being more effective, with the summary odds 
ratio for all studies being 9.1 (95% C.1. 4.3 to 19.4). If in a population treated 
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Figure 3.1 Odds ratio (and 95% confick!n:e intervals) for all 13 controlled studies. To assist with clinical 
inteIpretation of the odd; ratios, corresponding numbers reeded to treat (NNfs) are srown, based onasstuning the 
pitients' expected event rate (PEER) [the number expected to clear if using broad-band UVB] is 60 % or 85 %. 
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with broad-band UVB, we expect to see a good outcome in 60%, then the 
lower end of this confidence interval corresponds to a need to treat just 5 
patients with TL-01 instead of broad-band UVB to see 1 extra good outcome. 
The results of these studies, including a total of 455 subjects, are shown in 
Figure 3.1. Despite variations in study methodology, treatment regimens and 
outcomes investigated the results of all the studies are very similar. As 
expected from this, re-calculation of the summary odds ratio using a random 
effects model produced identical results. 
Examination of the odds ratios for the studies of better methodological quality 
(within-patient paired, randomised and observer masked as to treatment 
allocation) produced similar summary results, as did examination just of the 
studies for which odds ratios for the end-point of clearance could be 
calculated (Figure 3.2). The most frequent study end-point on which sufficient 
data was provided to allow calculation of odds ratios was assessment of 
treatments after a pre-decided number of exposures (Table 3.1), following 
which patients were offered the better treatment to whole body. The data 
from these studies does not therefore include numbers of subjects clearing 
completely, although it is probably reasonable to assume that the better 
treatment at pre-determined study end-points of 10 (van Weelden et al. 1988), 
12 (Karvonen et al. 1989), 18 (Walters et al. 1999), or 20 treatments (picot et al. 
1992b; Coven et al. 1997) is also the treatment that will clear more patients. 
The most frequent pattern of psoriasis studied was chronic plaque psoriasis, 
but the one study that recruited only guttate (exanthematous) pattern 
psoriasis patients showed a similar advantage in using TL-01 to the others 
(Barth et al. 1990). The majority of subjects included were of skin phototypes I 
to III but in one study 10 of 22 subjects were of skin phototypes V or VI 
(Coven et al. 1997). 
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F igur e 3.2 Odds ratio (and 95 % confidence intervals) for all controlled studies, paired half-body studies, 
all randomized studies, studies with observer masking to treatment allocation, and studies in which 
comparable outcome was cleared versus not cleared (rather than other end-points in Table 1). 
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What can we conclude from this? 
This review of the published studies comparing Tl-Ol UVB with broad-band 
UVB supports the conclusion, expressed by the authors of all but one relevant 
controlled trial (Hofmann et al. 1997), that TL-01 UVB is more effective than 
broad-band UVB. The main value of this quantitative review is that it gives a 
more precise estimate of the degree of magnitude by which TL-01 is more 
effective than broad-band lamps. If we look at all the comparable studies 
together, and conservatively look at the lower end of the odds ratio for a 
better response to TL-01, we can convert this into a number needed to treat (to 
see ~ne better outcome through using TL-01 rather than broad-band UVB) of 
5 if we assume we can get a good response in 60% of those treated with 
broad-band UVB. Even if we optimistically assume that 85% will reach 
clearance (or other favourable response) with broad-band UVB, we need to 
treat 11 or fewer with TL-01 to get an extra good outcome. 
How reliab~e are the findings of this review? We need to consider the 
possibility of missed studies (most likely unpublished, but possibly published 
in non-European languages or in non-indexed journals) that showed 
important different findings. Also, shortcomings in design could be found in 
all the studies we examined, and the outcome measures were mixed. 
We cannot rule out the possibility of missed unpublished studies, but the 
community of clinical photo-dermatology researchers is relatively small, and 
it seems unlikely thatwe could be unaware of sufficient unpublished studies, 
with . different results from those reviewed, for publication bias to have 
significantly affected our overall findings. One smaIl, but otherwise well-
designed, . study did have to be excluded (Hofmann et aI. 1997) because it 
concentrated ~y on examining the end-point of rate of clearing, and 
insufficient information was published to allow comparable odds ratios to be 
calculated. This paired study, comparing 5x weekly regimens, with arbitrary 
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starting doses followed by 20-50% increments, with adjunctive coal tar 
solution to each side, found no statistically significant differences between the 
therapies. They may have been treating a group of patients likely to respond 
particularly well to any form of UVB: 7 of 11 patients had guttate psoriasis 
(although 5 were described as also having plaques). 
Despite imperfections in study design, and in particular the fact that all were 
small, 146 patients (292 subjects) participated in paired within-patient 
controlled studies, the results of which are likely to be more reliable than 
those of the unpaired studies. The fact that we found no differences in 
direction, nor major differences in magnitude, of effect when comparing 
results from different study designs is reassuring. 
Although different outcomes were compared, they can all be considered as 
one binary outcome measure: good response versus relatively poor response. 
Relatively few subjects (64) were included in studies in which patients were 
continued ~n study treatment until clearance (rather than comparing 
treatments until a previously chosen end-point short of clearance with both 
therapies, and then withdrawing from study), but the summary results 
(Figure 3.2) are similar to those from analysing all included-study patients. It 
would have been of interest to compare end-points other than a simple better-
or-not outcome between studies, but most did not include sufficient data on 
continuous variables such as treatments or days to clearance. 
The findings of this review apply m~in1y to moderately severe and severe 
chronic plaque psoriasis, but the one study just involving those with guttate 
psoriasis showed a similar magnitude of benefit of TL-Ol over broad-band 
VVB. In that study the end-point was complete clearance, rather than 
clearance or minimal residual activity (trace disease) which are more realistic 
end-points to examine when treating chronic plaque psoriasis. We found no 
suggestion that TL-Ol is any less advantageous compared to broad-band UVB 
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in patients of high skin photo-types (SITs), but the majority of included 
subjects were of photo-types I to III, so we cannot confidently extrapolate our 
summary findings to SIT IV to VI patient populations. 
Narrow-band (TL-01) UVB is more effective than broad-band UVB for 
moderately severely and severely affected skin photo-type I to III chronic 
plaque psoriasis patients. It remains possible that for patients with less severe 
psoriasis than included in these studies the difference in efficacy is less 
marked, but there are indications that even for the usually readily treatment-
responsive guttate psoriasis (Barth et al. 1990) TL-01 is to be preferred. The 
magnitude of greater benefit is such that, on efficacy grounds, the use of 
broad-band UVB for psoriasis is hard to justify. 
A concern about any new phototherapy lamps relates to the risk it will cause 
skin cancers. As mentioned in Chapter 1, psoralen-UV A photochemotherapy 
carries an increased risk of non-melanoma skin cancer development (Stern et 
al' 1998), ~d there is a suggestion that it possibly also increases the risk of 
later development of melanoma (Stern et al. 1997). The risks associated with 
UVB lamps (broad-band or narrow-band) have not been so carefully studied, 
but appear to be significantly lower (Studniberg et al. 1993; Stern et al. 1994; 
de Gruijl 1996). In the absence of long-term follow-up data for TL-01 UVB, 
which has only been used for just over 15 years, the relative skin cancer risks 
associated with this lamp compared to broad-band UVB lamps remain 
unclear, but the best current evidence suggests the risks are likely to be less 
with TL-01 (Young 1995). 
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What is the evidence for use of TL-Ol for other dermatoses previously treated 
with broad-band UVB? 
As shown in the list of indications for TL-01 recorded during the Scottish 
phototherapy audit (Table 2.7, Chapter 2), TL-01 phototherapy is used for 
many indications, including all those previously treated with broad-band 
UVB. For all these indications other than psoriasis we lack any controlled trial 
data comparing broad-band and TL-01 lamps. 
Controlled trials comparing TL-01 with PUV A for atopic dermatitis and 
polymorphic light eruption (PLE) (Bilsland et al. 1993; Der-Petrossian et aI. 
2000) have been published. A previous study showed PUV A to be more 
effective than broad-band UVB as a prophylactic treatment for PLE (Murphy 
et aI. 1987), and by extrapolation we can conclude that TL-01 is likely to be 
more effec~ve than broad-band UVB. The controlled trial comparison of 
TL-01 and PUV A for atopic dermatitis was small, and could not exclude a 
moderate difference in efficacy of the two treatments. However, if we take the 
practical problems of PUV A administration and its adverse effects into 
account, the conclusion is that TL-01 should be used in preference to PUV A 
for atopic dermatitis. Clinical experience and open studies are supportive of 
the use of TL-01 phototherapy for many other conditions previously treated 
with broad-band UVB, for example patch-stage mycosis fungoides (Clark et 
aI.2000) . 
. As psoriasis is the major indication for phototherapy, accounting for over 80% 
of broad-band UVB courses administered (Figure 2.17, Chapter 2), a change 
over to TL-Ot" lamps on the basis of comparative studies for this indication is 
easy to justify ~ 
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For most of the other UVB indications, clear evidence for efficacy of any form 
of UVB is limited, and, except for pityriasis rosea (Arndt et al. 1983), 
controlled trial data alt<:>gether lacking. Although careful, but uncontrolled, 
observations of outcomes of broad-band UVB phototherapy for acne vulgaris 
(Mills et al. 1978) suggested that it was ineffective or, at best, led to a minimal 
improvement it remains widely used, and it accounted for 1 % of UVB courses 
recorded for the Scottish phototherapy audit (Chapter 2). It is possible, 
although unproven, that it can be effective if administered with 2 to 3x 
minimal erythemal dose starting doses intended to cause erythema and 
desquamation. Such treatment, most readily applied· with the more 
erythemogenic broad-band UVB lamps, is rarely if ever warranted now that 
more effective treatments are available, so a comparative trial of narrow-band 
and broad-band UVB for acne would be inappropriate. Acne vulgaris is 
however one of the many conditions for which we require more evidence on 
the efficacy of TL-01 UVB compared to other established treatments. 
Conclusion to meta-analysis of studies comparing TL-Ol with broad-band 
UVB for psoriasis 
Narrow-band (TL:"01) UVB is a more effective treatment for psoriasis, at least 
for chronic plaque psoriasis in skin photo-type I to III patients, than is broad-
band UVB. More work is needed to further refine how we use it for psoriasis, 
and to decide its place in the therapy of the many other conditions for which 
it is used. Only continued careful foll~w-up will let us know whether or not it 
is associated with an increased risk of skin cancer. 
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Comment 
This chapter has described a systematic, quantitative review of previous 
studies addressing an important question concerning phototherapy 
methodology. Although assessment of the reviewed studies individually, 
without an attempt to combine and summarise their findings, would have 
strongly suggested that TL-01 UVB is more effective than broad-band UVB for 
psoriasis (the most frequent phototherapy indication) none of these studies 
individually could give a reasonable idea as to the magnitude of difference in 
efficacy between these different UVB phototherapy lamps. Also, this review 
allowed assessment of the effects of including and excluding studies with 
different designs (and possible flaws), with the finding that our overall 
conclusions about the treatments' comparative efficacy remained the same 
when we examined only the studies considered of better methodological 
quality than the others. 
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Chapter 4 
An important aspect of plwtotherapy methodology is treatment frequency. This chapter 
describes a study designed to determine the optimal treatment frequency for TL-Ol 
ultraviolet B plwtotherapy of chronic plaque psoriasis in a skin plwtotype I to III 
population. 
Summary of a randomised controlled trial of three times weekly and five times 
weekly TL-Ol UVB phototherapy for chronic plaque psoriasis 
We planned to compare the efficacy of three- and five- times weekly narrow-band TL-
01 (311-313nm) ultraviolet B (UVB) phototherapy regimens for chronic plaque 
psoriasis. 
A randomised, observer-blinded, half body, within-patient paired study in the 
phototherapy unit in a university hospital was conducted. 
Twenty-one patients with chronic plaque psoriasis (13 men, 8 women; age range 21 to 
68; skin phototypes I [2 patients], II [14] and III [5]) entered the study. Sixteen reached 
clearance or minimal residual activity (MRA) on both sides. Of the other 5; three 
withdrew because they did not reach clearance or MRA on the 5x weekly side by a 
maximum of 30 treatments, one when he was satisfied with moderate improvement 
and one because of repeated failure to attend. 
The main outcome measures were number of exposures, cumulative dose and time to 
achieve psoriasis clearance. Also analysed were change in scaling, erythema and 
induration scores over the study period for all patients who entered the study, 
analysed on an intention to treat basis, and the frequency of adverse effects with each 
regimen. 
Those who completed treatment reached clearance or MRA after a median of 35 days 
with 5x weekly treatment compared to 40 days with 3x weekly treatment (P=O.OO7), but 
required a median of 23.5 compared to 17 UVB exposures (P=O.OOl) and 94 minimal 
erythemal dose multiples (MEDs) compared to 65 MEDs (p=0.015). Fifteen (out of 16) 
developed at least one episode of well-demarcated erythema during 5x weekly 
treatment compared to just 3/16 treated 3x weekly (P<O.OOl). There was no significant 
difference between regimens in duration of remission. 
In conclusion, for this skin phototype I to ill population, the slightly more rapid 
clearance of psoriasis with 5x weekly phototherapy is not, for the majority of patients, 
sufficient to justify the extra exposures. 
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Introduction 
In making phototherapy as effective and safe as possible, choice of lamp (as 
discussed in the previous chapter) is probably the most important factor. But 
other factors expected to influence efficacy and safety relate to how we use 
these lamps. An important aspect of UVB phototherapy methodology, and in 
the administration of any treatment for that matter, is the frequency of 
treatment. 
Frequency of UVB treatment for psoriasis 
In Scotland (Chapter 2, page 76), as in the UK as a whole (Dootson et al. 1994), 
UVB (all sources) is most frequently administered 2x to 7x weekly. We do not, 
as yet, know the optimum narrow-band (TL-01) ultraviolet B weekly treatment 
frequency for chronic plaque psoriasis. TL-01 UVB has largely replaced 
broad-band UVB in Scotland (Chapter 2), and is increasingly used further afield 
(Bilsland et al. 1997), because of its greater efficacy for psoriasis than broad-
band UVB (Chapter 3). When treating psoriasis, our aim is to clear psoriasis 
with as few unwanted acute effects as possible, and to minimise the risk of late 
adverse effects (particularly non-melanoma skin cancer) by minimising each 
patient's cumulative UVB treatments and dose. 
Traditionally outpatients attending Ninewells Hospital for phototherapy were 
treated 3x weekly, and inpatients 5x weekly. Although the question: "How 
often should we administer UVB?" has exercised dermatologists since at least 
1930 (Aitken 1930c), the answer has remained unclear even for conventional 
broad-band sources. However, a paired comparison study of 9 patients showed 
no demonstrable advantage in treating chronic plaque psoriasis (with 
"Sunlamp" irradiation) twice daily compared to once daily (petrozzi et al. 1981). 
A retrospective comparison of a 3x weekly with a 5x weekly broad-band (FS72 
T12 lamp) UVB regimen showed no significant differences in dose or number of 
treatments to· clearance and that the 3x weekly regimen was better tolerated 
(Adrian et al. 1981). 
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That study was a retrospective review, not a controlled study, and factors other 
than the differences in treatment frequency may have been important. If, on the 
basis of this limited evidence, we accept that 3x weekly is preferable to 5x 
weekly broad-band UVB, this is of limited help in deciding how frequently to 
administer TL-01. The optimum frequency of phototherapy with one ultraviolet 
source need not be the same as that for another. As the TL-01 lamp has a 
minimal output of the therapeutically unimportant (Parrish et al. 1981), but 
erythemogenic (van Weelden et al. 1988) wavelengths we might expect more 
frequent treatment than would be appropriate with broad-band UVB to be 
tolerated, and, possibly, to be more effective. 
Patients often comment that a fortnight sunbathing on holiday clears their 
psoriasis, while it may take 4 to 7 weeks of 3x weekly hospital phototherapy to 
achieve the same result. A recent study which compared Canary Islands 
heliotherapy with broad-band UVB phototherapy in Finland provided some 
evidence to support this frequently heard anecdote. It showed heliotherapy to 
clear psoriasis more rapidly and with a lower cumulative UVB dose than 
phototherapy (Snellman 1992). One of several possible explanations for this 
finding is that more frequent therapy was more effective. 
We conducted a study designed to 1) test the hypothesis that 5x weekly TL-01 
UVB would clear psoriasis more rapidly and with fewer UVB exposures and a 
lower cumulative dose than 3x weekly treatment, and by doing so to 2) help to 
answer a question of practical, clinical importance: "How frequently should we 
administer TL-01 phototherapy for chronic plaque psoriasis?" 
Methods 
Study design 
This was an observer-blinded, randomised paired (within-patient) comparison 
study. Patients gave their informed consent after an opportunity to discuss the 
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study implications and reading a patient information leaflet. The Tayside 
Committee on Medical Research Ethics approved the study. We treated each 
half-patient (sagittal plane) independently following our standard minimal 
erythema dose (MED)-based, low percentage dose incremental, (Wainwright et 
al. 1996) UVB phototherapy regimen (Table 4.1), with only the treatment 
frequency differing between sides. A random number table-generated treatment 
allocation list, held by a member of department not involved in recruiting 
patients to this study, was used to determine which (right or left) side was 
treated 3x and which side 5x weekly. Patients wore a half-body suit (adapted 
work overalls) made of material that allowed transmission of no detectable UVB 
and negligible UV A (Figure 4.1), (as assessed by Hitachi U-3210 double beam 
reflectance spectrophotometer). If the dose due to be delivered to each side 
differed, the higher dose side was treated first with the difference between the 
prescribed doses. The suit was then removed to allow administration of the 
remaining dose to both sides. At each visit patients were assessed and the 
psoriasis severity graded by an observer unaware of treatment allocation. The 
decision to stop treatment was made following our unit's standard· protocol. 
-
Those patients whose psoriasis cleared completely had their treatment stopped 
at that point. Those who reached a state of "minimal residual activity" (MRA) 
of psoriasis, defined as trace disease below knees or on sacrum only, were given 
a maximum of 4 treatments after this was first recorded. 
After discharge all patients were followed-up for a year, or until relapse, at 
monthly intervals by telephone or visit to our department for assessment. If 
there was any suggestion of psoriasis recurring on either side, the patient was 
asked to attend for review. Relapse-was defined as either 1) an increase of 
global score to 50% of that at baseline or 2) a return of psoriasis of sufficient 
severity for the patient to be unwilling to continue with emollient therapy 
alone. 
Table 4.1 UVB (TL-Ol) phototherapy regimen 
1 Determine MED (minimal erythemal dose) at 
24 hours 
2 Initial dose: 70% of MED 
Maximum exposure dose: 2066 mJcm-2 
3 Treat each side independently - 3x/week (Monday, 
Wednesday, Friday) or 5x/week (daily - Monday to 
Friday), as randomly allocated 
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4 Increments given at each visit, based on a percentage of 
previous dose and erythema response: 
No erythema - 20% increment 
Mild (grade I, barely perceptible) erythema - repeat 
previous dose and reduce to 10% increments 
Moderate (grade 2, well defined asymptomatic) erythema 
- postpone 1 treatment, repeat previous dose at next visit 
and reduce to 10% increments 
Severe (grade 3, painful, persisting for more than 24 
hours) erythema - no treatment, and further treatment at 
discretion of doctor (no grade 3 erythema occurred 
during the study) 
6 Other unwanted effects: 
If itch develops - encourage use of emollients 
If PLE develops - ask doctor to review (and check lupus 
serology), encourage emollients, and a) if mild adjust 
regimen as for grade 1 erythema; or b) if moderately 
severe, treat as for grade 2 erythema 
7 Missed appointments: 
One or two treatn:tents missed - repeat previous dose 
Three treatments missed - treat with penultimate dose 
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Figure 4.1 Illustration of patient wearing a half-body suit for a study 
comparing different phototherapy regimens. 
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Study setting 
The phototherapy and PUV A unit within the dermatology department in 
Ninewells Hospital, which serves Tayside. 
Subjects 
We recruited patients with chronic plaque psoriasis from outpatient clinics 
between November 1995 and June 1996. Patients were excluded if they had a 
history of skin cancer or solar keratoses or if they were on systemic 
immunosuppressive therapy. Other study-specific exclusion criteria included: 
age < 18 years; phototherapy, PUV A or any systemic therapy for psoriasis 
within .. the preceding 3 months, guttate psoriasis, known abnormal 
photosensitivity, and any expressed hesitation about ability to attend daily 
(except weekends) for treatment. 
Irradiation cubicle 
Either a Waldmann UV5000 cubicle, fitted with 24 Philips 100W TL-01lamps, 
or a Ninewells Medical Physics department-constructed cubicle (Figure 4.2), 
with 50 Philips 100W TL-01 lamps, was used. The same cubicle was used to 
treat both body-halves, and throughout each patient's treatment course. 
Irradiance was determined monthly with an International Light IL1400 meter 
calibrated with a spectroradiometer against a bank of TL-01 lamps, and the 
UVB exposure time-dosage table was adjusted as necessary. For 
measurements the meter was clamped at mid-height, 25 cm from the lamps, 
in the empty cubicle and the mean of 10 readings taken as the output. 
Irradiances in the Waldmann cabinet ranged from 3.53 to 2.95 mWcm-2, and 
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Figure 4.2 The phototherapy cubicle constructed by the Medical Physics 
department at Ninewells Hospital. 
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those of the Ninewells cabinet from 3.1 to 2.95 mWcm-2 during the course of 
the study. 
Minimal erythema dose (MED) determination 
This was done on upper back skin following our standard procedure. For skin 
phototype I and II patients, the doses administered were: 25, 50, 70, 100, 140, 
200, 280 and 390 mJcm-2• For skin type III patients, the first two doses in this 
series were omitted and doses of 550 and 770 mJcm-2 added. The MED was 
taken as the lowest dose to produce just perceptible erythema (Figure 4.3). 
Treatment regimen 
Our low incremental dose treatment regimen is detailed in Table 4.1. All male 
patients w<?re genital protection, and all patients were offered facial 
photoprotection (faceshield (Dawe et al. 1996) or topical sunscreen) if facial 
psoriasis was absent. Adjunctive therapy was restricted to approved 
emollients known not to significantly reduce UV transmission (Hudson-
Peacock et al. 1994) (white soft paraffin/liquid paraffin 50:50 mix, aqueous 
cream, Diprobase® cream or coconut oil) except for standard topical 
treatments for scalp, face and flexures. According to our usual practice, 
treatment was stopped when the psoriasis was deemed clear, or to have been 
in a state of "minimal residual activity" (MRA) for 4 treatments, whichever 
occurred first. It is unusual for patients to require more than 30 UVB 
exposures before reaching clearance/MRA. Below 5% of 2014 psoriasis 
patients treated with whole-body TL-01 in Ninewells Hospital between 1992 
and 1996 required courses in excess of 30 exposures (Scottish phototherapy 
audit data). We therefore set a maximum limit of 30 exposures for either side. 
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Assessment 
The psoriasis severity of each body-half was assessed at baseline (before the 
first treatment) and at each subsequent treatment visit by means of a 0 to 4 
scale for each of §Caling, grythema and induration (SEI) of symmetrical 
plaques (chosen at baseline) on the upper limbs (arm or forearm), trunk and 
lower limbs (thigh, leg or buttock). A 0 to 4 (" no" to livery severe" psoriasis) 
global score was also used. This scoring scheme was based on the standard 
psoriasis area and severity index (P ASI), (Fredricksson et al. 1978) and we had 
experience of its use in earlier studies. (Collins et al. 1996a; Wainwright et al. 
1996) 
Statistical metJwds 
The main end-points were time (days), dose and number of treatments to 
clearance. We also compared psoriasis severity scores at baseline and at the 
end of treatment. Further, individual patient data, as well as summary data, 
were examined graphically. The distributions of values, or when appropriate, 
differences in values between sides were examined in graphical form, 
including quartile-normal plots, and by use of the Shapiro-Francia W' test to 
decide if a normal distribution could be assumed. For those variables which 
I 
could not be assumed to arise from such a distribution we used non-
parametric tests, and for normally distributed variables both parametric and 
non-parametric methods. No differences in interpretation arose from the 
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Figure 4.3 For this study we took the minimal erythemal dose (MED) as 
the lowest dose to produce "just perceptible" erythema 24 hours after 
irradiation. This is the definition used in most European phototherapy units. 
I 
123 
different methods of analysis, so for consistency and clarity, only the results 
of the non-parametric tests are reported. The Wilcoxon matched-pairs signed-
ranks test (with a null hypothesis of no difference between the sides) was 
used for paired data and the Mann-Whitney U test for unpaired data. 
Confidence intervals (CI) for the differences in medians were calculated using 
a rank-based method. (Campbell et al. 1989) The proportions of patients 
developing erythema during treatment were compared by McNemar's exact 
test for paired proportions. Follow-up data were analysed by the plotting of 
Kaplan-Meier survival curves. A Cox regression model, taking into account 
the within-subject II clustering" of data, was used when statistically comparing 
the follow-up, "survival" (of the patients' psoriasis) data. In general, I have 
avoided describing results in dichotomous "significant" or "not significant" 
terms, favouring the reporting of confidence intervals and the actual p-values, 
but when the term "statistically significant" is used this means that the 
probability that the null hypothesis of no difference was true was below 0.05. 
Statistical calculations were performed with "Stata" (with Practical Statistics 
for Medical Research! add-on software to calculate confidence intervals for 
the medians). (Stata Corporation 1997) 
Results 
Twenty-one patients, 13 men and 8 women of mean age 43 (range 21 to 68) 
years, entered the study. They were of sun-reactive skin types I, II and III 
(Figure 4.4). Five patients (4 men and 1 woman) did not reach the end-point 
of clearance or minimal_ residual activity (MRA) on both sides: 1 was 
withdrawn due to failure to attend regularly (intercurrent illness), 1 declined 
to continue when he was satisfied with a modest improvement on both sides, and 3 
did not achieve clearance or MRA. Compliance with treatment was good. Only 5 of 
Practical Statistics for Medical Research course, Department of Medical Statistics 
and Evaluation, Royal Postgraduate Medical School, London, 1997. 
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Figure 4.4 Minimal erythema doses (MEDs) and skin types of study 
participants. 
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the 16 who completed the study missed any treatments. Of these five, 4 
missed only 1 treatment (5x weekly side only - 3 patients; both sides -1), and 
1 missed 4 treatments (5x weekly side only - 1; both sides - 3). Treatments 
were missed because of intercurrent illness (2), personal reasons (4) and unit 
closure for public holiday (2). 
The median psoriasis severity (SEI) scores of the 16 completing patients at 
each assessment is shown in Figure 4.5, and the baseline and final treatment 
visit SEI scores for these 16 patients, and (on an intention to treat basis) all 21 
entered patients, are described in Table 4.2. The median baseline psoriasis 
severity score (SEI=25) of those who completed the study was not 
significantly different from that of those who did not complete (SEI=27.5). (P 
= 0.57; 95% CI for difference in medians -6 to 5). 
Psoriasis took longer to clear or reach MRA with 3x weekly than with 5x 
weekly treatment, clearing in a median of 35 days (range 19-43) with 5x 
weekly uyB and in a median of 40 days (range 23-63) with 3x weekly 
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Figure 4.5 Median psoriasis severity (scaling, erythema and induration) 
score at each assessment. 
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Table 4.2 Median (and range) of psoriasis severity (SEI) scores at begining and end of 
treatment 
3xL week side 5xL week Probability:!: 95% c.Lt 
side 
Completing patients (n=16) 
Baseline: 25.5 (19-32) 25 (17-31) P=0.48 -0.5 to 0.5 
Final treatment visit: 2 (0-6) 3 (0-6) P=0.63 -1.5 to 1 
All patients (n=21) 
Baseline: 26 (14-34) 25 (14-34) P=O.22 -1 to 0 
Final treatment visit: 4 (0-18) 3 (0-13) P=0.76 -1.5 to 1.5 
+ Wilcoxon matched-pairs signed-ranks test (null hypothesis of no difference between sides) 
t Rank-based confidence interval for difference in paired medians 
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treatment (Figure 4.6). (P=0.007, 95% CI for difference in medians 2 to 11). 
However, this more rapid clearance with the 5x weekly regimen was achieved 
at the expense of a higher dose of UVB and more treatments. In multiples of 
each individual's MED, the 5x weekly sides required a median UVB dose of 
94 (range 27-164), compared to 64 (range 23-125) MEDs for the 3x weekly 
sides (Figure 4.7). (P = 0.01, 95% a 5-33). The sides treated 5x weekly 
received a median of 23.5 compared to 17 treatments for the 3x weekly sides 
(P=O.OOl, 95% a 3.5-8) (Figure 4.8). 
Inspection of the individual patient data showed only 2 patients with results 
suff~ciently different from the summary results to alter how we would 
consider treating these individuals in 'the future. One patient's psoriasis 
cleared 28 days sooner on the 5x weekly side, with 5 fewer treatments and a 
lower (by 36 MEDs) cumulative dose. However, his psoriasis relapsed 
exceptionally quickly - in 6 days on the 5x weekly treated side and 22 days on 
the 3x weekly side. Another's psoriasis cleared 26 days more quickly on the 
5x weekly ~ide, with 1 less treatment (but a slightly higher cumulative dose) 
compared with her 3x weekly treated side. No features of these two patients 
that were recorded before starting treatment distinguished them from the 
other 14 patients. 
Acute adverse effects were more troublesome with the 5x weekly compared 
with the 3x weekly regimen. While no patient suffered a painful (grade 3) 
erythema, 15/16 on 5x weekly treatment developed at least one episode of 
well-demarcated (grade 2) erythema as compared with only 3/16 on 3x 
weekly treatment (P<O.OOl). Two patients developed polymorphic light 
.' 
. eruption (PLE). One patient's episode of PLE affected both sides early during 
the course and the other's 5x weekly side only was involved after the final 
treatment. 
129 
Figure 4.6 Days to achieve clearance or minimal residual activity (MRA). 
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Figure 4.7 Dose in multiples of each individual's minimal erythemal dose 
(MED). Whilst dose expressed in this way (taking into account each 
individual's susceptibility to UVB erythema) is not necessarily more reflective 
of long-term cancer risk than dose expressed as an absolute dose (Jcm-2), 
expression of the dose like this does have the major advantage of allowing 
interpretation in other centres with differing dosimetry methods (see Chapter 
2, Figure 2.20 for Scottish phototherapy audit data on variation in dosimetry 
just within Scotland). 
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Figure 4.8 Treatments to achieve clearance or minimal residual activity 
(MRA). 
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The time to relapse for each side is shown in Figure 4.9. There was no 
significant difference in the probability of relapse between regimens (P=O.1). 
At relapse, only 3 required therapy other than topical emollients, tar or 
calcipotriol. Of these three, 1 started PUV A, 1 another course of UVB and 'the 
other entered a half-body comparison of PUV A and UVB phototherapy. Two 
others have since required non-topical therapy - one commencing UVB, and 
the other PUV A, 6 months after initial relapse. 
Discussion 
We have shown that for the majority of patients in our population, 3x weekly 
TL-01 UVB phototherapy is preferable to 5x weekly treatment. Oearance of 
psoriasis slightly more quickly (by a difference in medians of 5 days) with 5x 
weekly treatment is not, in our opinion, sufficient to justify the patient 
inconvenience, the higher frequency of significant erythema provoked during 
treatment, and the expected greater long-term risk related to the higher 
cumulative UVB dose and number of exposures required. Consequently, we 
no longer routinely use 5x weekly treatment for inpatients, as was our 
previous practice. 
Although individual patient response does vary, the absence of factors 
predictive of a better response to 5x weekly treatment (as occurred in only 2 
of our patients) suggests we should base our standard practice on the 
evidence applicable to the group as a whole. Occasionally, however, for 
example for a patient anxious to be clear for a specific occasion, it may be 
, reasonable to offer 5x weekly treatment for quicker clearance, despite the 
increased risk of acute, and presumably, chronic adverse effects. 
A within patient paired study allows us to control for all factors other than 
the single, altered variable under investigation. However, a potential 
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drawback relates to the possibility of a systemic phototherapy effect - we 
know that TL-01 UVB produces various alterations in systemic immune 
function as assessed in vitro (Guckian et al. 1995). In practice however, any 
such effect appears unable to clear psoriasis. In our experience and that of 
others, (Kienbaum et al. 1996) unexposed flexural psoriasis fails to clear with 
phototherapy as do, according to an as-yet unpublished study,1 any plaques 
covered during treatment. We therefore think it unlikely that any systemic 
effect of the 5x weekly treatment exerted a clinically important effect in 
clearing our study patients' 3x weekly-treated sides. Further support for this 
is given by the fact that the median number of treatments to clearance or 
MRA for the 3x weekly side was as expected from Dundee data collected 
during the Scottish phototherapy audit (Chapter 2). 
The evidence generated by this study indicates that in our Northern European 
population of chronic plaque psoriasis patients, a 3x weekly low incremental 
regimen with an MED-based starting dose is preferable to 5x weekly 
treatment. Only a few patients will benefit sufficiently from the slightly more 
rapid psoriasis clearance with 5x weekly therapy to warrant the associated 
disadvantages. We now only rarely use daily treatment for those requiring 
inpatient therapy for geographical reasons (no phototherapy unit within . 
reasonable travelling distance): for these occasional patients the 
disadvantages of an extra week in hospital with 3x weekly treatment may 
sometimes outweigh the advantages. 
1 Study presented at Scottish Dermatological Society meeting, Edinburgh, 2001 by 
RS. Dawe (H. Cameron, RS. Dawe, S. Yule, I. Man, S.H. Ibbotson and J. Ferguson. 
Ultraviolet 8 phototherapy clears psoriasis through local effects). 
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Figure 4.9 Remission duration following 3x and 5x weekly TL-Ol UVB 
phototherapy for psoriasis. 
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The optimal treatment regimen for populations with many patients of higher 
skin phototype remains unclear. It seems plausible that treatment in such 
patients might be less limited by acute erythema, and that more frequent 
therapy than for our study population might be preferable. A recent 
publication suggested that 2x weekly TL-01 UVB was in fact preferable to 4x 
weekly treatment in a Thai population. However, we need to be careful in 
interpreting this study's findings as it was not a randomised controlled trial, 
and treatment allocation (by whole-patient, not paired) was decided by 
patient choice. For now, the optimal treatment frequency for skin phototype 
IV to VI patients remains unknown. 
Comment 
The study described in this chapter provided information on an aspect of 
treatment methodology important to all those treating skin phototype I to III 
populations with narrow-band TL-01 UVB for chronic plaque psoriasis. The 
next chapter (Chapter 5) describes a study designed to help answer another 
question, important to all phototherapy units with (or considering acquiring) 
TL-01 treatment facilities: For the treatment of chronic plaque psoriasis, 
should we chose to prescribe psoralen-UV A photochemotherapy, or should 
we prescribe TL-01 UVB? 
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ChapterS 
This chapter describes a study designed to assess the comparative efficacy of 
ultraviolet B (using narrow-band TL-Ol lamps) and bath-PUVA for chronic plaque 
psoriasis. Our findings are analysed in conjunction with those of previous studies 
addressing the same question (which of PUVA and TL-Ol UVB is most effective?), 
but using different treatment regimens. 
A randomised, within-patient, controlled trial comparison of narrow-band 
ultraviolet B phototherapy and psoralen-ultraviolet A photochemotherapy (PUV A) 
for chronic plaque psoriasis 
The aim of this study was to compare the efficacy of narrow-band (TL-01) ultraviolet 
B (UVB) phototherapy and trimethoxypsoralen (TMP) bath-PUV A (psoralen-
ultraviolet A photochemotherapy) for chronic plaque psoriasis. 
A randomised, observer-blinded, intra-individually controlled, paired comparison 
- study was conducted. 
Both treatments were administered according to standard, optimised regimens. 
Treatment was continued until clearance or minimal residual activity (MRA), or a 
maximum of 30 treatments. 
The main outcome measures were treatments and time to clearance/MRA. We also 
assessed the proportion reaching clearance/MRA, change in psoriasis severity 
(sciiling, erythema and induration), and remission durations with each treatment 
Twenty-eight patients (skin phototypes I to 1lI) with chronic plaque psoriasis 
participated. Each patient's body halves (sagittal plane) were treated independently, 
one half with TL-01 UV-B the other with bath-PUV A. 
Analysed on an intention to treat basis, 22/28 (75%) reached clearance/MRA with 
TL-01 compared with 15/28 (54%) with PUVA (95% confidence interval for 
difference 4 % to 37%; P=0.03). Ten patients were withdrawn (4 because of inadequate 
response of PUV A-treated halves). Of the 18 who completed the study, all reached 
clearance/MRA with TL-01, but 3 were still not clear by 30 PUV A exposures. TL-01 
achieved clearance/MRA a median of 11 (4 to 24.5; P=0.002) days more quickly than 
PUV A, but required a median of 24.5 compared with 20 exposures (difference 0 to 5; 
P=O.Ol). Remission durations did not differ. 
In conclusion, when TL-01 and PUV A are both used according to regimens designed 
to be optimal (on the basis of Current knowledge), TL-01 UVB is more efficacious 
than PUV A for the treatment of chronic plaque psoriasis. This contrasts with earlier 
work, which indicated PUV A was moderately more effective. This discrepancy may 
be explained by differences in the treatment regimens compared. On the baSiS of this 
study's findings, and a careful review of the earlier work, it can be concluded that 
TL-01 UVB is the phototherapeutic treatment of choice for chronic plaque p~oriasis. 
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Introduction 
Which is the treabnent of first choice for moderately severe and severe 
chronic plaque psoriasis: narrow-band (TL-01) UV-B phototherapy or 
psoralen- UV-A photochemotherapy (PUV A)? In 1991, guidelines on psoriasis 
management recommended PUV A as the treabnent of choice. (Anon. 1991) 
Since then, however, as discussed in earlier chapters of this thesis, TL-01 UV-
B has become more widely available, replacing the less effective broad-band 
sources. Should TL-01 UVB also replace PUV A? Important factors 
encouraging increased prescription of TL-01 UVB, when PUV A might have 
been prescribed before, include the the absence of psoralen adverse effects, no 
need for eye protection outwith the treabnent cubicle, and the increased skin 
cancer risks associated with PUV A in the absence of any suggestion (at 
present) of similar risks with TL-01 UVB. However, relative efficacy is the 
major consideration. If the two therapies are equally effective, or even if 
PUV A is a little more effective, most patients and dermatologists would be 
expected to choose TL-01. If, on the other hand, PUV A is as much more 
effective than TL-01 UVB as most considered it be compared with broad-band 
UVB, then (despite its practical disadvantages) PUV A would be the therapy 
of choice. 
Three comparisons of TL-01 UV-B and PUV A as monotherapies (van Weelden 
et al. 1990; Tanew et al. 1999; Gordon et al. 1999), and one of etretinate+TL-01 
and etretinate+ PUV A (Green et al. 1992), for chronic plaque psoriasis severe 
enough to require such treabnent have now been published (Table 5.1). Three 
of these studies showed little difference in treabnent efficacy (Van Weelden et 
al. 1990; Green et al. 1992b; Tanew et al. 1999), and therefore concluded that, 
for the majority of patients, TL-01 UV-B is to be preferred over PUV A. The 
fourth of these studies(Gordon et al. 1999) showed PUV A to clear a greater 
proportion of patients than TL-01 monotherapy (odds ratio favouring PUV A 
of 3,95% confidence interval 1.2 to 7.8). 
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Of the 3 studies comparing TL-01 and PUV A monotherapy, only one used 
clearance as the main study end-point of interest, (Gordon et al. 1999) the 
others compared the two treatments after a pre-decided time or number of 
treatments, and were not designed to provide follow-up data. This one study 
(Gordon et al. 1999) was designed to compare TL-01 and PUV A when both 
given twice weekly, as in the first study comparing these therapies (van 
Weelden et al. 1990). In standard clinical practice in Scotland (audit data in 
Chapter 2), and the rest of the United Kingdom (Dootson et al. 1994), UVB is 
most frequently administered 3x weekly whereas PUV A is given 2x weekly. 
Although 3x weekly TL-01 clears psoriasis almost as quickly, and with fewer 
treatments, than 5x weekly treatment, as demonstrated by the study described 
in the previous chapter (Dawe et al. 1998), our experience, and preliminary 
,study data,1 suggests that 2x weekly treatment may be less effective. 
We designed a study to compare TL-01 UV-B and bath-PUV A, with both 
therapies administered as in everyday practice in a centre with over 10 years' 
experience of administering both therapies. 
Study presented at Scottish Dermatological Society meeting, Edinburgh, 2001 by 
H. Cameron (H. Cameron, R.S. Dawe, S. Yule, I. Man, S.H. Ibbotson, J. Ferguson. A 
comparison of 2x and 3x weekly narrow-band (TL-01) UVB phototherapy in the 
treatment of chronic plaque psoriasis). 
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Table 5.1 . Previous controlled studies comparing PUV A and TL-Ol UVB for psoriasis. 
Treatment frequency 
(per week) Number of subjects 
Study PUVA TL-Ol PUVA TL-Ol Study design 
van Weelden, 1990 2x 2x 10 10 Within-patient paired, randomized, observer-masked 
Green, 1992 2x 3x 15 15 Unpaired, randomized, not observer-masked; systemic 
retinoids 
Tanew,1999 3x 3x 25 25 Within-patient paired, non-randomized, npt observer-
masked 
-Gordon, 1999 2x 2x 49 51 Unpaired, stratified (matched by plaque size and skin 
photo-type) randomized, observer-masked \ 
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Participants and Methods 
Study design 
A randomised, observer-masked, within-patient, paired study was designed 
to compare standard TL-01 UVB and bath-PUV A. The Tayside Committee on 
Medical Research Ethics approved the study. 
As for previous half-body, paired studies (including that described in Chapter 
4) patients wore half-body suits (adapted work overalls) made of material 
which allowed transmission of no UVB and negligible ultraviolet A (0.6% 
transmission at 365nm, assessed with Hitachi U-3210 double-beam reflectance 
.. spectrophotometer). 
Assignment 
A treatment allocation list, generated from a random number table and held 
by a departmental secretary not otherwise involved in the study, was used to 
decide which side (right or left) of each patient was treated with TL-01 and 
which with PUV A. 
Masking 
We treated each half-patient (sagittal plane) independently, with the side 
allocated to TL-01 therapy treated first, followed by. bath-water application of 
the psoralen then ultraviolet A (UV A) irradiation to the other sid~. At each 
visit psoriasis severity was graded by an observer unaware of treatment 
allocation. The decision to stop treatment was made following our unit's 
standard protocol by the same masked observer. Patients and nurse 
phototherapists administering treatment were not masked. 
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Protocol 
Partidpants 
Consecutive patients with chronic plaque psoriasis, referred from general 
dermatology clinics for either PUV A or UVB between September 1996 and 
May 1999, were invited to participate. Exclusion criteria were: age < 18 years, 
a history of skin cancer or solar keratoses, or phototherapy, PUV A or systemic 
therapy for psoriasis within the preceding 3 months. 
Treatment regimens 
- Standard TL-Ol UVB and bath-PUVA regimens were used. The TL-Ol UVB 
regimen was the 3x weekly regimen used in the study described in Chapter 4 
(Table 4.1). For the bath-PUV A regimen, the psoralen used was 3'4'5' 
trimethoxypsoralen (TMP) 50mg in 100mI ethanol (Tayside Pharmaceuticals, 
, 
Dundee, UK). This was mixed in 150 litres 37°C bath-water to make a 
concentration of 0.33mg/L. The patient soaked in this bath-water for 10 
minutes, with immediate UV A exposure thereafter. This treatment was 
administered twice weekly to the side allocated to PUV A treatment, after the 
other side had been treated with TL-Ol UVB. The UV A starting dose, and 
incremental regimen, followed the standard regimen described in Table 5.2. 
All patients without facial psoriasis were offered facial photoprotection with 
either topical sUnscreen or faceshield (Dawe et al. 1996). Male patients wore 
genital protection. Adjunctive therapy was restricted to emollients known not 
to significantly impede ultraviolet transmission (Hudson-Peacock et al. 1994), 
and standard topical treatments for scalp, face and flexures. We set a 
maximum limit of 30 treatments to either side. 
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Minimal erythema dose (MED) and minimal phototoxic dose (MPD) detennination 
This was done on upper back skin following our standard procedures. For 
MED determination in skin phototype I and II patients, doses administered 
were: 25, 50, 70, 100, 140, 200,280 and 390 mJcm-2• For skin type III patients, 
the first two doses in this series were omitted and doses of 550 and 770 mJcm-2 
added. The MED was taken as the lowest dose to produce just perceptible 
erythema at 24 hours. For MPD determination in skin phototype I and II 
patients, doses of 0.05, 0.07, 0.10, 0.15, 0.22, 0.27, 0.33 and 0.39 Jcm-2 were 
administered, with the first two doses in this series omitted and doses of 0.47 
and 0.56 Jcm-2 added in for skin type III patients. The MPD was taken as the 
lowest dose to produce just perceptible erythema at 72 hours. 
Irradiation cubicles 
For TL-01 UVB, either a Waldmann UV5000 cabinet, fitted with 24 Philips 
100W TL-01 lamps, or a Ninewells Medical Physics department-constructed 
cabinet, with 50 Philips 100W TL-01 lamps, was used. For PUV A, a Dixwell 
cabinet fitted with 47 Philips R-UV A tubes was used. TL-01 and UV A 
irradiances were checked monthly. 
Reasons for administering psoralen in bath-water 
To compare TL-01 monotherapy (not psoralen+TL-01) with psor~en+UV A, 
the psoralen had to be administered after TL-01 irradiation. The majority of 
our patients requiring PUV A receive oral psoralens rather than bath-PUV A, 
which require~ extra nursing time (Halpern et al. 2000), but for this study we 
used our· standard bath-PUV A regimen (Table 5.2). This was: 
Table 5.2 Bath-PUV A regimen 
1 Determine MPD (minimal phototoxic dose) at 
72 hours 
2 Initial dose: 40% of MPD 
Maximum exposure dose: 15 Jcm-2 
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3 Increments given at each visit, based on a percentage of 
previous dose and erythema response: 
No erythema - 20% increment 
Mild (grade 1, barely perceptible) erythema - repeat 
previous dose and reduce to 10% increments Moderate 
(grade 2, well defined asymptomatic) erythema-
postpone 1 treatment, repeat previous dose at next visit 
and reduce to 10% increments Severe (grade 3, painful, 
persisting for more than 24 hours) - no treatment, and 
further treatment at discretion of doctor (no grade 3 
erythema occurred during the study) 
4 Other unwanted effects: 
If itch develops - encourage use of emollients 
If PLE develops - ask doctor to review (and check lupus 
serology), encourage emollients, and a) if mild adjust 
regimen as for grade 1 erythema; or b) if moderately 
severe, treat as for grade 2 erythema 
PUV A pain - medical review, with management 
(withdrawal of PUV A if necessary) at discretion of doctor 
5 Stopping treatment: 
Treatment stopped at clearance or after 4 exposures 
following first documentation of minimal residual 
activity (MRA), whichever comes first. 
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1) To make the study less onerous for patients. After one body-half was 
treated with TL-01 they would bathe in TMP solution, then immediately 
receive UV A radiation. If we had used our oral PUV A regimen this would 
have necessitated ingestion of the psoralen after TL-01 exposure and a 2 hour 
wait before UV A administration. 
2) Because bath-PUV A is at least as effective as (Turjanmaa et al. 1985; Lowe 
et al. 1986), and possibly more effective than, oral PUV A (Collins et al. 1990; 
Calzavara-Pinton et al. 1994c; Cooper et al. 2000), and our aim was to compare 
optimally effective TL-01 and PUV A regimens. 
Assessment 
The severity of psoriasis on each body-half was assessed before first treatment 
and at each subsequent treatment visit. We used a 0 to 4 scale for each of 
scaling, erythema and induration (SEI) of three symmetrical plaques chosen at 
baseline on upper limbs (arm or forearm), trunk, and lower limbs (thigh, leg 
or buttock). A 0 to 4 (no psoriasis to "very severe") global score was also used. 
This scoring scheme was the same as used when we compared 3x and 5x 
weekly TL-01 UVB administration (Chapter 5). 
Follow-up 
All completing patients were followed-up for 1 year, or until relapse, at 
monthly intervals by telephone and, if there was any suggestion of psoriasis 
returning on either side, by departmental visit for assessment. Relapse was 
defined as either 1) an increase in global score to 50% of that at baseline, or 2) 
a return of psoriasis 'Of sufficient severity that the patient was unwilling to 
continue with emollient therapy alone. 
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Literature review and statistical methods 
Literature review methods 
Articles comparing narrow-band (TL-01) UVB and PUV A to treat psoriasis 
were identified as those previously known to us, with search of EMBASE® 
(Elsevier Science, Amsterdam) and MEDLINE® (National Library of 
Medicine, Bethesda) using Ovid search software, version 7.8 (Ovid 
Technologies Inc, 1988) to exclude others. 
To summarise earlier studies and ours, the most readily comparable end-
point of treatment with the two modalities was identified. For studies with 
sufficient reported data to do this, the proportions of patients clearing with 
each therapy were compared, using the McNemar exact test (for paired 
studies) or the two-sample test for independent proportions, with 
Newcombe's methods to calculate the 95% confidence intervals for differences 
(Newcombe et al. 2000). Numbers needed to treat were derived (Machin et al. 
2000). Odds ratios and exact 95% confidence intervals were also calculated. 
For the paired, within-patient studies, we used the methods of Morris and 
Gardner (Morris et al. 1989), with reference to standard tables for the 
binomial distribution (Lentner 1982). These methods only utilised the paired 
study data from patients in whom the outcome was different on each side 
(ignoring the overall sample size), and so produced disproportionately 
imprecise odds ratio estimates for the paired studies. However the use of 
odds ratios allowed reasonable comparison of studies where the outcome was 
a direct comparison of sides (van Weelden et al. 1990; Tanew et al. 1999b), 
with those with outcome of clearance (clearance/MRA) versus not cleared. 
The meta-analysis macro of Sharp and Sterne was used to produce a 
summary diagram (Sharp & Sterne 1997), but because of clinically and 
statistically significant heterogeneity it was not considered appropriate to 
quantitatively combine the study results. 
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Study statistical methods 
The study was designed to have a power of 80% to detect a difference of 2 
treahnents or 7 days to clearance. Assumptions included two-sided alpha = 
0.05, and estimates of within-patient standard deviations were based on 
earlier paired psoriasis treahnent studies (that described in the last chapter, 
and one other (Wainwright et al. 1998» conducted in the Dundee 
dermatology deparhnent. We calculated that we would require 22 patients 
and, on the assumption that 80% would complete treahnent within the study, 
recruited twenty-eight. 
The main end-points were number of treahnents and time (days) to clearance. 
We also compared psoriasis severity scores at baseline and at end of 
treahnent and, as suggested as a measure of change in disease state over the 
complete treahnent courses (Ashcroft et a1. 1999), compared areas under 
psoriasis severity-time curves. Areas under the curve were calculated by a 
standard trapezoid method, using user-written add on software to "Stata" 
package.2 Not all variables followed a normal distribution so non-parametric 
tests were used. The Wilcoxon matched-pairs signed-ranks test was used, 
with confidence intervals for differences in medians calculated using a rank-
based method (Campbell et al. 1989). The proportions of patients developing 
erythema during treahnent were compared using McNemar's exact test for 
paired proportions. Follow-up data were analysed using a Cox proportional· 
hazards model, taking into account the within-subject nature of the data 
(Oeves 1999). Statistical significance was taken as p<0.05. "Stata" (Intercooled 
Stata for Windows, release 6; Stata Corp, College Station, Texas) and "CIA" 
(Bryant 2000), statistical s~ftware were used. 
2 Package "auccalc" from http://WNW.stata.com/usersldcowart. 
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Results 
Partidpant flow and follow-up 
Twenty-eight patients (11 women; median age 47, range 22 to 71 years-old) of 
skin phototypes I (6 patients), II (12 patients) and III (10 patients) participated. 
Recruitment was slow (Figure 5.1), with the most frequent reasons for 
patients declining to participate being 1) inability to take sufficient time off 
work/home commitments, and 2) previous successful treatment with UVB 
leading to an unwillingness to take part in a trial involving PUV A. All had 
plaque psoriasis of greater than one year's duration. Twenty-four had been 
treated previously with one or more courses of TL-Ol UVB or PUV A (11 UVB 
only), two had previously required systemic retinoids, and one methotrexate. 
The unusually high proportion (13/28, compared with 75/314 of all psoriasis 
patients treated in 1996) of participants who had received previous PUV A 
(only one of whom had not also received TL-Ol) suggests that those who 
agreed to participate included a disproportionate number who had 
responded poorly to, or had short remission following, previous TL-Ol UVB. 
Ten were withdrawn before study completion due to: inadequate response to 
treatment (on PUV A-treated body half) in 4 patients, protocol violation 
(topical steroids required for treatment-induced polymorphic light eruption) 
in 2, inter-current illness in 1, PUV A itch in 1, pregnancy in I, and to one 
patient's repeated failure to attend. The observer masking to treatment 
allocation was maintained. A concern that differences in pigmentation 
produced by the two treatments ~ght identify which treatment each side 
was receiving proved unfounded (for example see Figure 5.2). 
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Figure 5.1 Flow of patients through study. 
All referrals for whole-body PUVA 
or UVB for psoriasis 
,.--- September 1996 - May 1999 -
(n=1024) 
, 
Randomised Not randomised (n=996; 855 
(n=28) treated with UVB,141 with PUVA) 
·Decllned to participate 
·Did not fulfil inclusion criteria 
(not plaque psoriasis, age, 
pregnancy, previous skin cancer) 
-
TL-01 UVB (n=28 subjects) I PUVA (n=28) I 
Withdrawn before completion: 
-Inadequate response (on PUVA side) (n=4) 
-Protocol violation (required topical steroids) (n=2) 
-PUVA Itch (n=1) 
-Pregnancy (contraindication to PUVA) (n=1) 
·Intercurrent illness (n=1) 
-Failure to attend (n=1) 
Completed to clearancel minimal Completed to clearance/ minimal 
residual activity residual activity (n=15), or 
(n=18) Maximum of 30 exposures (n=3) 
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Figure 5.2 It was not possible to guess which therapy each side was 
receiving by the degree or type of pigmentation. It turned out that the right 
side here was receiving TL-01 (11th treatment visit), and the left side PUVA 
(8th treatment visit). 
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Analysis 
Analysed on an intention to treat basis, 21/28 (75%) reached clearance/ 
minimal residual activity (MRA) within the study with TL-01 compared with 
15/28 (54%) with PUV A, a difference of 21 % (95% confidence interval 4% to 
37%; P=0.03). The number needed to treat to benefit (NNTB) with TL-01 
rather than PUV A to see one extra patient achieving clearance/MRA was 5 
(95% confidence interval 25 to 3). This can be compared with the NNTB of 5 
(29 to 3) for PUV A instead of TL-Ol shown in the study by Gordon and 
colleagues (Gordon et al. 1999). To assist comparison of our TL-01 versus 
PUV A study results with the previous studies (in Table 5.1) the odds ratios, 
with conservatively calculated exact 95% confidence intervals, are illustrated 
in Figure 5.3. Also analysed on an intention to treat basis, the median fall in 
psoriasis severity score was 20 with TL-Ol compared with 17.5 with PUV A 
(95% confidence interval for difference 0 to 6; P=0.036) (Figure 5.4). The areas 
under the psoriasis severity score-time curves were significantly lower with 
TL-01 than with PUV A (P<O.OOl). 
All 18 patients who completed the study reached clearance/MRA on their 
TL-01-treated sides, but in 3 the PUV A-treated side was still not clear by the 
maximum of 30 exposures. TL-Ol treatment achieved c1earance/MRA a 
median of 11 (95% confidence interval 6.5 to 25; P=O.OOl) days more quickly 
than PUV A (Figure 5.5a), but required a median of 24.5 compared with 19 
exposures (95% confidence interval for difference 1.5 to 5.5; P=O.Ol) (Figure 
5.5b). The high number of TL-01 treatments required (compared with the 
median of 19 for all whole-body courses for psoriasis administered in our unit 
Figure 5.2 It was not possible to guess which therapy each side was 
receiving ~y the degree or type of pigmentation. It turned out that the right 
side here was receiving TL-01 (11th treatment visit), and the left side PUV A 
(8th treatrrlent visit). . 
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More TL-01 treated sides were affected by grade 1 (asymptomatic, not-well 
demarcated) erythema episodes (100% of patients) than PUV A (56%) (95% 
confidence interval for difference 16% to 73%; P=0.008). There were no 
detectable differences in percentages of patients experiencing grade 2 (well-
demarcated, not painful) erythema (33% with TL-01, 11 % with PUV A; 
difference -8 to 52%, P=0.22), or grade 3 (painful) erythema (3 patients [16%] 
with TL-01, 1 patient with PUV A; difference -9% to 31 %, P=O.5). Both 
patients withdrawn because they required topical steroids for PLE developed 
this on both sides, although in one it was more severe on the TL-01 treated 
side. The patient withdrawn because of intense itch on the PUV A treated side 
was then treated with whole-body UVB, and the PUV A itch resolved over 2 
weeks. 
After study completion, patients were asked which treatment they would 
prefer in future: all but 3 expressed a preference for UVB ("more effective" 
being the most frequent reason volunteered). Two stated they would prefer 
PUV A ("less time in box, less claustrophobic", "only 2 times a week - easier 
for work"),-and one had no preference. 
There was no difference between treatments in remission duration (Figure 
5.6). The short remission durations shown with both therapies reflect the 
definition used. Only two required another course of phototherapy at relapse, 
the rest requiring topical therapy (coal tar solution, calcipotriol, or moderately 
potent topical steroids) only. 
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Discussion 
This study showed TL-Ol UVB to be significantly more efficacious than PUV A 
in the treatment of chronic plaque psoriasis. Participants in our study may 
have been atypical of our psoriasis patient population as a whole (Figure 5.1). 
However, it might have been anticipated that selection bias would have 
tended to skew our findings in favour of PUVA rather than TL-Ol UVB. 
Patients who took part were more likely to have been treated with PUV A 
before, and appeared to have more treatment-resistant psoriasis, than non-
participants. Those who had previously responded well to UVB, and had 
therefore never before required PUV A, were less likely to participate in this 
study. 
Our findings contrast with previous studies which favoured PUV A. 
Presumably the main reasons for these apparently conflicting outcomes relate 
to the different treatment regimens. Two studies compared TL-Ol 
administered just twice weekly with conventional twice weekly PUV A (van 
Weelden ef al. 1990; Gordon et a1. 1999). However we have recently found 
that 2x weekly administration of TL-Ol may be suboptimal (preliminary study 
results3). 
The study by Green et al (Green et al. 1992), included in Figure 5.3, was a 
comparison of retinoid+TL-Ol versus retinoid+PUV A, and so not directly 
comparable with the other studies comparing TL-Ol and PUV A as 
monotherapies. Also, this study did not involve intra-individual controls, and 
the broad confidence interval (shown in Figure 5.3) included the possibility 
that the retinoid+TL-Ol combination might in fact be more effective than 
retinoid + PUV A. 
3 Study presented at Scottish Dermatological Society meeting, Edinburgh, 2001. 
156 
Tanew and colleagues administered both TL-01 and PUV A thrice weekly. A 
difference between their regimens and ours is that they aimed to compare 
equi-erythemogenic treatment courses, and excluded 4 patients from analysis 
because of more erythema episodes on the TL-01 sides. The regimens we 
compared were more typical of current usage. We found that TL-01, 
(Wainwright et al. 1998), produced significantly more mild erythema episodes 
administered according to our standard low-incremental regimen than 
PUV A. The greater relative efficacy of our TL-01 regimen may be related to 
this. 
Another difference between our regimens and those of the previous studies 
was our choice of the bath-water TMP psoralen. In the absence of a study 
directly comparing TMP bath-PUV A with oral 8-MOP PUV A, we cannot 
exclude the possibility that our PUV A therapy was suboptimal. However this 
seems unlikely, especially as evidence exists to suggest that bath-PUV A is 
more effective than oral PUV A (Collins et al. 1990; Calzavara-Pinton et al. 
1994c; Cooper et al. 2000). 
We found, that TL-01 UVB was more likely to clear psoriasis than PUV A. 
Amongst those who achieved clearance or minimal residual activity with both 
therapies, UVB worked more quickly but more treatments were required than 
withPUVA. 
Although our TL-01 regimen did result in significantly more subjects 
experiencing mild( asymptomatic erythema episodes than PUV A, there was 
no detectable difference in the frequency of more severe erythema grades. As 
only two patients experienced polymorphic light eruption as an adverse 
effect, this study does not allow comment on its relative induction. Although 
no patient preferred PUV A because of the difference in erythema frequency, 
one stated a preference for future PUV A based on the short treatment times 
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specific to TMP bath-PUV A, and one who preferred PUV A related this to the 
convenience of attending only twice weekly. 
We found no difference in remission durations between the therapies. The 
short remissions following both therapies could be attributed to the definition 
used, but may also relate to the severity of psoriasis studied. Although our 
definition of relapse was crude, and our remission data cannot readily be 
compared with those from other studies using different definitions, the ability 
to reliably compare remission durations was a strength of the within-patient 
comparison design. 
Neither this nor the previous controlled comparisons of TL-01 with PUV A for 
psoriasis could help answer the important questions about relative risk of 
future skin cancer development. As discussed elsewhere in this thesis, we 
know that PUV A is associated with a significantly increased risk of skin 
carcinomas (Stem et aI. 1998), particularly squamous carcinomas, and may 
contribute to a smaIl increased melanoma risk in those who have received 
multiple treatments (Stern et aI. 1997). The risks associated with UVB have not 
been so carefully studied, but appear to be significantly lower (Studniberg et 
aI. 1993; S~em et aI. 1994; de GruijI1996). In the absence of long-term follow-
up data for TL-01 UV-B, which has only been used for just over 15 years, the 
relative skin cancer risks associated with this lamp compared with broad-
band UV-B lamps remain unclear, but the best current evidence suggests the 
risks are likely to be less with TL-01 (Young 1995). 
To summarise, TL-01 UVB administered according to our standard regimen is 
more effective than PUV A for the treatment of chronic plaque psoriasis. 
Although more likely to produce asymptomatic erythema, it is preferred by 
most patients and, unlike PUV A, is not known to be associated with a 
significant increased risk of skin cancer. While there are some individual 
patients who, for particular psoriasis exacerbations appear to do better with 
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PUV A, we now only consider PUV A if TL-Ol has failed or has provided a 
disappointingly short remission. While other work has shown PUV A to be 
more effective, even that which showed the strongest PUV A preference 
suggested it was necessary to treat 5 patients (95% confidence interval 29 to 3) 
with PUV A to see one extra patient cleared compared with the use of TL-Ol 
(Gordon et al. 1999). 
Practical problems with PUV A include the frequent gastro-intestinal adverse 
effects and eye protection requirements with oral psoralens, or the 
inconvenience and time involved in bathing in psoralen solution, and its 
greater cost compared with UVB. In view of these disadavantages, and the 
well-recognised skin cancer risks, PUV A would have to be much more 
effective than TL-Ol to be considered as the treatment of first choice. The 
accumulated evidence from our study and the earlier work suggests that 
TL-Ol is the phototherapeutic treatment of choice for chronic plaque psoriasis. 
Comment 
This chapter describes a study, and the interpretation of its findings in 
conjunction with previous studies, designed to help determine which therapy 
, 
(PUV A or TL-Ol UVB) we should recommend as the first-line phototherapy 
for patients presenting with chronic plaque psoriasis. Chapter 6 describes the 
process of producing recommendations based, whenever possible, on the 
findings of such original clinical research and systematic reviews of the 
literature. 
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Chapter 6 
This chapter contains of a list of recommendations on the use of UVB plwtotherapy 
and plwtochemotherapy. These were incorporated in the report on the Scottish 
plwtotherapy audit (Chapter 2), circulated to all participating departments, and since 
discussed at a meeting of the Scottish PUV A and UVB users' group. 
The selection of topics for these recommendations was based on the findings of the 
Scottish phototherapy audit. The quality of the available evidence for each 
recommendation was graded according to the system used by the Scottish 
Intercollegiate Guidelines Network (SIGN). The ongoing process of updating, 
improving, and disseminating these recommendations is discussed. 
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Audit, clinical research, and the development of evidence-based 
recommendations 
The Scottish phototherapy and PUV A audit 
The Scottish phototherapy and photochemotherapy audit survey of 
1996/1997 (described in detail in Chapter 2) was intended to 1) determine 
whether or not the recommendations of the 1991 audit survey had been 
implemented, 2) to find out how we are using UVB phototherapy, as well as 
PUV A, and, following this, to 3) form a basis for making appropriate 
recommendations to assist efforts to continue to improve the phototherapy 
service available to patients with skin disease throughout Scotland. 
The findings of the 1996/1997 survey demonstrated that most of the 
recommendations made after the 1991 audit had been implemented. An 
important exception was the recommendation that all centres should have a 
reliable system to allow recall and monitoring of patients judged to be at a 
high risk of late adverse effects, principally skin cancer, because of their 
exposure to PUV A and UVB treatment. 
A major change in phototherapy practice in Scotland occurred over the five . 
years after the first audit: the marked increase in the availability of, and use 
of, ultraviolet B phototherapy, mainly utilising the new narrow-band (311-
313nm) UVB lamps. The major reason for differences in how TL-01 UVB was 
used between centres was the absence of clear evidence on which to base 
decisions regarding important aspects of treatment methodology, such as 
frequency of treatment. 
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Audit as a guide to necessary clinical research 
A survey of how a therapy is used cannot, itself, provide information on 
which to base specific recommendations. These must, when possible, be based 
on data from controlled studies (such as those described in Chapters 4 and 5), 
designed to provide information that can reasonably be extrapolated to the 
population to be treated. What a survey, conducted as part of an audit, can, 
and did (Chapter 2), provide are data on what aspects of treatment could be 
improved. For example, the audit showed some centres to require 
significantly more TL-Ol UVB exposures to clear psoriasis than others. 
Differences in patient selection for treatment may have played a part in this, 
but it is likely that differences in the efficacy of treatment prescribed were 
important, and that research designed to guide us as to the optimal treatment 
regimen for the majority of patients will suggest possible explanations for the 
differences. For example, it was found that patients with psoriasis treated 
twice weekly appeared to require more UVB treatments than those treated 
thrice weekly. Research was needed (and is now ongoing, following the study 
comparing 3x and 5x weekly TL-Ol UVB described in Chapter 4) to determine 
which of these two treatment frequencies is best. If it turns out that the 3x 
weekly regimen is more effective this finding would help explain the audit 
observation, and a change, encouraged by the dissemination of 
recommendations, to routine use of the more effective regimen would be 
expected to benefit patients who might previously have received sub-optimal 
therapy. 
The development of recommendations for phototherapy practice in Scotland. 
Literature searches were conducted using EMBASE® (Elsevier Science, 
Amsterdam) and MEDLINE® (National Library of Medicine, Bethesda) 
electronic databases using Ovid search software, version 7.8 (Ovid 
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Technologies Inc, 1988), and review of references of relevant reports. 
Appropriate literature was also identified in the bibliographies of standard 
textbooks and review articles (Abel 1992; Morison 1994; Honigsmann et al. 
1996). As recommended by CRAG (Oinical resource and Audit Group 1993), 
evidence for recommendations was graded according to the scheme of the 
United States Agency for Health Care Policy and Research (Table 6.1) 
(USDHHS 1992). 
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Table 6.1 
Evidence Levels 
la. from meta-analysis of randomised controlled trials 
lb. from at least 1 randomised controlled trial 
lIa. from at least 1 well-designed controlled study without randomisation 
lIb. from at least 1 other type of well-designed" quasi-experimental" study 
III. from well-designed non-experimental descriptive studies, such as 
comparative studies and case control studies 
IV. from expert committee reports or opinions and/ or clinical 
experience of respected authorities 
Recommendation Grades 
A (la,lb) 
B (lIa, 
lIb, III) 
C(IV) 
Requires at least 1 randomised controlled trial as part of the 
body of literature of overall good quality and consistency 
addressing the specific recommendation 
- Requires well-conducted clinical studies but no 
randomised clinical trials on the topic of 
recommendation 
Requires evidence from expert committee reports or opinions 
and/ or clinical experience of respected authorities. Indicates 
absence of directly applicable studies of good quality. 
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It should be borne in mind that aI/poor" recommendation grade does not 
imply that the recommendation is not important: what it tells us is that there 
is a lack of directly applicable published evidence, and so in most cases it is, 
itself, a recommendation that more research is needed. 
It will be noted that some of these recommendations are ideals to aim for, and 
not likely to be achieved soon, while others are already being implemented. ' 
Treatment indications Recommendation grade 
Narrow-band (TL-01) UVB is indicated for: 
• Psoriasis (moderately severe and severe chronic plaque) 
(guttate) 
Meta-analysis in Chapter 3, (Farber et al. 1985; Green et al. 1988; 
van Weelden et al. 1988b; Larko 1989; Karvonen et al. 1989; 
Storbecket al. 1991,1993; Kligman 1991; Picot et al. 1992a) 
(A) 
(A) 
• Atopic dermatitis (B) 
(George et al. 1993; Collins et al. 1995; Hudson-Peacock et al. 
1996) 
• Polymorphic light eruption (A) 
(Bilsland et al. 1993) 
• Actinic prurigo (B) 
(Collins et al. 1995) 
• Erythropoietic protoporphyria (B) 
(Collins et,al. 1995) 
• Chronic idiopathic urticaria, (q 
and many other conditions for which the evidence is anecdotal. For 
some rare conditions, ego subcomeal pustular dermatosis (Cameron 
et al. 1997; Orton et al. 1997), firm evidence of efficacy is unlikely to 
become available soon - but for others (such as the chronic 
urticarias, ichthyosis vulgaris, lichen planus, acne vulgaris) 
evidence is needed as a matter of urgency in order to ensure that 
we are neither wasting resources, and needlessly exposing patients 
to potential harm, if TL-01 UVB is ineffective, nor (in centres where 
these are not accepted indications for TL-01) depriving patients of 
effective therapy, and perhaps exposing them to greater risks 
associated with alternative treatments. 
In the absence of contraindications, PUV A may be considered for 
the 'above conditions if TL-01 UVB fails to produce' adequate 
improvement. In the case of psoriasis, if UVB-induced remission is 
short it may be worth trying PUV A. These recommendations 
concentrate on UVB: British Photodermatology Group guidelines 
provide a referenced review of PUV A indications (British 
Photodermatology Group 1993). 
Staffing 
Usually, dermatology nurses will provide phototherapy. In view of 
the level of responsibility expected of most phototherapy nurses 
they should be fully-trained, with at least 2 years experience since 
first on UKCC register. Phototherapy nurses should have sufficient 
experience of work in a dermatology ward and outpatient unit to be 
familiar with often-treated conditions, with supporting patients 
with these dermatoses and with the use of adjunctive treatments (eg 
scalp psoriasis treatments and bandaging for atopic dermatitis). 
There have to be sufficient nurses trained in phototherapy to allow 
for holiday cover, and training of other nurses in the unit. 
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(C) 
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Equipment 
Separate UV A and UVB cubicles are preferable to combined units (C) 
because: 
1) treatment times can be kept shorter (for patient convenience 
and to allow more patients to be treated) if cubicles are fitted with 
only one lamp type; and 
2) separate units minimise the risk of the potentially serious 
effects of accidental administration of UVB when UV A irradiation 
is intended. 
For TL-01 administration all cubicles in current use appear 
reasonable. The cubicle design (breadth, reflectors) is important, as 
well as number of lamps, in determining output - outputs of, for 
eXaInple, the widely used Waldmann 1000 units allow reasonably 
short treatment times if used for TL-01 monotherapy. If obtainable 
larger units may, however, be better for 1) higher outputs, and even 
shorter treatment times; 2) a greater distance between patient and 
lamps reduces the risk of erythema episodes due to changes in 
patient's position in the cubicle during the treatment course and 3) 
possibly less heat in cubicle, depending also upon other design 
factors. 
For MPD and MED-testing, there are advantages in having 
irradiation apparatus separate from the treatment cubicles. This 
must be accurately metered to ensure equivalence of doses 
administered by this apparatus and by the treatment cubicles. 
Separate apparatus saves time and the inconvenience involved in 
MED / MPD-testing in the treatment cubicles; and (given adequate 
staffing) allows patients to be treated at the same time as pre-
treatment MEDs and MPDs are determined. 
(C) 
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In PUV A units, a bath should be available to allow administration (C) 
of bath-PUV A when indicated - such as for a patient with a 
gastrointestinal malabsorption problem, making oral psoralen 
administration unreliable, or for a claustrophobic patient who 
would benefit from the short treatment times if topical TMP is used. 
Methodology - UVB 
Dosimetry 
TL-01 UVB metering should be· standardised throughout Scotland. (B) 
This could be done, following similar principles as those of the 
Scottish PUV A dosimetry guidelines. 
This would: 1) allow meaningful discussion of doses used in 
regimens throughout the country; 2) allow patients to be safely 
transferred from one centre to another during a treatment course; 3) 
make records of cumulative UVB doses more meaningful; and 4) 
would, for those centres not yet able to MED-test all patients, 
reduce the' risk of either under-treating or over-treating with the 
exchange of starting dose and incremental dose protocols between 
centres. 
Starting dose 
This should be based on determination of the individual patient's (B) 
MED rather than based on sun-reactive skin type (Rampen et al. 
1988). Most centres use 70% of MED for psoriasis. 
An MED-based starting dose has advantages of: 
1) SAFETY - there is no risk of unexpected burns through a starting 
- dose excessively high for the individual. Skin phototype (based on 
history of reactions to sunlight) does not predict erythemal-
responsiveness (Rampen et al. 1988). MED-determination picks up 
those few patients with an unrecognised photodermatosis such as 
solar urticaria or photosensitivity dermatitis/ actinic reticuloid 
syndrome, who could suffer serious consequences if exposed to 
whole-body UVB irradiation. It also ensures that the effects of any 
photosensitising drugs are taken into account in deciding starting 
dose. 
2) Treatment efficacy - a study directly comparing an MED-based 
UVB regimen with an arbitrary/skin phototype-based regimen has 
not been done. However, it seems reasonable to suppose that if an 
MED is not determined, starting dose will have to be set excessively 
low for the majority, to save serious burning in a minority of 
patients. An excessively low starting dose might still be sufficient to 
lead to photo-adaptive changes, impairing efficacy of subsequent 
doses even when the therapeutic dose threshold is passed. Even if 
this does not happen, a low starting dose means extra exposures 
(causing patient inconvenience, possibly increased risk of chronic 
adverse effects and waste of resources) before a therapeutic dose is 
reached. 
Doses for MED testing 
Should be a geometric, rather than arithmetic, series (Diffey et al. 
1991; British Photodermatology Group 1992). 
MED readings 
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(B) 
Both the MED-test irradiation procedure and reading of the MED (C) 
must be done by experienced, trained staff (whether nursing, 
medical, physiotherapist or medical physicist). 
Although there is no evidence that either tungsten-lamp or 
- fluorescent lamp lighting (of equal illuminance) leads to variation 
in MED determined (Diffey et al. 1992), adequate illumination is 
essential. 
(B) 
Treatment frequency 
For psoriasis, TL-01 UVB should be administered 3x rather than 5x 
weekly (Chapter 4, Dawe et a1. 1998), except in exceptional 
circumstances. Whether 2x weekly treatment is as effective is, as 
yet, unknown although an ongoing trial is expected to answer this. 
The optimum treatment frequency for atopic dermatitis, PLE and 
other conditions is unknown. Most now treat these other conditions 
following the same regimen as is used for psoriasis. 
Dose increments 
For psoriasis a low incremental regimen (20% reducing to 10% 
increments) is preferable to a high incremental dose regimen (40% 
reducing to 20% increments) (Wainwright et al.1996). 
Adjunctive therapy 
Emollients which act as sunscreens should be avoided (Lebwohl et 
al. 1995). For psoriasis treatment, there appears to be no benefit, in 
terms of more rapid clearance, in pre-treatment with an emollient 
(coconut oil) although this can improve patient comfort (George et 
al.1993b). 
For atopic dermatitis the usual advice is that emollient use must 
continue. As long as the emollient chosen is not a sunscreen and 
contains no potentially photoactive ingredients (for example, plant 
extracts or fragrances) it can be applied prior to treatment - ideally 
at the same time prior to each treatment. 
The necessary studies have not been done to decide whether or not 
calcipotriol, dithranol, tar or corticosteroid preparations will 
improve the efficacy of an otherwise optimal TL-01 phototherapy 
regimen. 
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(A) 
(A) 
(B) 
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Systemic retinoids (etretinate, acitretin, isotretinoin) may be used in (A) 
conjunction with TL-Ol UVB - particularly for high exposure 
patients. Etretinate-TL-Ol reduces the dose required to reach 
clearance by one-third (Green et al. 1993). In this randomised study, 
however, relapse rate at 6 months with Re-TL-Ol was 67% 
compared to only 50% with TL-Ol monotherapy or Re-PUV A 
therapy. 
Stopping treatment 
In order to minimise cumulative exposures and dose (and so reduce 
the risk of chronic adverse effects), maintenance therapy should not 
be used for psoriasis unless the alternatives are more toxic. 
Maintenance therapy with broad-band UVB slightly prolongs 
duration of remission of psoriasis (Stem et al. 1986), but at the 
expense of significantly more exposures (and patient 
inconvenience). For most patients, maintenance therapy with TL-Ol 
does not hold sufficient advantages (if any) to outweigh the clear 
disadvantages (patient inconvenience, extra exposures and cost). 
As with broad-band UVB it is customary, in most centres, to stop at 
(C) 
complete, clearance or an arbitrary 4 to 6 exposures after minimal (C) 
residual activity is reached. The rationale is that after near-
clearance there may still be residual subclinical psoriasis, and that a 
few extra treatments may prolong remission. There are, as yet, no 
objective data to confirm or refute this. 
For uncomplicated psoriasis a written unit discharge policy for 
nurses/ physiotherapists administering therapy can prevent 
-
unecessary treatments after clearance, prior to medical review. For 
"desensitisation". of the photodermatoses 15 treatments are usually 
used. Patients with other conditions will often require medical 
review to decide when to stop a course of phototherapy. 
(C) 
Methodology - PUVA 
For a more comprehensive list of recommendations regarding this 
treatment, see the British Photodermatology Group Guidelines for 
PUV A (British Photodermatology Group 1993). 
Pre-treatment tests 
Some may chose to carry out other procedures, but the following 
should always be checked: 
• LFTs if there is a history to suggest possible liver disease 
• Baseline ANF and anti-Ro antibodies before a first treatment 
course in those with a suspected photodermatosis. 
• History to exclude likely pregnancy; and advice to avoid 
pregnancy during PUV A 
• Patients own eye-protection should be tested by one of the 
methods recommended by the British Photodermatology Group 
OR only tested and approved eye-protection should be advised 
Psoralens 
A range of psoralens should be available for systemic and topical 
administration. 
Starting dose 
This should be based on MPD-assessment for safety, to ensure 
adequate psoralen in skin at time of irradiation, to take into account 
any other photosensitising drugs (or drugs that might alter 
psoralen metabolism) and for increased efficacy in psoriasis 
treatment - a reduction in cumulative exposures to clearance 
(Collins et al. 1996b). 
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(C) 
(C) 
(C) 
(C) 
(C) 
(A) 
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Treatment frequency 
Twice weekly PUV A is appropriate for a Scottish population of (B) 
psoriasis patients (Green et al. 1993). For psoriasis patients living far 
from a PUV A centre, once-weekly treatment can be used (Cox (B) 
1995). The optimal frequency for other conditions has not yet been 
determined - many use 3x weekly treatment for PLE prophylaxis. 
Dose increments 
As the dose-response curve for PUV A erythema is flatter than that (B) 
for TL-01 UVB erythema (Cox et al. 1989), higher incremental 
regimens than for TL-01 should be appropriate. No study 
comparing different PUV A incremental regimens has been 
conducted, but most use a 40% reducing to 20%, or similar, 
regimen. 
II Aggressive" regimens with maximal suberythemogenic doses 
cause more frequent "burning" episodes (Carabott et al. 1989; 
Green et a1. 1993). A widely used regimen involves 40% increments, 
reducing to 20% depending on erythema response. The optimum 
regimen remains undetermined. 
Adjunctive therapy 
There is some evidence (randomised controlled trial) for calcipotriol 
(Speight et al. 1994), although how effective the PUV A regimen it is 
used with is crucial: adjunctive treatment is most likely to help if 
the primary treatment is -inadequate. 
(B) 
(A) 
Systemic retinoids reduce the UV A dose to clearance (Green et al. (B) 
1992), and should be offered to patients regarded as at significantly 
increased risk of. skin cancer as long as there are no 
. contraindications. 
Methotrexate and cyclosporin should NOT be used as adjunctive 
therapy (Fitzsimmons et al. 1983; Bos et al. 1989; van de Kerkhof et 
al. 1997). This applies also to UVB phototherapy. It is probable that 
other immunosuppressives (eg. azathioprine, hydroxyurea) in 
combination with PUV A or phototherapy will also increase the skin 
cancer risk. 
Stopping treatment 
Maintenance therapy should not be used routinely, but reserved for 
exceptional patients, usually with mycosis fungoides rather than 
psoriasis, for whom the risks are likely to be outweighed by the 
benefits. 
Follow-up of #at-risk" patients - UVB and PUVA 
A system should be established to allow recall of all patients 
identified as at increased risk of adverse effects. Ideally, this system 
should be- flexible enough to allow for changes in the definitions of 
an "at-risk" patient as we gain more knowledge of the long-term 
effects of TL-Ol UVB. For most centres a computerised database 
system would be appropriate. 
One current, cautious, definition of "at risk" (used in Dundee) 
includes patients: 
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(B) 
- who have received more than 150 PUV A exposures (B) 
- who have received more than -150 UVB exposures (the risk 
associated with this is -probably far less than with 150 PUV A (C) 
exposures but following up all these patients will help in generating 
epidemiological data concerning the long-term risks of TL-Ol 
phototherapy. 
- who have had previous non-melanoma skin cancer, melanoma, 
Bowen's disease or solar keratoses. 
- who have, separately, received methotrexate or cydosporin. 
In areas where patients may receive UVB or PUV A in more than 
one centre, follow-up of at-risk patients, and choice of appropriate 
therapy, would be aided by the adoption of a patient-held 
cumulative exposure record. The information from such a record 
could be added to an individual unit's records on completion of 
each course of therapy there. 
At~risk patients should have a yearly review by a dermatologist. 
Patients regarded as at increased risk should be alerted to this and 
told to seek advice about any possible skin cancers or pre-cancerous 
lesion. These patients' general practitioners should also be informed 
that their patients may be at increased risk of skin cancer 
development. In most departments, this follow-up is best 
organised" through the phototherapy unit by the consultant 
responsible for the phototherapy / PUV A service. 
Equity of access to phototherapy 
Ultraviolet B phototherapy, administered by trained staff using 
modem equipment, should be available to all for whom this is 
regarded as the treatment of choice. 
In some areas, more resources to reduce waiting lists for present 
facilities would fulfil this recommendation. In the more 
geographically remote regions this aim may never be fully 
achieved, but suggestions for consideration are: 
- The development of a home phototherapy service (Cameron et al. 
200Oc) (with equipment and patient training provided by the 
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(C) 
(C) 
(C) 
(B) 
"local" dermatology department, which is responsible for 
monitoring and follow-up) can help some, well-motivated patients. 
- In some areas, the best approach may be the development of an 
existing physiotherapy phototherapy service. This would require 
modernisation of the service, with provision of equipment allowing 
whole-body treatment with the most effective and safest available 
equipment. This approach is only appropriate in areas with a 
physiotherapist interested in phototherapy, who regards it as an 
important part of his or her practice. The involvement of the local 
dermatology department, and medical physics department 
assistance with dosimetry, should be encouraged. 
Some areas for future clinical research 
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As is clear from the above list of recommendations, many had to be based on 
very limited evidence. A few areas of required research are listed below. 
Necessary research: phototherapy and PUV A indications 
• Is TL-Ol phototherapy effective for chronic idiopathic urticaria, acne vulgaris, . 
pityriasis lichenoides chronica, granuloma anulare, lichen planus, mycosis 
fungoides and the many other conditions for which there is only open study 
and anecdotal evidence of efficacy? 
• Can we predict which atopic dermatitis patients will respond best? 
• .What is the phototherapeutic action spectrum for all the conditions treated, 
excepting psoriasis (the only condition for which this information is 
available)? Would other UV lamps be more effective than TL-Ollamps for 
any of these indications? 
• How effective is PUV A in comparison to methotrexate, acitretin or 
cyclosporin for palmo-plantar pustulosis? 
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Necessary research: phototherapy and PUV A methodology 
• What is the appropriate incremental regimen for atopic dermatitis? Most 
use the same regimen as for psoriasis but this may not be optimal for atopic 
dermatitis - some dermatologists in Scotland have an impression that lower 
increments, or even keeping at a constant low dose throughout the course, 
might be more appropriate. 
• Is 2x weekly TL-Ol phototherapy for psoriasis as effective as 3x weekly 
therapy? 
• In many centres adjunctive topical treatments are still used when psoriasis 
is treated with TL-Ol; but their value is uncertain. Does calcipotriol 
ointment, coal tar or dithranol in conjunction with TL-Ol phototherapy lead 
to improved clearing/ lower dose/ fewer exposures to clearance? 
• For localised treatment for hand and foot conditions are topically applied 
psoralens as effective as oral psoralens? If "no", can our topical treatment 
regimens be modified to make them more effective? 
Necessary research: phototherapy and skin cancer 
What is the risk of skin cancer development with UVB phototherapy? 
Hopefully, we will eventually have the necessary data to answer this question 
for the TL-Ol source because (as with PUV A, but unlike the situation with 
broad-band UVB) the patient treatment records have been kept by most 
centres since its introduction. 
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Development and dissemination of recommendations 
The recommendation in this chapter have been discussed at a meeting of the 
Scottish PUV A and phototherapy users' group, and an abbreviated overview 
presented at a meeting of the Scottish Dermatological society. Also, they were 
included in the report on the Scottish phototherapy audit circulated to all 
participating centres. Each centre was given their individual centre 
identification number, used on graphs in the audit report, so they could see 
how some aspects of their practice compared with that in other centres. For 
example, the consultant responsible for the service in centre 11 (Figure 2.15) 
could note that they used more treatments per course for psoriasis than 
others. The interpretation of this would be most appropriately made locally, 
but if it was decided that the reason was likely due to sub-optimal therapy, 
rather than selection of patients with relatively unresponsive psoriasis for this 
treatment, then this would be expected to encourage improvements in 
treatment methodology, such as introducing MPD testing to determine 
starting UV A dose. 
Some recommendations, such as the need to develop efficient follow-up 
systems for patients at risk of skin cancer as a result of treatment, might be 
best implemented by national action, with development of a computerised 
database of all patients given PUV A or UVB, and recording of, at a minimum, 
cumulative exposures for each therapy. For this to work well, it will be 
necessary for every department to agree on certain aspects of the treatment 
process, and would be assisted by some standardisation in how these 
treatments are used, for example by the introduction of a standard 
UVB/PUVA referral form to be used by everyone. The development of 
national (Scotland-wide) clinical standards for phototherapy, with guidelines, 
based on good evidence, followed by all centres could be used to help 
everyone in implementing agreed recommendations. For those aspects of 
. treatment methodology for which we lack any directly applicable, good 
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quality, evidence from clinical research, it should be recognised that local 
variations in practice are to be expected, and may even be beneficial. 
Standardisation of aspects of practice for which we lack good evidence could 
be counter-productive as it might reduce the impetus to carry out the 
necessary research. 
A centralised computer database follow-up system for phototherapy and 
PUV A patients, to which all centres could be linked, would not only assist 
with the local follow-up of at risk patients, but would make future audit of the 
service much easier. For example, data on between-centre differences in 
numbers of treatments per course for psoriasis could, with the agreement of 
everyone concerned, be collected automatically. 
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Chapter 7 
This chapter starts with a short discussion of the history of the use of knowledge 
derived from quantitative observation and clinical experiment in guiding medical 
practice, related to the history of phototherapy described in Chapter 1, the Scottish 
phototherapy audit, and clinical research to help establish the most appropriate 
phototherapy regimens now. 
This is followed by a discussion of what the Scottish phototherapy audit has achieved 
so far, and what still needs to be done to implement its recommendations, and to aid 
future efforts to establish how our use of phototherapy is changing. 
This discussion includes comment on the use of quantitative reviews (meta-analyses) 
to help answer questions about the magnitude of the difference in efficacy between 
treatments (broad-band versus narrow-band UVB, narrow-band UVB versus PUVA). 
The results of the two clinical studies included in this thesis (in Chapters 4 and 5) are 
re-visited, with comment on how we should use the findings of such studies to guide 
standard treatment regimens. Possible problems in extrapolating these findings to 
different patient populations are mentioned, as is the need for further clinical 
experimentation to answer other questions about what are the most appropriate 
treatment regimens. 
Finally, this chapter includes further discussion concerning methods of developing 
and implementing recommendations, based on knowledge of what we are doing 
(survey phase of the audit), and experimentally derived evidence to guide us as to what 
we should be doing. 
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Bringing together the components of this thesis 
The preceding chapters describe the development of dermatological 
phototherapy in Scotland, recent research aimed at answering important 
questions about how we should use these treatments, and the role of clinical 
audit in establishing how we are using them. A theme of this thesis, 
connecting the strands of original clinical research, careful quantitative review 
of previously published clinical studies, and audit is that these together form 
a basis on which we can base treatment recommendations. 
Medical arithmetic and experimentation (evidence-based medicine) 
Such attempts to base medical practice on experimentally derived evidence, 
and knowledge of current practice derived from quantitative observation, are 
not new. In the eighteenth century, many publications, largely by Scottish 
trained authors, exemplified the increasing interest in practice based on 
"medical arithmetic and experimentation" (recently re-named "evidence-
based medicine"), rather than practice based largely on dogma derived from 
the current pathophysiological theories (Trohler 2000). 
However, not everyone then, or more recently, has approved of attempts to 
develop guidelines based on evidence from observation and experiment. For . 
example, Robertson, a naval surgeon, gained his MD from Aberdeen 
University for his quantitative comparisons of treatments for fevers. These 
studies showed Peruvian bark to be more effective than the blood-letting 
favoured by the traditiorlaIists, who based their practice purely on the c~ent 
pathophysiological theories. Robertson had to defend his "Observations on 
the jail, hospital or ship fever" (Robertson 1783) against those who 
pronounced medical·statistics "dry and insipid reading or altogether useless 
in the practice of physic". Another 18th century clinical statistician was 
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prevented from re-entering the army medical service because he was 
regarded as a ilJacobin, leveller, republican and democrat ... " (Millar 1798). 
Presumably those who now oppose evidence-based medicine do so, at least in 
part, as a result of similar fears: they worry that proponents of evidence-based 
medicine threaten lIto subvert the traditional order of things" (frohler 2000). 
Perhaps some are concerned that the current increasing emphasis on 
evidence-based medicine might harm, through competition for funding (and 
other resources, including interested clinicians), our rapidly expanding 
knowledge about the pathophysiological mechanisms of disease. Of course all 
aspects of medical research are important, whether carried out at population, 
individual, cellular, or molecular level. But for the readily forseeable future it 
is likely that the findings of clinical research, such as that described in 
Chapters 5 and 6, will continue to provide the evidence most immediately 
helpful in guiding treatment decisions. 
The Scottish phototherapy and PUV A audit: achievements to date 
The Scottish phototherapy and PUV A audit (Chapter 2) has contributed to 
knowledge of how we are using phototherapy and PUV A. It is likely that the 
improvements in the PUV A service described in Chapter 2 relate, at least in 
part, to the 1991 survey and subsequent recommendations. 
It is now clear that how UVB phototherapy is used varies significantly from 
centre to centre. For example, regarding phototherapy indications, chronic 
ordinary (idiopathic) urticaria is an important indication nation-wide, with 
1.5% of courses prescribed for this, yet several departments have never 
treated urticaria with UVB. Such differences in when phototherapy is used, 
and the differences in how it is used (in the treatment regimens), are not 
surprising when there is no, or limited, published data on which to base 
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practice, and emphasises the need for more research. To return to the example 
of UVB for chronic urticaria, are those who attend centres where UVB is not 
prescribed for this indication disadvantaged by not receiving a useful 
treatment (and possibly by exposure to the adverse effects of other therapies), 
or are those centres that do use UVB for urticaria simply wasting resources, 
and needlessly exposing patients to an increased risk of developing skin 
cancers in future? We do not know. Some other unanswered questions, which 
I regard as particularly important, are included at the end of the last chapter. 
Assessing the evidence: the Tole of meta-analysis 
The meta-analysis described in Chapter 3 illustrates the potential of such 
"research on the research literature" in helping to clarify the answer to a 
question already fairly extensively studied. On the basis of this meta-analysis, 
it is clear that narrow-band TL-Ol lamps are preferable to broad-band UVB 
lamps for the treatment of plaque psoriasis in populations of predominantly 
Northern -European extraction and skin phototypes I to III. Despite 
imperfections in study methodology (when looking back with the benefit of 
hindsight) I would regard a new large randomised, controlled trial to 
compare TL-Ol with broad-band UVB lamps for psoriasis in this sort of 
population as unnecessary, a waste of resources, as the question has already 
been answered. However, lessons from the deficiencies of the previous 
studies will hopefully guide any future study comparing these two UVB 
modalities. The results of such a study in a predominantly high skin 
phototype population would be of interest, and of particular importance in 
resource-poor countries. 
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Clinical studies: interpretation and extrapolation of results 
The clinical studies described in Chapters 4 and 5 illustrate attempts at 
answering questions identified as important during the audit. The study 
comparing 3x with 5x weekly TL-Ol UVB phototherapy (Chapter 4) clearly 
showed that, for the majority of patients in our population, 3x weekly 
treatment is preferable. 
This study also, however, illustrates the importance of allowing flexibility in 
the implementation of recommendations based on controlled studies. While 
we can reasonably extrapolate our study results to other skin phototype I to 
III 'skin phototype patients of northern European origin who have chronic 
plaque psoriasis, this study has not determined the optimal treatment 
frequency for those in other populations, with different types of psoriasis. 
Recommendations based on the findings of this study can only be used very 
cautiously, in the absence of any good more directly applicable evidence, to 
guide those treating different patient populations. Also, in our study there 
were two- patients whose responses to the treatments compared suggested 
that these particular individuals would be most appropriately treated 5x 
weekly. ,Although 3x weekly treatment can be advised as the standard 
treatment frequency in populations of patients like our study participants, 
there will always be individual patient exceptions. It is important that we do 
not bind ourselves so strictly by guidelines that we cannot continue to take 
the experiences and preferences of individual patients into account when 
choosing therapy. Guidelines are to guide, not dictate, clinical practice. 
The chapter on a study comparing PUV A with TL-Ol UVB illustrates some of 
the factors we must consider when extrapolating from findings in a study 
population to all the patients we will be treating in future. As illustrated in 
Figure 5.1, the proportion of those who are considered for a study who are 
eligible for entry, and who agree to participate, can be small. This 
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information, on the proportion of the potential study population who actually 
take part, is often still not included in published study reports, but will often 
be small, especially if the study is time consuming or complicated for 
participants. 
As it turned out in this study, TL-01 UVB was more effective than PUV A. We 
would have expected selection bias to favour PUV A. Most participants had 
previously received treatment with phototherapy or PUV A. Those who did 
well with the simpler treatment (TL-01 UVB) were less inclined to take part in 
time consuming study than those who had not responded well. As we would 
have expected selection bias to favour PUV A it is possible that TL-01, as 
adIninistered in this study, is even more superior to PUV A than the study 
showed. We can reasonably extrapolate our study findings to our wider 
potential patient population. Of course the caution mentioned above 
regarding the need for flexibility in treating individuals, a few of whom will 
fare better with PUV A, applies. 
What about populations attending other units: one study (Gordon et al. 1999) 
did produce conflicting results, and strongly favoured PUV A for efficacy in 
clearing psoriasis. This may in part have reflected differences in the patients 
considered suitable for PUV A or UVB, but differences in treatment 
methodology are probably the explanation. The use of meta-analysis tools, 
particularly a forest plot (Figure 5.3) to graphically compare the different 
studies' results, were helpful in judging how different the results really were. 
Re-analysis of the published data of the earlier studies illustrated the value of 
presenting results in terms' of -clinically relevant measures of effect, 
particularly the concept -of number needed to treat (NNT). The Gordon ~t al. 
(1999) study showed an odds ratio of 3 favouring PUV A. Only after 
"translating" this figure into a NNT of 5, that is five patients would need to be 
treated with PUV A . to see one clearing who would not have cleared with 
, UVB, is it easy to apply this study finding to clinical practice. 
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Developing and implementing recommendations 
One of the benefits of producing evidence based recommendations is that it 
highlights the major areas where appropriate evidence is lacking. However, 
even in the absence of strong evidence, guidelines agreed upon by a group of 
interested people (ideally including not only dermatologists, but nurse and 
physiotherapist phototherapists, and patients) would prove useful to the 
many phototherapists who currently want advice as to whether or not what 
they are doing is still appropriate. Hopefully, Scotland-wide clinical 
standards for phototherapy can incorporate such guidelines. It is· important 
that they are produced and agreed upon by representatives of everyone 
concerned, and that it is clear that they are guidelines, and not designed to 
restrict variations in clinical practice where we currently lack good evidence, 
nor to discourage flexibility in the application of evidence from study 
population data to individuals. 
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ChapterS 
This concluding chapter summarises the current state of phototherapy in Scotland. It 
incorporates comment on the most important next steps to improve the Scottish . 
phototherapy service, including further research required to guide how we use PUV A, 
UVB, and new developments in phototherapy such as UV AI. 
I 
i> 
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Now, exactly a hundred years after it first became available in Scotland, 
phototherapy using artificial ultraviolet sources retains an important, and 
expanding, place amongst the treabnents available for many inflammatory 
skin diseases. It is likely to remain important. Knowledge about the 
mechanisms involved in the inflammation of conditions such as psoriasis is 
increasing, and may lead to new therapies targeting important components of 
the disease process. But, for the readily foreseeable future, we will continue to 
rely on rather non-specific anti-inflammatory and immunosuppressive 
therapies. Although topical anti-inflammatories, particularly corticosteroids, 
work for many conditions, they are not suitable for all, and are not always 
sufficiently effective. Other treabnent is then required and phototherapy and 
PUV A do, through their predominantly local actions on the skin, achieve a 
degree of selectivity, reducing the risk of adverse effects, not obtainable with 
the currently available systemic immunosuppressive agents. 
Major advances in phototherapy have included the development of more 
effective lamps for the treabnent of psoriasis. Fortunately these narrow-band 
(TL-Ol) lamps are also proving effective in other conditions. Psoralen-UV A 
photochemotherapy (PUV A) retains its primary place in the treabnent of 
certain conditions, such as plaque stage mycosis fungoides, but for psoriasis, 
polymorphic light eruption prophylaxis, and for atopic dermatitis TL-Ol UVB 
has usurped its place as the standard phototherapy. Regardless of its 
disadvantages, in particular the concern about side effects, and it not being 
significantly more effective in whole study populations, PUV A does remain 
important for those particular individuals for whom it is more effective. 
Lessons have been learnt from the past failure to properly document broad-
band UVB treabnents, or to follow-up patients. Such careful follow-u'p of 
patients treated in the initial large PUV A studies showed that there were real 
risks of skin canc~r development as a late adverse effect. Since the 
introduction of TL-Ol UVB, every deparbnent in Scotland has kept treabnent 
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records, and it is hoped that a system to ensure the follow-up of all UVB and 
PUV A patients will be set up in every unit. If agreement amongst 
departments, and funding support, can be obtained a centralised computer 
database system could have the added advantage of greatly reducing the 
work involved in future audits of the phototherapy service. 
Much clinical research is still required to clarify when we should use UVB, 
and when PUV A, and to determine the optimal treatment regimens for every 
responsive disease. Recommendations based on good quality research data 
should assist with the dissemination of the findings, and guide the 
development of standard phototherapy regimens, while not discouraging 
appropriate adaptation of how these treatments are used in individual 
departments, and for individual patients. 
New developments in the phototherapy of skin diseases continue to emerge, 
and clinical experimentation, and audit of outcomes, will tell us what place 
such potential advances as UV AI (340 to 400nm UV A) should have in our 
therapeutic armamentarium. 
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Narrow-band (TL-O 1) ultraviolet B phototherapy for chronic 
plaque psoriasis: three times or five times weekly treatment? 
R.S.DAWE, N.J. WAINWRIGHT, H.CAMERON AND J.FERGUSON 
PllOtodemllltology UIlIt. Department of Dermatology. Nille\\'ells Hospital alld MediCCII School. DUlldee DD 1 9S1: U.K. 
Accepted for publication 22 December 1997 
.. Summary Three and five times weekly narrow-band TL-O 1 (311-313 nm) ultraviolet (UV) B phototherapy 
regimens for chronic plaque psoriasis were compared in a randomized, observer-blinded, half-body, 
within-patient paired study. Twenty-one patients [13 men, eight women, age range 21-68 years, 
skin phototypes I (two patients). II (14) and III (five)] entered the study. Sixteen reached clearance or 
minimal residual activity (MRA) on both sides. Of the other five, three withdrew because they did not 
reach clearance or MRA on the 5 x weekly side by a maximum of 30 treatments. one when he was 
satisfied with moderate improvement and one because of repeated failure to attend. Those who 
completed treatment. reached clearance or MRA after a median of 35 days with 5 x weekly treatment 
compared with 40 days with 3 x weekly treatment (P = 0'007). but required a median of 2 3·5 com-
pared with 17 UVB exposures (P = 0·001) and 94 minimal erythema dose multiples (MEDs) 
compared with 64 MEDs (P = O' 0 1). Fifteen (of 16) developed at least one episode of well-demarcated 
erythema during 5 x weekly treatment compared with just three of 16 treated 3 x weekly 
(P<O·OO1). There was no significant difference between regimens in duration of remission. For 
this skin photo type I-III population. the more rapid clearance of psoriasis with 5 x weekly 
phototherapy is not. for the majority of patients, sufficient to justify the extra exposures and 
higher UVB dose. We no longer use 5 x weekly phototherapy for psoriasis. 
We do not. as yet. know the optimum narrow-band (TL-
01) ultraViolet (UV) B weekly treatment frequency for 
chronic plaque psoriasis. UVB phototherapy using TL-
01 lamps is in widespread use due to its greater 
~fficacyl-6 and. possibly. safety1.7-11 compared with 
~?ad-band UVB sources. Our aim when administering 
t IS treatment is to clear psoriasis with as few unwanted 
- acute effects as possible. and to minimize the risk of late 
adVerse effects (particularly non-melanoma skin 
~ancer) by minimizing each patient's cumulative UVB 
reatments and dose. 
Traditionally. as in many centres, we have treated our 
, ~ut-patients 3 x weekly and in-patients 5 x weekly. The 
;~atment frequency in published studies involving TL-
C DVB for psoriasis ranges from 2 x to 5 x a week. 
S Utrent TL-Ol treatment frequencies in routine use in 
( cottish treatment centres are 2, 3 and 5 x per week 
unpublished observation, R.S.Dawe, Scottish PUVA 
~~d phototherapy audit data). In the U.K., as a whole, 
B (all sources) is administered 2 x to 7 x weekly.u 
i tAlthough the question: 'How often should we admin-;ger DYE?' has exercised dermatologists since at least 
30.13 the answer has remained unclear even for 
f01998B" . 
rthsh Association of Dermatologists 
conventional broad-band sources. However. a paired 
comparison study of nine patients showed no demon-
strable advantage in treating chronic plaque psoriasis 
twice daily compared with once daily.14 A retrospective 
comparison of a 3 x weekly with a 5 x weekly broad-
band (FS72 1'12 lamp) UVB regimen showed no sig-
nificant differences in dose or number of treatments 
to clearance and that the 3 x weekly regimen was 
better tolerated.15 Even if we accept (bearing in mind 
the retrospective design of this study, and the likely 
differences other than treatment frequency between 
the two groups compared) that 3 x weekly is preferable 
to 5 x weekly broad-band UVB. this is of limited help in 
deciding how frequently to administer TL-Ol. The opti-
mum frequency of phototherapy with one UV source 
need not be the same as that for another. As the TL-Ol 
lamp has a minimal output of therapeutically unim-
portant,16 but erythemogenic1 and carcinogenic17 
shorter UVB and uve wavelengths it is possible that 
more frequent treatment than with broad-band UVB 
would be beneficial. 
Patients often comment that a fortnight sunbathing 
on holiday clears their psoriasis. while it may take 4-
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7 weeks of 3 x weekly hospital phototherapy to achieve 
the same result. A recent study which compared Canary 
Islands heliotherapy with broad-band UVB photother-
apy in Finland provided some supporting evidence-
showing heliotherapy to clear psoriasis more rapidly 
and with a lower cumulative UVB dose than photo-
therapy. IS One of several possible explanations for this 
finding is that more frequent therapy was more 
effective. 
We conducted a study designed to (i) test the hypo-
thesis that 5 x weekly TL-01 UVB would clear psoriasis 
more rapidly and with fewer UVB exposures and a lower 
cumulative dose than 3 x weekly treatment. and (ii) 
help to answer a question of practical clinical impor-
tance: 'How frequently should we administer TL-Ol 
phototherapy for chronic plaque psoriasis?' 
Materials and methods 
Stlldy design 
This was an observer-blinded, randomized. paired 
(within-patient) comparison study. Patients gave their 
informed consent after an opportunity to discuss the 
study implications and reading a patient information 
leaflet. The Tayside Committee on Medical Research 
Ethics approved the study. We treated each half-patient 
(sagittal plane) independently. following our standard 
minimal erythema dose (MED)-based. low percentage 
dose incremental. 1 ? UVB phototherapy regimen 
(Table 1). with only the treatment frequency differing 
between sides. A. treatment allocation list generated 
from a random number table was used to determine 
which (right or left) side was treated 3 x and which side 
5 X weekly. Patients wore a half-body suit (adapted work 
overalls) made of material which allowed transmission 
of no detectable UVB and negligible UVA (as assessed by 
Bitachi U-3210 double beam reflectance spectro-
photometer). If the dose due to be delivered to each 
side differed. the higher dose side was treated first with 
the difference between the prescribed doses. The suit 
Was then removed to allow administration of the 
remaining dose to both sides. At each visit patients 
Were assessed and the psoriasis severity graded by an 
observer unaware of treatment allocation. The decision 
to stop treatment was made following our unit's 
standard protocol. 
After discharge all patients were followed up for a 
Year. or until relapse. at monthly intervals by telephone 
or visit to our department for assessment. If there was 
any suggestion of psoriasis recurring on either side. the 
patient was asked to attend for review. Relapse was 
defined as either an increase of global score to 50% of 
that at baseline or a return of psoriasis of sufficient 
severity for the patient to be unwilling to continue with 
emollient therapy alone. 
The study was carried out in the Phototherapy and 
PUVA unit of the Dermatology Department. ~inewells 
Hospital, which serves the Tayside area. 
SlIbjects 
We recruited patients with chronic plaque pSOrIaSIS 
from out-patient clinics between November 1995 and 
June 1996. Patients were excluded if they had a history 
of skin cancer or solar keratoses or if they were on 
systemic immunosuppressive therapy. Other study-
specific exclusion criteria included: age < 18 years; 
phototherapy. PUVA or. any systemic therapy for 
psoriasis within the preceding 3 months; guttate 
psoriasis; known abnormal photosensitivity and any 
expressed hesitation about ability to attend daily (except 
weekends) for treatment. 
Irradiation cllbicle 
Either a Waldmann UV5000 cubicle. fitted with 24 
Philips 100 W TL-01 lamps. or a cubicle constructed 
by the Ninewells Medical Physics Department. with 50 
Philips 100 W TL-01lamps. was used. The same cubicle 
was used to treat both body halves and throughout each 
patient's treatment course. Irradiance was determined 
monthly with an International Light IL1400 meter 
calibrated with a spectroradiometer against a bank of 
TL-O 1 lamps. and the UVB exposure time-dosage table 
was adjusted as necessary. For measurements the meter 
was clamped at mid-height. 25 cm from the lamps. in 
the empty cubicle and the mean of 10 readings taken as 
the output. Irradiances in the Waldmann cabinet 
ranged from 3·53 to 2·95 mW/cm2• and those in the 
Ninewells cabinet from 3·1 to 2·95 m W I cm 2 during the 
course of the study. 
Minimal erythema dose determination 
This was done on upper back skin following our 
standard procedure. For skin photo type I and II patients. 
the doses administered were: 25. 50. 70. 100. 140. 
200.280 and 390mJ/cm2. For skin type III patients. 
the first two doses in this series were omitted and doses 
of 550 and 770 mJ/cm2 added. The MED was taken as 
the lowest dose to produce just perceptible erythema. 
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Table 1. UVB (TL-Ol) phototherapy regimen 
1 
2 
Determine minimal erythema dose (MED) at 24 h 
Initial dose: 70% or MED 
Maximum exposure dose: 2066 mJ/cm2 
3 
4 
Treat each side independently: 3 x per week (Monday. Wednesday. Friday) or 5 x per week (daily. Monday to Friday) as randomly allocated 
Increments given at each visit. based on a percentage or previous dose and erythema response: 
No erythema: 20% increment 
Mild (grade 1. barely perceptible) erythema-repeat previous dose and reduce to 10% increments 
Moderate (grade 2. well defined asymptomatic) erythema-postpone one treatment. repeat previous dose at next visit and reduce to 10% 
increments 
Severe (grade 3. painrul. persisting ror more than 24 h) no treatment. and rurther treatment at discretion or doctor (no grade 3 erythema 
occurred during the study) 
6 Other unwanted errects: 
rr itch develops-encourage use of emollients 
Ir polymorphic light eruption develops-ask doctor to review (and check lupus serology). encourage emollients. and (a) ir mild adjust 
regimen as ror grade 1 erythema: or (b) ir moderately severe. treat as ror grade 2 erythema 
7 Missed appointments: 
One or two treatments missed-repeat previous dose 
Three ireatments missed-treat with penultimate dose 
Treatment regimell 
Our low incremental dose treatment regimen 19 is 
detailed in Table 1. All male patients wore genital 
protection. and all patients were offered facial photo-
protection. Faceshield10 (Ultra Violet Products Ltd. 
Cambridge. U.K.) or topical sunscreen. if facial psoriasis 
was absent. Adjunctive therapy was restricted to 
approved emollients (white soft paraffin/liquid paraffin 
SO: SO mix. aqueous cream. Diprobase cream or coco-
nut oil) except for standard topical treatments for scalp. 
face and flexures. According to our usual practice. 
treatment was stopped when the psoriasis was deemed 
clear. or to have been in a state of 'minimal residual 
activity' (MRA) for four treatments. whichever occurred 
first. We set a maximum limit of 30 exposures for either 
Side. 
Assessmellt 
The Psoriasis severity of each body half was assessed 
at baseline (before the first treatment) and at each 
~Ubsequent treatment visit by means of a 0-4 scale 
Or each of scaling. erythema and induration (SEI) of 
~.Ymmetrical plaques (chosen at baseline) on the upper 
limbs (arm or forearm). trunk and lower limbs (thigh. 
eg or buttock). A 0-4 ('no' to 'very severe' psoriasis) 
~lobal Score was also ~sed. This scoring scheme was 
. ased on the standard psoriasis area and severity 
Index;21 we had had experience of its use in earlier 
studies.19,.22 
Statistical methods 
The main end-points were time (days). dose and number 
of treatments to clearance. We also compared psoriasis 
severity scores at baseline and at the end of treatment. 
Further. individual patient data. as well as summary 
data. were examined graphically. The distribution of 
values. or. when appropriate. differences in values. 
between sides was examined in graphical form. includ-
ing quartile-normal plots. and by use of the Shapiro-
Francia W' test to decide if a normal distribution could 
be assumed. For those variables which could not be 
assumed to arise from such a distribution we used non-
parametric tests. and for normally distributed variables 
both parametriC and non-parametric methods. No 
differences in interpretation arose from the different 
methods of analysis. so for consistency and clarity. we 
report only the results of th,e non-parametric tests. The 
Wilcoxon matched-pairs Signed-ranks test (with a null 
hypothesiS of no difference between the sides) was used 
for paired data and the Mann-Whitney U-test for 
unpaired data. Confidence intervals (CI) for the differ-
ences in medians were calculated using a rank-based 
method.23 The proportions of patients developing ery-
thema during treatment were compared by McNemar's 
exact test for paired proportions. Follow-up data were 
analysed by the plotting of Kaplan-Meier survival 
curves. compared by the logrank test. 24 Statistical 
calculations were performed with 'Stata' (with Practical 
Statistics for Medical Research add-on software to cal-
culate CI for the medians. Department of Medical Statistics 
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and Evaluation. Royal Postgraduate Medical School. 
London. 1997).25 
Results 
Twenty-one patients. 13 men and eight women of mean 
age 43 years (SD 13·6. range 21-68). entered the 
study. They were of sun-reactive skin types I. II and III 
(Fig. 1). Five patients (four men and one woman) did not 
reach the end-point of clearance or MRA on both sides: 
one was withdrawn due to failure to attend regularly 
(intercurrent illness). one declined to continue when he 
was satisfied with a modest improvement on both sides. 
and three did not achieve clearance or MRA on both 
sides by the maximum of 30 exposures (to the 5 x 
weekly side). Compliance with treatment was good. 
Only five of the 16 who completed the study missed 
any treatments. Of these five. four missed only one 
treatment (5 x weekly side only-three patients; both 
sides-one). and one missed four treatments (5 x 
weekly side only-one; both sides-three). Treatments 
were also missed because of intercurrent illness (two). 
personal reasons (four) and unit closure for public 
holiday (two). 
The median psoriasis severity (SEI) scores of the 16 
completing patients at each assessment are shown in 
Figure 2; and the baseline and final treatment visit SEI 
scores for thes~ 16 patients. and (on an intention-to-
treat basis) all 21 entered patients. are described in 
Table 2. The median baseline psoriasis severity score 
(SEI = 25) of those who completed the study was not 
significantly different from that of those who did not 
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Figure 1. Minimal erythema doses (MEDs) and skin phototypes (ST) 
for the 21 patients who entered the study. The five patients who did 
not complete the study were all ofST-II; four with MED of 140 and one 
of 100mJ/cm2. 
complete (SEI = 27· 5). (P = 0- 5 7; 95% CI for difference 
in medians - 6 to 5). 
Psoriasis took longer to clear or reach MRA with 3 x 
weekly than with 5 x weekly treatment. clearing in a 
median of 35 days (range 19-43) with 5 x weekly UVB 
and in a median of 40 days (range 23-63) with 3x 
weekly treatment (Fig.3a). (p=0.007. 95% CI for 
difference in medians 2-11). However. this more rapid 
clearance with the 5 x weekly regimen was achieved at 
the expense of a higher dose of UVB and more treat-
ments. In multiples of each individual's MED. the 5 x 
weekly sides required a median UVB dose of 94 (range 
27-164). compared with 64 (range 23-125) MEDs for 
the 3x weekly sides (Fig.3b). (p=0-010. 95% CI 5-
33). The sides treated 5 x weekly received a median of 
23·5 compared with17 treatments for the 3 x weekly 
sides (P = 0·001. 95% CI 3· 5-8) (Fig. 3c). 
Inspection of the individual patient data shO\'\'ed only 
two patients with results sufficiently different from the 
summary results to alter how we would consider treat-
ing these individuals in the future. One patient's 
psoriasis cleared 28 days sooner on the 5 x weekly 
side. with five fewer treatments and a lower (by 36 
MEDs) cumulative dose. However. his psoriasis relapsed 
exceptionally quickly-in 6 days on the 5 x weekly 
treated side and 22 days on the 3 x weekly side. Another 
patient's psoriasis cleared 26 days more quickly on the 
5 x weekly side. with one less treatment (but a slightly 
higher cumulative dose) compared with her 3 x weekly 
treated side. No features of these two patients before 
starting treatment distinguished them from the other 
14 patients. 
Acute adverse effects were more troublesome with the 
5 x weekly compared with the 3 x weekly regimen. 
30 
A 3x1week 
c 5x1week 
o 
o 5 10 15 20 25 30 
Assessment number 
Figure 2. Median psoriasis severity (Scaling. Erythema and Indura-
tion-SEI) scores for 3 x weekly and 5 x weekly treated sides at each 
assessment for completing patients (Il = 16). The graph orinduration 
scores alone (on file) is similar. 
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Table 2. Median (and range) of psoriasis se\'erity (SEn scores at beginning and end of treatment 
3 x per week side 5 x per week side Probability" 95% Cra 
Completing patients (1/= 16) 
Baseline 25'5 (19-32) 25 (17-31) P=0·48 -0'5toO'5 
Final treatment visit 2 (0-6) 3 (0-6) P=0·63 -1'5tol 
All patients (1/=21) 
Baseline 26 (14-34) 25 (14-34) P=0·22 -1 to 0 
Final treatment visit 4 (0-18) 3 (0-13) P=0·i6 -1·5 to 1·5 
"Rank-based confidence interval for dijjereuce iil paired medians. 
bWilcoxon matched-pairs signed-ranks test (null hypothesis of no difference between sides). 
While no patient suffered a painful (grade 3) erythema; 
15 of 16 on- 5 x weekly treatment developed at least one 
episode of well-demarcated (grade 2) erythema as com-
pared with only three of 16 on 3 x weekly treatment 
(P<O·OOl). Two patients developed polymorphic light 
eruption (PLE). One patient's episode of PLE affected 
both sides early during the course and the other's 5 x 
weekly side only was involved after the final treatment. 
The time to relapse for each side is shown in Figure 4. 
There was no difference in the probability of relapse 
between regimens (P=0·73). At relapse, only three 
required therapy other than topical emollients, tar or 
caicipotriol. Of these three, one started PUVA, one 
another course of UVB and the third entered a half-
body comparison of PUVA and UVB phototherapy. Two 
others have since required non-topical therapy: one 
commenCing UVB, and the other PUVA, 6 months 
after initial relapse. 
Discussion 
We have shown that for the majority of patients in our 
Population, 3 x weekly TL-Ol UVB phototherapy is 
~referable to 5 x weekly treatment. Clearance of psor-
Iasis slightly more quickly (by a difference in medians of 
5 days) with 5 x weekly treatment is not, in our opinion, 
~~fficient to justify the patient inconvenience, the 
Igher frequency of significant erythema provoked 
~Uring treatment, and the expected greater long-term 
risk related to the higher cumulative UVB dose 
a 'n number of exposures required. Consequently, 
~e no longer routinely use 5 x weekly treatment for 
In-patients, as was our previous practice. . 
Although individual patient response does vary, the 
absence of factors predictive of a better response to 5 x 
weekly treatment (as occurred in only two of our patients) 
SUggests we should base our treatment decisions on the 
eVidence applicable to the group as a whole. Occasionally, 
however, for example for a patient anxious to be clear 
for a specific occasion, it may be reasonable to offer 5 x 
weekly treatment for faster clearance. despite the increased 
risk of acute and, presumably, chronic adverse effects. 
A within-patient paired study allows us to control for 
all factors other than the single, altered variable under 
investigation. Bowever, a potential drawback relates to 
the possibility of a systemic phototherapy effect-we 
know that TL-Ol UVB produces various alterations in 
systemic immune function as assessed ill vitro.26 In 
practice, however, any such effect appears unable to 
clear psoriasiS. In our experience and that of others,27 
unexposed flexural psoriasis fails to clear with photo-
therapy as do, according to ongoing study, any plaques 
covered during treatment (data on file). We therefore 
think it unlikely that any systemic effect of the 5 x 
weekly treatment exerted a clinically important effect 
in clearing our study patients' 3 x weekly treated sides. 
Further support for this is given by the fact that the 
median number of treatments to clearance or MRA for 
the 3 x weekly side was as expected. 
Our findings should be of value to other phototherapy 
units treating a similar patient population. Now, over 
10 years after the introduction of the TL-Ol source, its 
advantages over broad-band UVB sources for chronic 
plaque psoriasis are becoming steadily more clear. We 
also have open study evidence of its efficacy in atopic 
dermatitis,28-3o and controlled study evidence of its 
value in PLE,31 although more information is required 
to assess its value, and method of use, in the many other 
TL-O I-responsive conditions. A priority, however, 
remains the generation of further objective information 
on its effective and safe use in psoriasi's and atopic 
dermatitis. The evidence generated by this study indi-
cates that in our northern European population of 
chronic plaque psoriasis patients, a 3 x weekly low 
incremental regimen with an MED-based starting dose 
is preferable to 5 x weekly treatment. 
© 1998 British Association of Dermatologists. British Journal oj Dermatology. 138. 833-839 
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Figure 3 (a). Days to clearance or minimal residual activity (MRA). 
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used to represent individual outlying values. (b) Dose [in multiples of 
each individual's minimal erythema dose (MED)] to clearance or ~IRA. 
(c) Number of treatments to clearance or MRA. 
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Service outcome was evaluated at these centres by means of a two sided 
questionn.1ire completed by 30 consecutive new patients with atopic eczema 
during their initial consultation and again 6 weeks later (Phase 3). 
98% c C the centres responded to the Phase I questionnaire. TIle validation 
visits ;·;\'caled only minor discrepancies between reponcd and observed 
facilities. Over 90% of the centres h'ld facilities for measuring height and 
weight in children, 98% had access to patch testing and 91 % had access to a 
photochemotherapy unit. Although 91% had trained nursing staff available in 
outpatients oniy 76.5% of these had time to demonstrate treatments. 97% of 
centres had access to inpatient paediatric facilities but only 58.5% of these had 
access to nurses with any dennatological experience. 89"10 had a rapid access 
appoinunent system for patients who deteriorate and 77.5% of these were 
patient initiated although the average waiting time was greater than 3 days in 
33% of cases. 96% had access to a dietician with the waiting list being under 8 
weeks in 81% of cases. Only 62.5% of the centres had access to counselling 
services and the waiting list for this was more than 8 weeks in 39% cases. 80% 
of c'!ntres provided information leaflets for all new patients but only 50% of 
~\.' ,'ntres sent out new appointment leiters requesting the patient to bring 
alol1s their current and previous eczema treaunent. 
These Phase I results highlight some possible shonfalls in the service that 
we provide for patients with atopic eczema and fonn the basis for discussion 
of future audit standards. 
This audit was conducted on behalf of the B.A.D. and supponed by a grant 
from the NHS Executive 
THE SCOTTISH PHOTOTHERAPY AUDIT: THE NEED FOR 
EVIDENCE BASED GUIDELINES? RS Dawe,1.2 RM MacKie,2 
J Ferguson.' 'Photodermatology Unit, Ninewells Hospital and 
Medical School, Dundee, DD1 9SY and 2Dermatology Department, 
Western Infirmary, Glasgow, G11 SNT. 
Ultraviolet B phototherapy (UVB) and photochemotherapy 
(PUVA) are widely used. An audit of PUVA use in Scotland in 1991 
(W. Perkins) led to a range of recommendations to improve PUVA 
use. Since then more information on the skin cancer risks of PUVA 
has emerged. This has coincided with the increasing use of the 
. 3rrow-band TL-01 UVB lamps which are more effective at 
Clearing psoriaSiS than broad-band UVB lamps. 
The aims of this audit were 1) To assess the current use of 
both UVB photother"py and PUVA throughout Scotland and to 
make appropriate recomendations, and 2) To find out if the 
recommendations of the 1991 PUVA audit have been 
implemented. 
Information was collected from all 19 dermatology department 
Phototherapy/PUVA units and 19 separate physiotherapy 
department phototherapy units. Information was obtained by 
questionnaire, visits to departments and notes review. 
Recommendations for good practice were based on observations 
made and graded according to the quality of evidence. 
. Ultraviolet B (using TL-01 lamps in 19 departments) is 
Increasingly used for a wide variety of conditions. PUVA use has 
deClined since 1994. The recommendations of the 1991 PUVA 
audit have been successfully implemented with the exception, so 
far, of developing in all centres a reliable system for follow-up of 
patients regarded as at increased risk of skin cancer. UVB and 
PUVA methodology is generally appropriate and based on 
aCCepted standards. There is, however, significant variation 
between centres in outcome measures, such as number of 
treatments required to clear psoriasis, reflecting differences in 
aspects of treatment methodology. 
UVB phototherapy and PUVA are widely available and used 
appropriately. However,' a number of evidence-based guidelines 
deSigned to improve the current service can be made. 
Acknowledgement: We thank all tho!ie who took part. Funding: 
Clinical Resource and Audit Group of the Department of Health, 
The SCottish Office. 
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THE NATURAL HISTORY OF THE PHOTOSENSITIVITY 
DERMATITIS AND ACTINIC RETICULOID SYNDROME 
RS Dawe,1 IK Crombie,2 J Ferguson. 1 'Photobiology 
Unit, Department of Dermatology and 2Department of 
Epidemiology and Public Health, Ninewells Hospital and 
Medical School, Dundee. 
The natural history of the photosensitivity dermatitis 
and actinic reticuloid (POlAR) syndrome (syn. chronic 
actinic dermatitiS) has not previously been clearly defined. 
Knowledge of the course of this condition is important to: 
1) advise patients on their prognosis; and 2) for possible 
clues to pathogenesis. 
We conducted an historical cohort study, following up 
178 patients diagnosed between 1972 and 1995, for 1 to 
24 (median 4) years. All patients were re-assessed 
clinically and by monochromator phototesting and, in 54 
patients, by repeat patch testing to previously identified 
contact allergens. The probability of clinical improvement 
and of defined "complete resolution" during follow-up was 
assessed by plotting Kaplan-Meier survival curves. 
The majority showed clinical improvement, however 
complete resolution of abnormal photosensitivity, defined 
as 1) no longer clinically photosensitive and 2) 
phototesting results within normal population limits, 
occurred in only 23 (13%). Taking into account the 
variation in follow-up duration, resolution of abnormal 
photosensitivity can be expected in 7% after 5 years, 22% 
after 10 years and 50% after 16 years of follOW-Up. Only 
one of 54 patients in whom repeat patch testing was 
performed lost all previously identified contact allergens; 
and loss of 1 or more contact allergen was not associated 
with resolution of abnormal photosensitivity (p=O.81; 
logrank test). 
The abnormal photosenSitivity, but not the contact 
allergic dermatitis, component of the POlAR syndrome 
spontaneously resolves in some patients . 
ENVIRONMENTAL FACTORS AND MELANOMA: HORMONES, 
SUNBURNS AND SUNBEDS. 
V Bataille, *A Winnett. *p Sasieni. **JA Newton Bishop, ***A 
. Swerdlow. *J Cuzick. 
ICRF Skin Tumour Laboratory Royal London Hospital London. 
*ICRF Statistics Dept London. **ICRF Cancer Medicine Leeds. 
***London School of Hygiene and Tropical Medicine. London. 
Although studies on familial melanoma support the role of genetic 
factors in melanoma. sun exposure is important in the aetiology of 
this tumour. Exposure to natural and artificial ultraviolet radiation 
as well as honnonal factors have been investigated in many case-
control studies of melanoma but results have been conflicting. The 
results reported here are part of a case-control study of melanoma 
in the UK including 426 cases and 411 controls. As well as 
undergoing a skin examination. the subjects were interviewed 
concerning sun exposure, sunbeds and reproductive factors. 
A past history of one or more severe sunburns was associated 
with a relative risk (RR) for melanoma of 1.2 (0.9-1.6) when 
adjusted for age and sex. More than 10 severe sunburns yielded a 
RR of 1.8 (0.9-3.7). However. when adjusted for skin type the 
RR was 1.0. Sunburn at an early age. outdoor occupation and 
residence in hot countries were not associated with an increased 
risk of melanoma. Use of sunbeds for 100 hours or more gave a 
RR of 1.2(0.9-1.9) when adjusted for age. sex and skin type. 
There were 278 female cases and 254 female controls. Use of the 
contraceptive pill was not a risk factor: RR of 1.0 (0.9-1.0), No 
.Pi i' .. ,. ." ii, • '.' 
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A systematic review of anti streptococcal 
intencntions for guttate and chronic plaque 
psoriasis 
C.M.OWEN. R.J.G.CHALMERS. T.O·SULLIVAN and 
C.E.M.GRIFFITHS 
Dermatology Centre. Ulliversity of Mallcliester. Hope 
Hospital. Salford. UK. 
The Cochrane Collaboration was developed in 1992 to provide 
systematic. up-to-date reviews of randomized controlled trials 
of health care interventions and to disseminate this informa-
tion to health care workers. providers and consumers. Many 
accepted treatments for skin conditions have never been 
formally evaluated or compared with alternatives and much of 
dermatological practice is based on tradition rather than 
evidence. The Cochrane Skin Group. formed in 1997. consists 
of an international network of individuals committed to 
producing and updating reviews of trials relating to skin 
conditions. A further role of the group is to identify priorities 
for research. We present the results of a review of anti-
streptococcal interventions in the treatment of guttate and 
chronic plaque psoriasis and discuss its implications. 
Guttate psoriasis is closely associated with preceding 
streptococcal sore throat or tonsillitis. Some claim that 
chronic plaque psoriasis may also be exacerbated by 
streptococcal infection. In view of this. many dermatologists 
recommend antibiotic therapy for flares of guttate psoriasis in 
particular and some ,advocate tonsillectomy for those with 
severe psoriasis associated with recurrent tonsillitis. The 
objective of this review was to assess the evidence for 
effectiveness of antistreptococcal interventions in the manage-
ment of acute guttate and chronic plaque psoriasis. An 
extensive search of electronic databases (including Medline. 
Embase and The Cochrane Controlled Trials Register) and 
other sources identified only one randomized study which met 
the inclusion criteria. 20 psoriasis patients. predominantly of 
guttate type and with evidence of l3-haemolytic streptococcal 
colonization. were randomized to receive 1 of 2 oral antibiotic 
Schedules in which either rifampicin or placebo was added to 
the Unal 5 days of a 14-day course of phenoxymethylpenicillin 
~)r erythromycin. No patient in either arm of the study 
Improved during the observation period. No controlled studies 
of tonsillectomy were identified. 
Although both antibiotics and tonsillectomy have fre-
qUently been advocated for patients with recurrent guttate 
PSoriasis or chronic plaque psoriasis. there is. to date. no good 
eVidence that either intervention is beneficial. There is clearly 
a reqUirement for further research in this area. The following 
~tudies would help to determine whether antistreptococcal 
II1lerventions should be recommended in patients with guttate 
<tnd chronic plaque psoriasis. 
1. Treatment: Antistreptococcal antibiotic vs. placebo in acute 
guttate psoriasis. • 
© 2000 British Association of Dermatologists 
2. Prophylaxis: Antibiotics vs. placebo for symptoms of sore 
throat in patients following resolution of an episode of guttate 
psoriasis. 
3. Long-term prophylaxis: Antibiotics vs. placebo in patients 
with chronic plaque psoriasis with evidence of recurrent 
streptococcal sore throat. 
4. Tonsillectomy vs. no tonsillectomy: for patients with severe 
recurrent guttate or chronic plaque psoriasis with evidence of 
recurrent streptococcal sore throat. 
A comparison of TL-O 1 UVB phototherapy and 
bath-PUVA for chronic plaque psoriasis 
R.S.DAWE. H.CAMERON. S.YULE. I.MAN. 
N.J. WAINWRIGHT. S.H.IBBOTSON AND J.FERGUSON 
Photobiology Ullit. Departl1letlt of Dermatology. NillelVeIIs 
Hospital alld Mrc/ical Scliool. DUlldee. UK. 
We designed a study to help answer the question: is there any 
difference in efficacy between 3x weekly narrow-band (TL-01) 
UVB phototherapy and 2x weekly TMP bath-PUVA for chronic 
plaque psoriasis? This was an observer-masked. within-patient 
(half-body) paired study. 
Twenty-eight patients (11 women; median age 47. range 
22-71 years old) participated. Ten were withdrawn before 
study completion due to: inadequate response to treatment (on 
PUVA-treated body half) [4 patients]. protocol violation 
(topical steroids for polymorphic light eruption) [2]. inter-
current illness [1]. pregnancy [1]. severe PUVA itch [1]. 
repeated failure to attend [1]. The median reduction in scaling. 
erythema and induration (SEI) score for all 28 patients. 
analysed on an intention-to-treat basis. was 20· 5 with UVB 
and 18 with PUVA [95% C.r. for difference 0·6; P = 0,04]. 
All 18 who completed the study reached clearance or 
minimal Fesidual activity (MRA) with UVB. but in 3 the PUVA-
treated side was still not clear by a maximum of 30 exposures. 
UVB treatment achieved clearance a median of 11 [95% C.1. 
4'5-24'5] days more quickly than PUVA. but required a 
median of 24·5 compared to 20 exposures [95% C.1. for 
difference 0-5]. UVB produced more asymptomatic. well-
demarcated erythema episodes (32% of all patients) than 
PUVA (14%) [95% C.L for difference 036%]. Kaplan-Meier 
survival analysis showed no significant difference between 
modalities in time to relapse (P = 0·34). 
Overall. administered according to our standard protocols, 
TL-01 UVB is at least as effective as bath-PUVA. 
Psychological distress affects the efficacy of 
PUVA in patients with psoriasis o' 
B.KIRBY,I H.L.RICHARDS. l .2 K.McELHONE. l 
D.G.FORTUNE,1.2 C.J.MAIN2 AND C.E.M.GRIFFITHS l 
1 Dermatology Centre. University of Manchester and 
2Department of Behavioural Medicille. Hope Hospital. 
Salford. UK. 
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Furthermore. the vasculitic skin lesion had appeared in both 
patients. several weeks after administration of these agents. 
We believe that the time relationsh ip to the operation (21 
and 7 days. respectively) and the concurrent pericardial 
involvement. m ay both be implicated in its occurrence. 
probably through immune complex form ation and deposition. 
Immune complexes have been demonstrated in patients with 
the post-pericardiotomy syndrome. possibly associated with 
antiheart antibodies. 3 We suggest an immunologically 
mediated reaction may be induced either by the cardioplegic 
agents used during the operation or by a delayed reaction to 
blood cell units given during the CABG. 
Department of Medicille ;B' 
and the Unit of AlItoillllnlllJe Disease Researc/l, 
Sheba Medical Center. 
Te l-Hasho/ller. 
Sackler FaCIlity of Medicine. 
Tel-Aviv University. 
Tel-Aviv. Israel 
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Urticarial vasculitis 
SIR. I write to provide follow-up information on a patient 
reported recently.l In 1995 this patient developed a chronic 
lower leg ulcer which failed to respond to combined high-dose 
aza thioprine and prednisone. A liver biopsy was performed 
showing periportal inflammation and a repeat cryoglobulin 
determination was positive. Urticaria. the initia l cutaneous 
problem. has not recurred since immunosuppressive therapy 
was reinitiated nor after discontinuing this. At present. no 
immunosuppressants are being administered. a nd alpha 
interferon is being given for treatment of hepatitis C. It 
would appear that this patient had urticarial , vasculitis 
evolving into the more typical cryoglobulinaemia-associated 
vasculitis as a manifestation of chronic hepatitis C infection. 
Professor and Chief. Allergy/ Immunology Section. 
Department of Medicine-Cronin 104. 
St Vincents Hospital-NYMC. 
153 W 11 Street. 
New York. NY 10011. U.S.A. 
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BorrolVing from museums a nd industry: two photo-
protecti ve devices 
SIR . In photodermatology. as in other medica l diSCiplines. 
technological del'elopn',ents often lead to improl'emen ls in 
patient care. We Irish to share experience of the use 0' 1'0 
del'i ces . one originally designed to protect museum exhi bits 
and the other biotechnology industry workers. 
Our a ttention was drawn to the UVC-803 Face Shield (Fig. 
1). ava ilable from Ult ra Violet Products Ltd. Science Park. 
i\lilton Road. Cambridge. by Abel's text. l It is designed to 
protect those 1I'0rk ing with transilluminators in biotechnol_ ~ 
ogy a nd foren sic science. but is also useful to both patients and 
staff in a PUVA and phototherapy unit. It prel·ent · urc. UVB 
and UVA transmission (Fig. 2 ). 
Many pati ents attendin g for phototherapy or PU\,,\ d I not 
require face treatment. Facial photo-protection in the irradia-
tion cubicle reduces the frequency and sel'erity of ea rly 
unwa nted effects including erythema. pigmentat i,m and 
reactivation of cold-sores. It should a lso reduce the ri sk of 
late compli cations such as malignancy. Staff im'oil'ed in 
meterin g tasks a lso requ ire adequate protection as does the 
parent or stafr member supervisi ng trea lmen t of a youn g child. 
Prior to this new clear. light-weigh t face shield I\'e used 
either a welder's helmet or topica l sun screen. The hc ln ~ :'~ '." as 
heary and uncomfortabl e so most patients prefcrr('d tile 
sunscreen despite difflculties in ensuring it covered exactly the 
same area of skin at each visil and the length of time required 
to remove it after trea tment. 
All our patients \\'ho req uire facial photo-protection prefer 
the new face sh ield to helmet or sun screen. It is now also in 
routine use by staff during maintena nce a nd m etering tasks. 
Another device that colleagues mi ght find lIsefu l is 1I1l! eum 
200 Film. manufactured by Sun Guard. Florida . U.S.A . and 
obtainable in the U.K . from Bonwyke Window Films. un;myke 
Figure 1. UVC-803 face shield. 
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House. 41- 43 Redlands Lane. Farnham. Hampshire. This 
clear. lightweight film . initially prod uced to protect museum 
exl ' ibits from ultraviolet radiation, is of value to patients with 
se 'ere photosensitivi ty to UVB and UVA wavelengths. The 
sticky-backed fi lm is almost undetectable when applied with 
care to house. hospital or windowglass in ca rs. When fitted to 
car windows it will not interfere with vision or the winding 
down of side windows and allows increased freedom of ac tivity 
for many patients. The film prevents transmission of nea rly all 
UVR wavelengths (Fig. 3) and after 1 yea r of south-facing 
window sunlight exposure (data on fi le) the transmission 
spectrum is unchanged. It is of particul ar value in the 
ma tagement of severely affec ted patients with the idio-
path ic photodermatoses in which UVB and U\ A wave-
lengths are importa nt (photosensitivity dermat itis/actinic 
reticuloid syndrome. aclinic prurigo. so lar urti caria) and 
the photogenodermatos is- xeroderma pigmentosum. 
Both these devices. ori ginally developed for quite di/Terent 
purposes. have proven helpful in patient ca re. 
PllOtoricmwtology Ull il. 
Departlll l'1lt of Derllla tology. 
Ni l! wells Hospital allri Medical School. 
DIlI :del! DDI 9SY. U.K. 
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Bistorical vignette 
Medical history from the Journal 
~;-d ina ry Meeting of the Dermatological Society of London 
cld On 13 February 1895. 
~r eolcott Fox showed a girl of 11 years with an un usual 
~n ged Eruption of the fingers. On the flexor aspect of the left 
ring-fin ger was a ring of eruption extending from the 
p.roximal phalanx to the distal phalanx and half way up the 
sides of the finger. This oval ring was characterized by a 
~nl00th. rounded. projecting border, white in colour, 
OUghy in consistence. qui te an eighth of an inch wide. 
an about one-sixteenth of an inch in height. The enclosed 
area Was normal. or perhaps a little reddened. There were 
~o Subjective symptoms. except that the border was slightly 
cnder on pressure. On the little finger of the right hand was 
a Similar ring but rather' smaller and broken up in places 
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into rounded nodules. The affection was cutaneous, and 
seemed to in volve all the layers of the skin . The mother 
stated that the rings each began in a nodule before 
Christmas and gradually extended peripherally . . .. The 
exhibi tor said that he was at a loss to make a diagnosis. The 
indolent spread of the rings . .. . the depth to which the skin 
was involved. and the absence of vesication and desquama-
tion, seemed to put 'ringworm' out of court. l 
Reference 
1 Fox TC. Society [ntelligence. Dermatological SOciety of London. 
Br J Derlllotol1 89 5; 7: 9 1-2. 
A nice description of granuloma annulare. 
Julian Verbov, Editor 
1996 British Associa tion of Derma tologists. British Joumol of Dermatology. 135. 1003 - 1017 
Britisll JOllmal of Dermatology 1997: 137: 144-148 .. 
Prolonged benefit following ultraviolet A phototherapy for solar 
urticaria 
R.S.DAWE AND J.FERGUSON 
PllOtodemwtology Ullit. Dcpartlllcllt oj Dcrlllatology. NillclI'elIs Hospital alld Medical School. Dlmdre. DDI 9S1: Scotlalld. L'.K. 
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Summary Two patients with severe idiopathic solar urticaria. previously resistant to a variety of therapic:' 
including plasma exchange. benefited from springtime courses of ultraviolet A (UVA) monotherap 
Sites which are normally exposed to sunlight were treated. in a cabinet fitted with Philips R-UV;' 
lamps (emitting UVA and visible wavelengths. with peak at 350 nm). twice daily for 2-3 wc-,.'k,. On,' 
patient has been treated in this way for 3. and the other for 2. consecutive years. R~peal 
monochromator phototesting 3 months after their latest courses of UVA showed a persisten' 
reduction in severity of abnormal photosensitivity. Both patients describe a sustained improvemei 
In Iheir condition lasling om 6 monlhs afier Ireatment. I ' 
I 
Idiopathic solar urticaria is an uncommon condition 
that presents with immediate erythema and wealing on 
exposure to ultraviolet (UV) and/or visible wavelengths. 
The diagnosis is confirmed by provocation testing with 
appropriate wavebands and exclusion of known causes 
of solar urticaria -drugs or cutaneous porphyrias. l It 
can be severely handicapping and the response to treat-
ment is variable. Spontaneous resolution is unusua1.2.3 
Sunlight avoidance measures alone. including sun-
screen use. are rarely sufficient. Antihistamines provide 
adequate relief for some.4-& Although doxepin may 
occasionally be helpful/ as may antimalarial drugS.8-10 
our experience with these has been disappointing. 
Phototherapy with various sources (broad-band 
11 VB 12 U"A 13-17 d' 'bl UVB. narrow-band TL-01 U. vn. an VIS I e 
light13•18 ) helps some patients. as does photochemo-
therapy.19-21 Plasma exchange. used for a few severely 
affected patients.22 has for the majority proved disap-
pointing despite reports of persistent remission in three 
cases.23-25 
We describe the successful use of UVA phototherapy. 
followed by prolonged improvement in two cases. 
Case reports 
Patient 1 
A 36-year-old woman was diagnosed as having idio-
pathic solar urticaria in 1991. Monochromator photo-
testing2& confirmed Jhe diagnosis. and showed UVB. UVA 
and visible (305 ± 5 to 430 ± 30nm half-maximum 
144 
bandwidth) eliciting wavebands (Table 1). Red lig~!l 
(650 ± 30nm) irradiation before and ah~r uv./i 
(365 ± 30nm) neither inhibited nor augmt.:nted th 
induced urticarial response. She was taking no medic, . 
tion and her po~phyrin plasma scan was negativ, 
Intradermal testing with her own irradiated plasm' 
was negative. . 
Sunlight avoidance measures. including appropria i I 
sunscreens. various antihistamines and a trial of hydrox.~1 . 
chloroquine were of minimal benefit. The severitv of h;~! 
photosensitivity with UVB preclu.ded TL-01 l';l~tothell; 
apy. A trial of plasmapheresis was of no benefit. She w.:I; 
unable to walk the 800 m to work even in the car'; . 
morning. to shop during daylight hours and to Ii; 
outside with her children. Monochromator phototestir! : 
in May 1994 confirmed the continuing severity of hi' : 
condition. Her UVB (TL-O 1) minimal urticarial do I 
, I I (MUD) was below 6 mJ/cm-. Her UVA (R-lTA lam;! 
MUD after oral 8-methoxypsoralen (8-MOP) '.';as 0'3;: 
cm
2 (erythema and flare with 0'1 J/cm1 ). \\'here: I 
with R-UVA lamp irradiation alone her ~IUD wil 
not as low. at 2 J/cm2 (erythema and flare wi; j 
O' 5 J/cm2 ). This phenomenon of a photosensitizil': 
dru~ ~oweri~g the threshold for induction of one 11 
the IdIOpathIc photodermatoses remains unexplaiIl€!' 
although we have noted it occasionally in po:i i 
morphic light eruption as well as solar urticar'! 
'I These results meant that neither TL-01 phutothcrai I 
nor PUVA would be practicable treatments. and! i 
course of UVA phototherapy was given following ti I 
protocol in Table 2. I' 
II 
© 1997 British Association of Dermato\og! I, 
" 
: 1" 
UVA FOR SOLAR URTICARIA 145 
( 
/
' Table 1. Minimal urticarial doses in mJ/cml (patient 1) 
.: 
1 
Ko\'ember 1991 April 1996 before April 1996 immediately August 1996 3 months 
presentation 3rd UVA course after UVA course after 3rd lJVA course 
,',' 
r 
I 
Medication Kil Nil Loratidine 10 mg/day l'\i1 
Wm'rl>mld (IIIn) 
Testing on upper back 
305:±: 5 <1·8 >33 NT >47 
335:±: 30 <100 560 NT >4700 
365:±: 30 <100 12.000 NT >10.000 
400:±: 30 560 22.000 NT >47,000 
, 430:±: 30 ;600 >82.000 NT >82.000 
I 46() :t 30 >81.000 Teslil:,: on volar forearm 
335:t 30 
Testing on buttocks 
335:±: 30 
>. no urticaria demonstrated with doses up to that stated. 
NT. not tested. . 
lOOO 4700 >4700 
KT NT 3300 
She has now had 3 yearly courses of UVA photo-
therapy. For the first we treated only face. neck and 
dorsal hands. During her last course (1996) she was 
'\ treated wearing a T-shirt and shorts. Apart from one 
episode of urticaria affecting popliteal fossae. treatment 
has been uncomplicated. 
i'" \ 
episode of solar urticaria affecting untreated buttock 
skin through clothing. After each course of UVA she 
aimed to expose herself to sunlight for up to half an 
hour daily. This was not always possible. yet she did not 
de\'elop solar urticaria on re-exposure after a few days 
without outdoor sunlight. 
\ 
I 
After each course of phototherapy she reported that 
the benefit lasted until the next spring. In 1995 her only 
sUmmertime episodes of solar urticaria affected her 
soles when she attempted sunbathing. and palms 
When putting out washing. Last year (1996). after her 
third UVA course. she stopped antihistamine therapy 
Hnd did not take special precautions. yet had only one 
The improvement she describes has been paralleled by a 
steady rise in the doses required to provoke urticaria. This 
year. phototesting on unexposed back skin was much 
improved even before UVA phototherapy compared with 
previous years' results. and was normal 3 months after the 
course of UVA. Only a high dose of 335 :±: 30 nm wave-
band irradiation could provoke urticaria on buttock skin. 
TUble 2. UVA phototherapy regimen for solar 
Urticaria 
;:", 
Treatment given In Dixwell stand-up cubicle with 48 x 100 Wand 12 x 40 W Philips R-UVA 
lamps (peak emission at 350 nm). 
Irradiance = 18·8 mW/cm2 
1. Determination of minimal urticarial dose (MUD) and immediate minimal erythema dose 
(MED) 
2, First exposure-70% of hIUD or immediate MED reading (whichever is lower) 
3. Subsequent exposures-initially Increase dose once daily. with increment based on a 
percentage of previous dose and on immediate erythema or urticarial responses. If no 
problems after first 10 exposures give Increment with each dose. 
a. If no immediate erythema or urticaria-40% Increment given 
b. If just perceptible immediate erythema-same dose given 
c. If well demarcated or symptomatic immediate erythema. or mild urticaria (no systemic 
symptoms)-same dose: then 20% increments. 
Treat twice a day, 5 days a week for 18-26 exposures. Treat only habitually exposed ~ites. 
Keep patient In the phototherapy unit for 1 h observation after each exposure and ensure 
exposures always separated by a minimum of 6 h. 
4. Maximum dose administered = 15'6 J/cm2• 
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Patiellt 2 
A 60-year-old man presented in 1984 following abrupt 
onset of his complaint. Solar urticaria. with UVA and 
visible (33 5 ~ 30 to 600 ~ 30 nm) eliciting wavebands. 
was confirmed by monochromator photo testing. His 
plasma porphyrin scan was normal. Intradermal testing 
with irradiated autologous plasma and serum was 
positive. 
Antihistamines produced some improvement. as did 
8-l\IOP PUVA and TL-Ol UVB phototherapy. Both allowed 
an increase in tolerable sunlight exposure from 5 min to 
a more acceptable 1 h. with up to 4 months sustained 
subjective improvement. However. he remained signifi-
cantly handicapped. Plasmapheresis produced a marked. 
but short-lived. improvement. 
"We used UVA phototherapy because of the significant 
benefit that patient 1 gained from this the year before. 
The same treatment protocol was followed (Table 2). He 
has now had two spring courses of UVA (in 1995 and 
1996). The only complication has been asymptomatic 
immediate erythema affecting skin of trunk (including 
that covered by a white T-shirt) midway through his last 
course. As with patient 1 advice was given that he 
should cautiously. but deliberately. seek sunlight expo-
sure (15 minutes daily. to be gradually increased) after 
the treatment course. 
He has .since been able to stay outdoors for as long as 
2-3 h at a time: longer than ever before since onset of 
solar urticaria 12 years ago. The only episodes of sun-
light provoked urticaria have been on palms and volar 
wrists: sites relatively shaded during treatment. Although 
impro\'ement in his life quality following 0\1\ has not 
been as dramatic as for patient 1. partly because of his 
being restricted by other medical problems. he has 
found UVA phototherapy to be of greater benefit 1han 
any of the previous treatments tried. 
Phototesting on his back (not exposed to UVA during 
treatment) and his volar forearm (a treated Site) was 
conducted before. immediately after. and 3 months after 
his last course of phototherapy (Table 3). Urticaria Could 
no longer be induced on either site immediately after 
phototherapy (testing with 4 30 ~ 30 nm \\'a\'eband) 
and 3 months later could only be elicited on his back 
with doses two to 10 times higher (depending L.)011 
waveband) than before. and could still not be prO\"oked 
on the forearm. 
Discussion 
These two patients with exceptionally severe idiopathic 
solar urticaria have both benefited greatly from photo-
therapy using a source emitting predominanth eVA 
(with peak at 350 nm) as well as visible wm'el~ngths, 
The degree of improvement. especially in patient 1. and 
the long-lasting benefit after treatment raises the pos-
sibility of spontaneous resolution. However. as sponta- l 
neous resolution in this condition is unusual.1.3 we i 
suspect the improvement is treatment-related. f 
The mechanism of action of UVA phototherapy in I' 
solar urticaria is unclear. The patients descril-cd by II 
" .: 
_Ta_b_lc_3_._1.._Ii_ni_m_a_l_ur_ti_ca_r_ia_l_do_s_es_i_n_m_J_Ic_m_2_(_pa_t_ic_nt_2_l ___________________________ j! 
Medication (daily dosel 
Waveballd (11111) 
Testing on upper back 
305 = 5 
335=30 
365 = 30 
400 = 30 
430 = 30 
460 = 30 
500 = 30 
600 = 30 
Testing on volar forearm 
430 = 30 
May 1996 before 
2nd UVA course 
Ranitidine 300 mg 
Cetirizine 20 mg 
>39 
>3900 
> 12,000 
>47,000 
4700 
2200 
8200 
>82,000 
3300 
>. no urticaria demonstrated with doses up to that stated, 
NT. not tested, 
May 1996 immediately 
after 2nd UVA course 
Ranitidine 300 mg 
Cetirizine 20 mg 
NT 
NT 
NT 
NT 
>10,000 
NT 
NT 
NT 
>10.000 
August 1996 3 months ' 
after 2nd lTA course 
Ranitidine 3()O mg 
:\T 
:\T 
:\T 
47,000 
1 ;,000 
18,OO() 
> 1 l),flOO 
> ll).!)()() 
ji 
t! 
f I 
II 
i! 
II 
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Ramsay.13 who were treated with sources matching 
!) .. their photosensitivity action spectrum. lost their induced 
tolerance within 72 h of missing a treatment. Other 
repor i '. describing patients whose improvement follow-
ing li\:-\ phototherapy was sustained over the summer 
months. suggested that careful. deliberate sunlight expo-
sure after treatment was important in maintaining the 
benefit. 1 ;.In Only one patient. treated with a predomi-
nantly UVA source and a UVB/UVA source. is described 
as having achieved almost complete remission following 0' phototherapy. 14 
I ' 
f 
A d!!llculty in determining the mechanisms of action 
of trc"cment in idiopathic solar urticaria is that this is 
likely to be a heterogeneous group of conditions. at least 
if patients are classified according to response to intra-
't, ~ dermal injection of their own, or others', plasma. serum 
I) or tissue fluid,.27 or by wavelength dependency . .28 . .29 
I Solar urticaria may. in some patients, be due to a true, 
I ~{ IgE-mediated, allergy to a mast cell-binding photo-
allergen. 30 
Various hypotheses have been put forward to explain 
~.'- tolerallL'l~ induction by exposure to the inducing stimu-
~; Ii IllS, a phenomenon also recognized in other physical 
/, \ urticarias. In solar urticaria the tolerance induced by 
l\'j I, UVA irradiation is capable of providing protection . against other eliciting wavelengths. 1 ;.In Tolerance indUCtion seems not to be due to depletion of mast cell histamine, and Keahey et al. regard depletion of a 
f'; circulating serum factor as unlikely, given that in their 
)' three patients untreated shadowed sites did not show 
I. increased tolerance. I6 They postulated an increase in 
'; \ mast cell degranulation threshold produced directly by 
lJV irradiation. However. repeated injection of ill vitro 
Irradiated autologous plasma or serum can also induce 
tOlerance.31 It has been suggested that during the state 
of tolerance IgE binding sites on mast cells may be 
~CCllPied by a photo allergen and, until new IgE is 
f~rmed. IgE med~ated release of u~ticogeni~ substanc~s 
d 0111 mast cells IS blocked. 3o•3l PIgmentatIOn and epI-
\ 1 
, I 
. I 
\ ( , 
, ~ 
: r 
~ 
I 
I, 
erl11al thickening induced by UVA may also be impor-
tant. although such induced photoprotection would be 
~l(pected to be more effective at blocking UVB/UVA 
tansl11ission than visible wavelengths. 1 5 . 
p Any expl~mation for the effect of UVA in these two 
I <Ilients has to explain the prolonged duration of 
. lllPr 
8( oVement. lasting for up to a year. and the apparent 
. Cad . Sit Y Improvement each year. It must also explain why 
" lid:. shielded from UVA during treatment (altho~gh 
" ills Ittedly exposed to visible light through clothmg) 
.••. th 0 ~how a demonstrable improvement. If we accept 
:;"e Il11munological hypothesiS "for solar urticaria 
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pathogenesis. perhaps one of the mechanisms is a 
true immunological desensitization phenomenon. with 
phototherapy leading to the production of a blocking 
antibody or other factor. 
Whatever the mechanism of action, UVA photother-
apy, delivered according to the protocol described here. 
has proved remarkably effective in these two patients. 
We now consider its early use for new patients present-
ing with idiopathic solar urticaria. 
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(TL-O l) UV13 phototherapy. she was commcnced on " second 
course using the sa me regimen but without the sulph a-
meth oxypyridazine. She aga in respo nded \\"ell. with complete 
clearance of the eruption (F igs ] and 2) . Un fortunately. 2 
months after completion. the condi tion began to relapse . 
The position of SCPO as a distinct entity. separa te from the 
spectrum of pustul a r psoriasis. is sti ll hotly debated. [n ol'cr 15 
yea rs . our patient has nel'er developed any features to suggest 
a di agnosis of psoriasis. i\ lost cases of SCPD respond to 
treatment wi th dapsone or sulpha dru gs. although this is not 
inva ri able. 2 Indeed. Ill any other trca tments hove been advo-
ca ted includin g ant ibioti cs. oes trogens. immu noglobulins and 
co rticosteroid s. No ne has pro\'en to be the uni for m t il erapentic 
choice. Less toxic treatments \Yould be an adva nt age for th is 
beni gn. chronic. but tro ublesome dermatosis. 
Our patient hi ghlights the difticully of maintainin g a sa tis-
fa ctory therapeutic response and that this may requ ire the 
long-term use of potentia lly toxic drugs . [ n our patient. a 
sa tisfa ctory response was ach iel'cd with PU\ff\. albeit only for 
a short time. There a re only four reports of SCPD responding 
to PllVA. I.l - 5 In add ition to im provin g with PUVr\. our pa tient 
has twice ach ievcd a sa ti sfac tory clinica l rcspo nse with 
narrowband (TL-01J UVB photot herapy. 
Park et III. describe a 12-yea r-old boy wit h SCPD who 
ac hieved a til era peutic response. mainta ined for 8 mon ths, 
after a course of broadband UV I3 treatment. We suggest that 
narrowband UVB phototherapy deserves furth er eva lu ation in 
the trea tment of patients with SCPO who fail to improve with 
dapsone or other sulpha dru gs. 
PIIO/otiC/'IIl(/ tO/og!J Ullit , A lllers/1(/111 Hospital. 
A III ersll(/III , Bllckill[llulI ll sliire, HP7 Off), U.K. 
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Subcorneal pustular dermatosis (Sneddon-Wilkinson 
disease) treated with narrowband Cl'L-O 1 J UVI3 
phototherapy 
SIR, A 76-year-old woman presented with a 2-week history 
of a symmetrical polya rthropathy of thc metacarpophalan-
geal joints. She had rin gs of pustu les . some with hypopyon, 
symllletr ically ill'fecting th e , ' xillar~' skin . the Ill cdia l thi ghs 
and benea th the breilst, . Ili ,topa th ology of a ])u, tu le shDlI'l'd a 
subcoJ'lleal blister conl<1in ing a fe\\' ncut rophils with Sc,lt ll'rL'd 
ac ute and chron ic inll amnlCltnry ce ll s in th e derm b . There ' , -; 
no aca ntholys is allli dircL·t illll11unoll uoresct' nce II'as negati\l'. 
~ I ieroscopy of pus shal\'l'd no organism, and clii tu rt' was 
nega tive. Blood tcsts rt'l't'aled an acute ph ase rc,ponse II'i th a 
ra ised plasma vi scosi t~ · and a po l~T l onal increase in immuno-
globulins. espec ia lly Igr\ and Ig(;. Her latex rh eu lll atoid factor 
tes t \l'as pos itive. \l' ith raised Igr\ and Ig:\1 ,lI1tibodies on EUSA. 
r\ diagn os is of su hcom t'a l pustular derm atosis ISnl'ddon-
Wilkinson disease) I\'a , made and dupsone. 50 mg daily. COIl1-
menced. r\ reI\' d,IYs I,lt l' r. s li l' dL'I'l' loped palpahle pllrp llril 1111 
th e legs and bUllocks. lI'hieh resolved with in a fell' ( L t. of 
stopp ing the dapsone .. \l illoCyclilll'. 2()() mg daily. and tupical 
steroids I\'e re start ed. and the crupt ion alld synovi tis resoh-ed 
withill R \\'eeks. r\ part from the raised Ig,\ rh eumatoid fac tor. 
her blood indices returned LO normal. 
Sl'l't'n 1lI0nths ufkr prl'selllHtion . she sulTt'rl'd a sel'ere 
rec urrcnce of her skin disease. bllt not of her arthritis. despite 
being on min ocyclinl'. I ie I' l' ru pt ion cleil1't'd after I week of oral 
predn isolone. 20 mg/day. but recurred if thc predn isolone 
Figure 1. Before photolhera py. 
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Figure 2. Mt er 31 11\/B exposures. 
dosage II d., reduced below 1 () IlIg duily. Sulplius,da 'l. ine. 1 g 
daily. wns or no benl.'iil. 
Narrowband (TL-OJ.) ult rav iolel (UV) 13 pllOtotil crapy was 
introduced using a . min imal erythemal dose-based . thrice 
Wcekly. incrementa l regimen. This appeared to be successful 
(Figs 1 and 2). l3y the ;nd or the course of 3 l expo urcs (total 
UVB dose 27.981 mJ /clll l ) . her condition was much improved. 
despite some residu,11 pustu les on the axillae. luteral aspects of 
lhe thighs and b'lCk. Predn isolone was ' lopped II'ithout an 
c~~lcerba ti lJ!1 of her condition which. for 5 1I10nths after com-
P ctlng lh l' course 01 phototli erapv. was conlrolled on only 
Illit~ oeyclin e. 100 mg/day. . 
Subcorneal pustular dermatosis I is a rare condition of 
UnknOwn aetiologv. occasionally associat ed with an arthro-
Pathy l l ' - d b I" I ' I I d 1 
. reatments reporte as ene Icta 111(' Ut e apsone, 
~~)r[jcos teroids . l topical PUVA. l systcmic relinoids \ and brciad-
C'1I1d UVI3 phototherapy. ~ Orton ct III. (Orton Dl. Wakelin S. 
~orge SA. pers. COl11l11un. ) reported the use or TI..-01 UVB 
PI otothcrapv in a resistant case with clearance following 53 
t, -lJ~utn: cnl ' . Tlte Illech,mism of action of broad- or narrowband 
H B In subL'orn eal pustu lar dermalosis remains unknown. 
OWever. cl'rect s on the skin imlllun e' system including an 
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inhi bito ry inlluence on neutrophil chemotacti c fil ctors. sllch 
as leukotriene B ... may be important. 5." 
Subcorneal pustular dermatosis has a variable course and it 
is possible that in our patient spontaneous iInpro\'ell1ent 
co incided with phototherapy. Ne\·ertheless . we thin k that UVB 
phototherapy is \\'orth trying in cases where control is difficult. 
Dt'/](lrt lll el/t of Del'l1 111 tO/(J[I!}. 
Ni/ tell 'ells Hospital Cll/d AkdiCClI Scllool. 
Dlil/dt'f 001 9SY U.K. 
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A disposable tilce mask for PU\'t\ and ultrm'iolct 
photot herap), 
SIIC We were interested to read that Dall'e and colleagues 
reco l11l1lend u~e of the UVC-80 3 fa ceshield by pati enl s under-
going I'UV,\ and ultnll'iolct (lI V) 13 phototherapy. t We used 
this faces hicld for a number of years in our un il but were 
fru strated by the need to clean the headband between patients. 
especially in the li ght or any risk of cross-infec tion. and the 
ye llowing and scratching of the I' isor which occurs over time. 
We recognize the need. during PUVA and UVH phototherapy. 
to shield the face if it is not involved wit h psoriasis. as it receives 
frequent exposure to sunli ght Hnd is the most common site for 
non-melanoma skin cancers. A furth er reason for protecting 
the face is Lo prevent tanning which some psoriasis sufrerers 
find distressing to explain away. particularly durin g the winter 
months (R.Jobling. pers. commun .) . In additi on to fa ceshields. 
protection can be achieved with sunscreens. which are messy 
and lime consuming to apply. or an opaque material (e.g. a 
tOll'el) over the face. which is cl austrophobic. 
As we fe lt none of these options was ideal. we designed. in 
conjunction with the Centre ror Industrial DeSign at the Uni-
versity of Northumbria. the disposable face mask in shown in 
Fig. 1. This protects the race and ears. but is easily cut and 
shaped to alloll' treatment of hairline or isolated psoriatic 
plaques on face. It is visibly clear but blocks a ll UVA . UVB and 
UVC radi il tion (i.e. all wavelengths below 40'0 nm) . Each mask 
is specific to a patient throu ghout their course of treatment 
and is then thrown away. It is assembled with a single move-
ment in seconds and fold s flat between treatment sessions for 
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PUVA for diffuse cutaneous reticulohistiocytosis 
SIR, A 65-year-old man gave up swimming, embarrassed by an 
itchy rash affecting his trunk, On presentation 3 months later. 
he had a symmetrical eruption of multiple, firm , pink-brown 
papules and small nodules on the trunk, arms and thighs 
(Fig. 1a, b). His forearms and legs were less affected and his 
face and hands spared. A diagnostic biopsy showed a mixed 
infiltrate of histiocytes. lymphocytes , neutrophils, eosinophils 
and a few multinucleated giant cells with 'grou nd glass ' 
cytoplasm. A fat stain (SR 19) showed fin e lipid droplets within 
the cytoplasm of the histiocytic cells, These microscopic 
findin gs were suggesti ve of reticulohistiocytosis . 
He had a past history of osteoarthritis. but had no active 
inOammatory arthropathy. He was under inves tigation for 
brea thlessness , which was found to be due to a dilated cardio-
myopathy of uncertain ca use, Clinical assessment and investi-
gation did not reveal any malignancy. and no evidence of 
Figure 1. The patient. (a)before PUVA. and (b) close-up of left forearm. 
extracutaneous reticulohistiocytosis was found. In particular. 
a magnetic resonance imaging scan of the heart and myo-
cardial biopsy did not show multicentric reticulohistiocytosis 
to be the cause of his heart failure. 
Potent topical steroids provided limited relief from itch, but 
did not alter the appearance of his eruption. After his con-
dition had perSisted for 17 months. confined to his skin. we 
started an empirical course of 8-methoxypsoralen-ul traviolet 
A photochemotherapy (PUVA) . He was treated twice a week, 
with 20% increments following a starting dose of 70% of his 
minimal phototoxic dose, As his face was una ffected it was 
protected from UVA irradiation with a face-shield. After eight 
exposures, itch was reduced and the eruption was beginning 
to fade. By his 14th exposure he was asymptoma tic and his 
skin was clear. One year after stopping PUVA his eruption has 
not recurred. 
Spontaneous -resolution, known to occur in multicentric 
reticulohistiocytosis.1.2 cannot be excluded. However, the long 
unchanging course of his condition prior to PUVA , and rapid 
improvement during treatment. suggest that PUVA was 
responsible for clearance. Classification of the non-Langerhans 
cell histiocytoses remains complex,3 Some regard diffuse 
cu taneous reticulohistiocytosis and multicentric reticulo-
histiocytosis as conditions within a spectrum of disease:! ,5 
Our diagnosis of diffuse cutaneous reticulohistiocytosis. rather 
than multicentric reticulohistiocytosis in this patient depended 
on the exclusion of extracutaneous involvement. 
Reported treatments for diffuse cutaneous and multicentric 
reticulohistiocytosis include surgery for an underlying malig-
nancy.6 systemic immunosuppressive therapy and cyto-
toxiCS.2.7- lO For those with crippling arthritis. or other severe 
systemic involvement. such treatment is justified. Although 
malignant melanoma is one of the malignancies associated 
with multicentric reticulohistiocytosis. lJ .1 2 there is no evidence 
that patients with non-malignancy associated reticulohistio-
cytosis are at increased risk of melanoma if exposed to PUVA. 
For a patient like ours. with disease restricted to th e skin and 
no evidence of associated malignancy. a trial of PUVA therapy 
may be preferable to more toxic systemic therapy. 
Department of Derlllatology. 
Ninewells Hospital and Medical Sc/lOol. 
Dllndee DDI 9SY. U.K. 
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Severe skin pain after combined ultraviolet B and ultraviolet 
A phototherapy for atopic dermatitis 
SIR. It has been reported that eight (4%) of 210 patients 1 and 
17 (5%) of 335 patients2 who received oral 8-methoxypsor-
alen photochemotherapy (PUVA) developed abnormal skin 
~ain. Here we report a patient who had similar skin pain 6st ~fter phototherapy with combined ultraviolet (UV) A and 
VB for atopic dermatitis. 
A 28-year-old man. with a 5-year history of adult-type 
~toPic dermatitis. initially underwent topical PUVA therapy 
Or 3 months with a successful outcome. He had no abnormal 
sensation on his skin or other side-effects. However. 10 months 
after the last topical PUVA·session. the atopic skin lesions had 
~orsened. He therefore received combined UVA/UVB photo-
~ erapy using a UVA/UVB combination unit at our university 
oSPital. The initial UVB dose (40 mJ/cm2) was just below the 
~~tient's minimal erythema dose. established by phototesting. 
Ii e UVA dose was started at 3 J/cm2. Several hours after the 
t rst phototherapy session. the patient complained of unexpec-
bed excruciating skin pain over the whole body. which later 
A~came localized to the back. and disturbed his sleep at night. 
t . though the abnormal symptoms perSisted for 1 week. he 
(~Ied one more phototherapy session with a lower dose of UVB 
a O.mJ/cm2) to confirm this'peculiar phenomenon. but this 
~tn resulted in severe burning or pricking skin pain over the 
W ole body. He was not given systemic or topical phototoxic 
ag~nts during the phototherapy. Erythrocyte. faecal and 
~rtnary porphyrin levels were not raised. Systemic adminis-
ar~tion of analgesics. including indomethacin or mefenamic. 
d~ld and antihistamines. had no significant effect on the 
a;SCo~fort. Although previously reported patients with hyper-
atgesla related to PUVA therapy occasionally showed associ-
hed neurological or emotional disturbance.4 our patient 
~ OWed no such abnormalities. In our patient. the excruciat-
nng pain occurred after combined UVA/UVB phototherapy. and 
ot after PUVA therapy. suggesting that simple irradiation of 
CORRESPONDENCE 721 
UVB and/or UVA is able to be a causal factor of skin pain. 
Although the aetiology is unknown. UVB-mediated inflam-
matory substances or neurotransmitters. such as bradykinin. 
serotonin or substance P. might be responsible for the skin 
pain because our patient showed a quick response. in contrast 
to PU\l\-treated patients. This aspect has not been reported 
previously. 
Department of Dermatology. 
Hirosaki University School of Medicine. 
Hirosaki 036. 
Japan 
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Systemic plasmacytosis with deposition of interleukin (IL)-6 
and elevated expression of IL-6 mRNA in the skin lesions 
SIR. Systemic plasmacytosis was first described by Watanabe 
et al.1 in 1986. The disease is characterized by infiltration of 
mature plasma cells in more than two organs. and polyclonal 
hyperimmunoglobulinaemia. Multiple brownish eruptions. 
microscopically characterized by prominent hyperplasia of 
mature plasma cells. are found. This disease had been thought 
to be seen only in Japanese. in whom 54 similar cases have 
been reported.2 However. a similar case with a peculiar skin 
eruption was recently reported from Spain. 3 As for the 
pathogenesis of plasma cell hyperplasia. a close relationship 
with interleukin (IL) 6 has been suggested.4 but it still remains 
unknown why plasma cell hyperplasia is observed in the 
dermis of systemic plasmacytosis. 
A 45-year-old Japanese woman had had asymptomatic 
brownish eruptions on the trunk for 7 years. They were 
scattered. well-demarcated hard papules and nodules (Fig. 1) 
which had generally spread and increased in size. She was 
transferred to our hospital on 2 May 1996 for evaluation of the 
eruptions. Superficial lymph nodes in the neck. axillary and 
inguinal regions were palpable. Laboratory findings were as 
follows; haemoglobin 6·5 g/dL (normal. N: 12-15'5). platelets 
S14x109/L (N; 150-450x109). erythrocyte sedimentation 
rate 1 S6 mm in the first hour (N: < 15). serum total protein 
9·2 g/dL (N; 6'3-7'9). 'Y-globulin level 54·4% (N; 9'6-20'0). 
and polyclonal hypergammaglobulinaemia with IgG 6289 mgt 
dL (N: 770-1700). IgA 513 mg/dL (N: 90-450) and IgM 
443 mg/dL (N: 60-250). C-reactive protein (CRP) was 17·1 mgt 
dL (N: < 0·1). Urinalysis was normal. A bone marrow aspirate 
showed a hypocellular marrow with a slightly increased number 
of plasma cells (6%). Pathological examination of involved skin 
revealed dense perivascular infiltrates composed mainly of 
plasma cells beneath a normal epidermis. These plasma cells 
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Narrowband ultraviolet B (TL-O 1) phototherapy for psoriasis: 
which incremental regimen? 
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Summary Narrowband (311-313 nm) ultraviolet B phototherapy with the Philips TL-01 lamp is used 
increasingly in the treatment of psoriasis with little information available on the optimum irradiation 
regimen. We compared a high and a low incremental dose regimen in 20 patients with symmetrical 
chronic plaque psoriasis using a randomized half body study and thrice weekly exposures. Paired 
trunk, leg and arm plaques of psoriasis were scored blind prior to and at each treatment for scaling. 
erythema and induration. Patients were treated to clearance or minimal residual activity and 
followed up until relapse. The low increment regimen achieved a 10% reduction in the median 
cumulative dose to clearance (16,401 vs. 18,246mJ/cm2) with one extra treatment in 50% of the 
patients. However, the duration of treatment (median 53·5 days) was identical for both regimens 
except for one patient because there were 50% fewer episodes of erythema requiring postponement of 
treatment with the low increment regimen. We now favour the low increment regimen for 
phototherapy in our psoriasis population. 
The Philips TL-Ol lamp with its output primarily at 
311 nm is now widely used in the U.K. and Europe as a 
light source for phototherapy in dermatology. The emis-
sion spectrum of the lamp lies almost entirely within the 
therapeutic action spectrum for psoriasis photother-
apyl.2 and several studies have favoured the lamp over 
the traditional broadband ultraviolet (UV) B sources in 
the treatment of psoriasis.3- 8 The extensive use of 
photo chemotherapy (PUVA) is now clearly associated 
with an increased risk of non-melanoma skin 
cancer,9.10 and other studies, albeit few in number at 
present, have not shown any marked benefit of PUVA 
Over TL-Ol phototherapyY·12 Additionally, UVB photo-
therapy can be used in pregnancy, in children, and does 
not require concomitant medication or eye protection 
after treatment. 
Such factors have promoted the use of the TL-Ollamp, 
but as yet there is little published on the optimum 
irradiation regimen to be employed with this source to 
achieve complete psoriasis clearance with the minimum 
number of exposures, the minimum cumulative UV dose 
and with as few acute and chronic side-effects as possible. 
The variables in a phototherapy regimen include the 
starting dose, the exposure frequency and the dose 
increments. A pilot study in our department, looking at 
the last of these variables, had suggested that a lower 
dose regimen than that commonly used for broadband 
410 
UVB phototherapy might be effective in clearing psor-
iasis.u We decided, therefore, to carry out a full study 
comparing a high and a low incremental dose regimen in 
the treatment of chronic plaque psoriasis. 
Subjects and methods 
Subjects 
Twenty patients with moderate to severe, symmetrical 
chronic plaque psoriasis affecting the trunk and limbs 
were recruited from out-patient clinics between Novem-
ber 1994 and October 1995. Each patient was provided 
with study information and after full discussion, written 
consent was obtained. The study was approved by the 
Ethical Committee. 
Exclusion criteria 
These were: age < 18 years, systemic or phototherapy/ 
PUVA for psoriasis in the preceding 3 months, a history 
of skin cancer, ongoing systemic immunosuppressive 
therapy or topical treatment for psoriasis, apart from 
emollients and treatment of the scalp or photopro-
tected areas. 
Study design 
A half body, single blind method was employed where 
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Table 1. Narrowband ultraviolet B (TL-01) irradiation regimens 
Determine MED prior to phototherapy 
Treat each body half independently x 3/week (Mon .. Wed .. Fri.) 
Initial dose to both sides: 70% MED 
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1 
2 
3 
4 Increments given at each exposure according to erythema response at 48 h and allocated regimen 
High increment regimen. Erythema response at 48 h: 
None-40% incremental increase. 
Grade 1 (mild)-barely perceptible erythema-repeat previous dose and reduce to 20% increments thereafter. further reduce to 10% 
increments when necessary. 
Grade 2 (moderate)-well defined. asymptomatic erythema-postpone one treatment. repeat previous dose at next \'isit. with 20% 
increments thereafter. further reducing to 10% increments when necessary. 
Grade 3/4 (severe)-symptomatic erythema and/or bullae. Postpone therapy until recovery then penultimate dose with 10% increments 
thereafter. 
Low increment regimen. Erythema response at 48 h: 
None-20% incremental increase. 
Grade 1 (mild)-barely perceptible erythema-repeat previous dose and reduce to 10% increments. 
Grade 2 (moderate)-well defined. asymptomatic erythema-postpone one treatment. repeat previous dose at next visit and reduce to 10% 
increments. 
Grade 3/4 (severe)-symptomatic erythema and/or bullae lasting more than 24 h. Postpone therapy until recovery then penultimate dose 
5 
with 5% increments thereafter. . 
Maximum exposure dose: 2066 mJ/cm2 
Maximum number of treatments: 35 
Missed treatments: 1 or 2 treatments-repeat previous dose 
3 treatments-treat with penultimate dose 
> 3 treatments-doctor will review dose required. 
MED. Minimal erythema dose. 
for each patient. one body half was randomly allocated 
to a high increment dose regimen while the other half 
Was treated with a low increment dose regimen. Both 
regimens were based on a minimal erythema dose 
(MED) determined prior to treatment. Where there 
Was a difference in dose between the sides. the difference 
Was administered first. protecting the lower dose side 
With a half body suit (100% Microguard Overall; Orvec 
International. Hull. UK.) folded in on itself. through 
which no UV transmission was detectable using a 
lIitachi U-3210 double beam reflectance spectrophot-
Ometer (Nissei Sangyo Co .• Finchampstead. Berks. UK.). 
The suit was then removed and both sides treated 
together with the remaining dose. UVB protective gog-
gles 01' faceshield. 14 and. in males. genital protection. 
Were Worn throughout phototherapy unless psoriasis 
affected these areas and required treatment. Concomi-
tant topical treatment was allowed if required. in the 
form of barrier cream (sun protection factor 25) to the 
face. moderately potent topical steroid to shadow sites 
and coal tar based preparations for the scalp. The use of 
emollients throughout the study was encouraged but 
th~se were not applied in the 4 h prior. to exposure as 
thiS would interfere with the assessment of scaling. 
Pat' . . lents were assessed at each visit and after completmg 
Phototherapy were followed up with further review 
apPointments or monthly telephone calls until their 
psonasls relapsed. During this period. patients were 
encouraged to use emollients but specific antipsoriasis 
treatments were excluded. Relapse was tal<en as the point 
when the patient demanded further active treatment. 
Treatment regimens 
These are summarized in Table 1. The starting dose for 
both sides of the body corresponded to 70% of the MED 
and thereafter incremental doses were determined 
according to the erythema response. The maximum 
exposure dose for both regimens was 2066mJ/cm2, 
Each side of the body was treated independently until 
clearance or minimal residual activity (MRA) was 
achieved. subject to a maximum of 35 exposures on 
each side. A three times weekly exposure regimen was 
chosen in keeping with our current practice. 
Minimal erythema dose determination 
This was done by our standard method of irradiating a 
template of eight 1 x 1 cm squares on the upper back 
with a range of doses from a TL-O 1 UVB source placed 
20 cm from the patient. The doses administered are: 25. 
50.70.100.140.200.280.390.550 an:d 770 mJ/cm2 
(the lower eight doses are used for skin types 1 and 2 
and the upper eight doses for skin types 3 and 4). The 
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Table 2. Median number of days in treatment. exposures and cumulative doses to clearance/minimal residual activity 
High increment regimen Low increment regimen P-value 95% CI for difference in medians 
Days 53·5 53·5 0·32 0 
IQR 45-60 45-60 
Range 35-97 35-97 
Exposures 20·5 21 <0'005 0'5-1·0 
IQR 17-23 17-24 
Range 13-31 14-32 
Cumulative dose (mJ/cm2) 18.246 16401 <0'005 1107'5-3347 
IQR 11.642-22.170 8573-19.452 
Range 6848-30.529 4630-30.242 
Cumulative dose (MEDs) 133·2 117·1 <0'005 
IQR. interquartile range; lVrED. minimal erythema dose; CI. confidence intervals. 
erythemal response is evaluated at 24 h postexposure 
and the MED is taken as the dose producing perceptible, 
but defined, erythema at the test site. 
Irradiation cubicle 
Treatments were carried out in a cubicle (constructed 
by the Medical Physics Department at Ninewells Hospi-
tal) containing 50 Philips 100 W TL-Ol fluorescent 
lamps. The irradiance in the cubicle was measured 
monthly according to a standardized protocol using 
an International Light (IL-1400) meter (Able Instru-
ments, Reading, UK.) calibrated using a spectroradi-
ometer. During the study it varied from 3·2 to 2· S m W I 
cm2 and the exposure times were adjusted accordingly 
to achieve the required doses. 
Assessments "" 
For all patients, the psoriasis on each body half was 
scored independently prior to therapy and thereafter at 
each treatment by a blinded observer. It was graded for 
scaling (S), erythema (E) and induration (I) at three 
symmetrical plaque sites on each body half, chosen 
from the trunk and the upper and lower limbs. Each 
parameter was scored on a 0-4 scale and an overall 
psoriasis severity (SEI) score calculated for each body 
half by summing the scores for each of the three chosen 
plaques. The scheme was based on the widely used 
psoriasis area and severity index system. A global (0- . 
4) score representing the overall psoriasis severity was 
also recorded. 
Erythema following phototherapy was graded and 
. any consequent adjustments to the phototherapy regi-
men made as summarized in Table 1. The number of 
exposures, the cumulative dose and the number of days 
in treatment were recorded for each patient on each 
body half along with any adverse effects. The date at 
which each body half cleared was recorded and the 
patient followed up to collect relapse of psoriasis data for 
each body half. 
Statistical methods 
The paired data for each body half consisting of expo-
sures, cumulative doses, psoriasis scores, days in treat-
ment and remission were in general not normally 
distributed and therefore the Wilcoxon Signed Rank 
Test was used. Relapse data were analysed using 
Kaplan-Meier survival plots. 
Results 
Twenty patients, 11 men and nine women with chronic 
plaque psoriasis, aged 20-79 years (median 31; inter-
quartile range 27-41· 5), were recruited to the study 
over an 11-month period. Skin types 1 (n = 3), 2 
(n = 11) and 3 (n = 6) reflected our local population 
and their MEDs ranged from 70 to 550mJ/cm2• Two 
patients deemed themselves adequately clear of psoriasis 
and withdrew from the study before the defined end- . 
point of clearance or MRA. 
For the .IS patients who completed the study, the 
median cumulative dose to clearance was lower on the 
low increment side than the high increment side 
(16,401 vs. IS,246mJ/cm2 ; 1><0'005), but the 
median number of treatments required was marginally 
higher (21'0 vs. 20· 5; P < 0·005). In eight patients the 
same number of treatments was required on each side, 
in nine one extra and in one three extra treatments were 
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Figure 1. Median psoriasis scores (SEI: scalings. erythema. induration) 
and cumulative doses in minimal erythema dose (MED). at each 
treatment. 
needed on the low increment side. However, the median 
duration of treatment (53' 5 days) was identical under 
both regimens for all patients except one, in whom the 
low increment side took 7 days longer to achieve clear-
ance (Table 2). The rate of decline in the median 
psoriasis scores (SEI) with treatment was similar 
under both regimens and is shown in conjunction 
with the increasing cumulative doses on each side 
(Fig. I). 
Acute side-effects were limited to erythema and there 
were almost twice as many erythema episodes (grades 1 
and 2) on the high increment side as on the low 
increment side. Although there were no episodes of 
painful erythema (grade 3) under either regimen, 12 
episodes of grade 2 erythema occurred in 11 patients on 
the high increment side compared with just four such 
episodes in four patients on the low side (Fig. 2). More 
specifically, both skin type 1 and one of five skin type 3 
patients experienced grade 2 erythema under both 
40 
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Figure 2. Erythema episodes. 
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Figure 3. Relapse data-the probability of psoriasis not having 
relapsed is plotted against follow-up time. 
regimens; eight of 11 skin type 2 patients experienced 
grade 2 erythema on the high increment side with only 
one of 11 having such erythema on the low increment 
side. 
The remission times ranged from 2 to 739 days 
(median 129 days) with no significant difference 
between the sides (Fig. 3). In one patient. the remission 
on the high increment side was 7 days longer. that side 
having cleared 7 days sooner. 
Discussion 
The study showed that the low increment regimen was 
effective in clearing psoriasis and did so with a 10% 
reduction in the median cumulative dose. No additional 
treatments were required in 44% of patients and just 
one extra in 50% of patients. In spite of this slight 
increase in the average number of treatments, the 
number of days in treatment was the same in 94% of 
patients. The reason for this apparent discrepancy and 
one of clear relevance to patients. is that under the low 
increment regimen there were fewer postponements of 
treatment on account of grade 2 erythema. With the 
high increment regimen there were three times as many 
such episodes. The time taken for the psoriasis to relapse 
was the same under both regimens in all but one 
patient. as illustrated by the almost coincident lines in 
Figure 3; 50% of patients had not relapsed at 
18·4 weeks. We recognize that our definition of relapse, 
defined by the date when the patient feels further active 
treatment is necessary. is influenced by factors other 
than the extent of psoriasis recurrence. Nevertheless. we 
felt that this definition was of mpre practical applica-
tion, was more relevant t6 the patient and would detect 
any significant difference in psoriasis recurrence 
between the body sides. 
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In the long term. any reduction in the cumulative 
UVB dose is worthwhile. if not at the expense of more 
exposures. The low increment regimen achieves this 
and is also associated with fewer erythema episodes; we 
therefore favour this regimen and have altered our 
clinical practice accordingly. 
Narrowband UVB is more effective than conventional 
broadband UVB phototherapy with apparently no 
greater risk. 3-8 However. the long-term risk of photo-
carcinogenicity. which is probably less than with 
PUVA. 15.16 is as yet undetermined in clinical practice. 
In the meantime. therefore. the optimum mode of use to 
minimize risk needs to be defined and based on objective 
data. Our study comparing different dose increment 
regimens contributes to this definition. The low incre-
ment regimen is now in routine use in the Tayside 
Service. 
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The conservative approach of sunlight avoidance and broad-spectrum 
sunscreen is often disappointing in patients with moderate to severe poly-
morphic light eruption. A springtime course of prophylactic artificial 
hardening with ultraviolet B (UVB) phototherapy or psoralen plus ultra-
violet A (PUVA) photochemotherapy will often allow patients to tolerate 
more sunlight and give them greater freedom during the summer. In this 
retrospective study we describe ten years' experience of such "desensitiza-
tion" treatment. Individualized therapy with attention to detail will 
maximize the effectiveness of this treatment. 
Key words: polymorphic light eruption (PLE); 
narrowband UVB phototherapy; PUVA 
photochemotherapy: desensitization 
Dr I. Man, Photobiology Unit, Department of 
Dermatology, Ninewells Hospital and Medical 
School, Dundee 001 9SY, UK 
Polymorphic light eruption (PLE) is a common 
idiopathic photodermatosis, with higher preva-
lence in the temperate climates (1, 2)_ Patients pres-
ent with a pruritic, often papular, eruption of pho-
toexposed sites occurring usually between spring 
and autumn. Therapeutic intervention has been 
mainly aimed at preventive measures with the use 
of broad-spectrum sunscreen and behavioural sun-
light avoidance. This approach to management 
may be effective in patients with mild PLE (3), but 
is often unsatisfactory in more severely affected in-
dividuals. 
It is commonly observed that PLE frequency 
and severity decreases as the summer progresses (4, 
5). Although the mechanism is not fully under-
stood, this "hardening" process has been put into 
therapeutic use. Desensitization with artificial 
sources in early spring has been shown to be an 
effective prophylactic treatment (6-9). Early 
studies (10, 11) indicated that psoralen plus ultra-
violet A (PUVA) was superior to broadband ultra-
violet B (UVB), but more recently Bilsland et aI. 
(12) demonstrated in a carefully controlled study 
that the newer narrowband TL-Ol UVB source is 
as effective as PUVA. 
Both UVB and puvA are now widely used and 
are regarded as the treatments of choice in patients 
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with moderate to severe PLE (13). Nevertheless 
treatment regimens vary greatly between centres, 
as revealed by a recent Scottish Audit of photo-
therapy and photochemotherapy (14). 
In ~his retrospective study we describe ten years' 
expenence of UVB and PUVA desensitization in 
the prophylactic treatment of PLE. This may guide 
others using, or intending to use, these forms of 
therapies. 
Method 
Patients 
Between 1986 and 1995, with~n the Tayside region, 
northeast Scotland, 287 patIents with PLE were 
se.e~ and in~estiga~ed at the photodermatology 
climc. The dIagnOSIS was established by history, 
monochromator and UVA provocation testing, lu-
pus serology, porphyrin scan and histology, as ap-' 
propriate. Desensitization treatment was offered in 
early spring to 170 patients with moderate to se-
vere PLE (i.e. those whose condition causes sig-
nificant disruption of normal life). Each course of 
treatment was carefully documented. Notes were 
reviewed on all patients who had UVB and/or 
PUVA between 1986 and 1995. The total number 
of treatment courses administered, the frequency 
199 
of provoked PLE and each subject's response to 
treatment during the subsequent summer months 
were tabulated and analysed . 
Treatment regime 
Our standard treatment protocols fo r UVB and 
PUVA throughout the period of study are shown 
in Table 1. The starting dose was 70% of the prede-
termined minimal erythema dose (MED - defined 
as minimal perceptible erythema) for UVB and 
70% of the minimal photo toxic dose (MPD) for 
PUVA. This was followed by a 10-20% incremen-
tal increase depending on erythema or PLE re-
sponse (Table 1). Treatment was administered daily 
for inpatients or three times weekly for outpatients 
for 10 to 15 treatments. If PLE was provoked, top-
ical steroid was used and the dose adjusted accord-
ingly, as shown in this table. 
Although the majority of patients received 
whole body irradiation, over recent years, especi-
a lly in those with severe PLE, we have trea ted ha-
bitually exposed sites only, i.e. patients wore short-
sleeved shirt and shorts during treatment. In ex-
tremely photosensitive pa tients, potent topical 
steroid was applied to treated sites immediately 
after exposure. Such measures were introduced 
either prior to or during the course of trea tment. 
Post treatment advice. Following each course of 
trea tment , patients were encouraged to cautiously 
seek sunlight exposure to keep thei r artificial 
Table 1. TL-01 and PUVA treatment protocol in PLE desensitization 
TL-01 UVB desensitization 
• determination of minimal erythema dose (MED) with readings at 24 h 
• initial irradiation dose - 70% of MED 
• 20% increments at each visi t if no erythema 1 or provoked PLE2 
• outpatients - 3 times weekly for 5 weeks (total 15 treatments) 
inpatients - daily for 2 weeks (total 10 treatments) 
PUVA desensitization 
• 8 MOP or 5 MOP 
• determination of minimal phototoxic dose (MPD) with readings at 72 h 
• initial dose - 70% of MPD . 
• 20% increments at each visit if no erythema 1 or provoked PLE2 
• 3 times weekly for 5 weeks (total 15 treatments) 
11f erythema 
• Grade 1 - previous dose repeated 
• Grade 2 - postpone 1 treatment and same dose repeated, followed by 10% 
increments 
• Grade 3/4 - no treatment until recovery, then dose reduc~d by half foll owed 
by 10% increments 
21f provoked PLE 
• itch or mild PLE - topical steroid if required 
• moderate - same dose and moderate/potent topical steroid, followed by 
10% increments 
• severe - postpone 1 or 2 treatments, potent topical steroid and restart with 
penultimate dose followed by 10% increments 
Desensitization of polymorphic light eruption 
photoprotection ' topped up '. Broad spectrum 
sunscreen, however, should be applied if they in-
tended to stay outdoors for longer periods of time. 
Patients were followed up in a utumn or the fol- . 
lowing spring. If successful , treatment was re-
peated yearl y, in early spring. In pa tients who 
fa iled to respond sa tisfactorily to TL-Ol , PUVA 
was offered the following yea r. 
Results 
The majority of PLE patients had a normal action 
spectrum on monoch romator phototesting. Ab-
normal photosensitivity was demonstra ted in 32 
(11 %), 25 of whom had sole involvement of the 
UVA wavelengths (335- 365 ± 30 nm) . PLE lesions 
were induced in 16.3% of cases following 25 J/cm2 
UVA provocation on two consecutive days (Dr 
Honle Portable Dermalight 2000, filter HI , high-
pressure metal halide lamp, spectral output 320-
400 nm). 
Between 1986 and 1995 170 PLE patients (152 
female, 18 male; age range 9- 73 yea rs) were 
trea ted . Of these, 133 patients received U VB trea t-
ment (1 28 TL-Ol and 5 broadband), 8 patients re-
ceived PUVA and 29 patients had bo th UVB and 
PUVA. A total of 330 courses of UVB (325 TL-O I 
a nd, in 198617, 5 broadband), and 109 courses of 
PUVA were administered (Fig. 1). 
Evaluable data were obta ined for 28 1 courses of 
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Fig. 1. No. of PLE patients "desensit ized" with UVB and 
PUVA between 1986 and 1995. Total no. of courses admin is-
tered: 325 narrowband TL-O 1, 5 broadband U VB and 109 
PUVA. 
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Table 2. Subjective response following each treatment course 
Patient response 
Good1 
Moderate2 
Poor/no response3 
lno PLE; 2mild PLE; 3recurrent PLE. 
UVB (%) 
176 (63) 
73 (26) 
32 (11) 
PUVA (%) 
57 (58) 
30 (30) 
12 (12) 
UVB and 99 courses of PUVA. At follow-up, the 
majority of patients obtained either good benefit 
(63% UVB, 58% PUVA) with no PLE episodes, 
or moderate improvement (26% UVB, 30% PUVA) 
with reduction in severity and frequency of PLE 
compared to pretreatment years. There was a fail-
ure rate of 11 % of UVB and 12% of PUVA treat-
ment courses, following which patients continued 
to have recurrent PLE during the summer (Table 
2). Of the 29 patients who received both PUVA 
and TL-O 1, 21 reported an overall preference: 12 
favoured PUVA, 4 preferred TL-OI and the re-
maining 5 responded equally well to both forms of 
therapies. 
The responses to 49 courses of UVB and 10 
courses of PUVA were excluded from the study be-
cause patients either failed to attend the follow-up 
clinic or the response had not been clearly docu-
mented in the notes. However, of those 49, 11 pa-
tients had since had a further course of UVB and 
2 had PUVA with good response. Four patients 
had moved from the Dundee area and were uncon-
tactable. 
Desensitization was well tolerated by most pa-
tients, although mild PLE was often provoked dur-
ing treatment. At least 1 episode of PLE was in-
duced during 48% of UVB and 44% of PUVA 
treatment courses. As most were mild, subsequent 
adjustment of doses with or without the addition 
of topical steroid allowed completion of the course 
of treatment. Systemic steroids were not required. 
Discussion 
In moderate to severe PLE, when sunscreen and 
sunlight avoidance fails to offer satisfactory pro-
tection, desensitization phototherapy and photo-
chemotherapy should be considered. Successful 
outcome was noted in the majority of patients, ir-
respective of a history of hardening. . 
Despite its widespread use, treatment regImens 
vary greatly between centres (14). In our depart-
ment, narrowband TL-O 1 . has gradually replaced 
broadband UVB and PUVA in most cases of pso-
riasis and atopic eczema patients, and is now the 
treatment of choice in PLE desensitization. PUVA 
is generally reserved for the minority who failed 
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to gain satisfactory photoprotection from TL-O I. 
Advantages of TL-OI include I) absent psoralen 
and its associated gastrointestinal upset, 2) avoid-
ance of wearing photoprotective glasses in the 
post-treatment period, and 3) the ability of use iri 
children and pregnancy. It may also be quicker and 
cheaper to administer. Furthermore, TL-Ol UVB 
is probably safer than PUVA in terms of the risk 
of non-melanoma cutaneous malignancy (15, 19). 
The mechanism of action of phototherapy and 
photochemotherapy artificial "hardening" in the 
prophylactic treatment of PLE is not fully under-
stood. Thickening of the· stratum corneum, 
hyperpigmentation and alteration of cellular im-
munity may playa role (16-18). 
When discussing a desensitization course with a 
PLE patient, it is important to highlight that each 
patient will respond differently and as such treat-
ment will be individualized. In our experience, at 
least one episode of mild PLE was provoked in half 
the treatment courses. The first course is often ex-
ploratory and patients should be forewarned of a 
50% chance that PLE may be provoked but that it 
. should not prevent them from continuing treat-
ment. In the few cases where PLE episodes were 
more troublesome, greater caution in the in-
cremental dose steps, along with the use of topical 
steroid, usually allowed the patient to continue to 
completion. Although systemic steroid has been 
used concurrently with PUVA to suppress induced 
PLE (16), we have not required this approach. 
In recent years we have tended to treat sunlight-
exposed sites only, especially in those severely 
affected in whom provoked PLE is likely to be a 
problem during desensitization. These individuals 
are advised to wear the same thick cotton short-
sleeved shirt and shorts at each treatment. The 
clothing must be worn in exactly the same position 
each time to prevent sunburn-like reaction in those 
areas not previously treated. Although, in the 
literature, the suppressive effect of PLE by topical 
steroid is uncertain, our experience in the few 
markedly photosensitive patients is that potent 
topical steroid applied to the treated areas immedi-
ately after each exposure does reduce the incidence 
and severity of PLE episodes. 
Following the treatment course, patients should 
be encouraged to cautiously seek sunlight exposure. 
to keep their artificial photoprotection "topped 
up", otherwise the effect may be lost within 4-6 
weeks (7). One possible explanation for poor re-
sponders (T~ble 2) is that t~e trea.tment course may 
have been gIven too early 111 spnng and this com-
bined with poor spring sunshine, a situation com-
mon in Scotland, may result in loss of photopro-
tection. In this study, 65% of the poor responder 
group was treated between March and May. The 
remammg 35% was treated, at patients' request 
usually prior to holidays, earlier or later in the 
year. In these individuals, it is possible that over-
exposure to foreign sunshine might account for 
some who reported treatment failure. 
The photoprotective effects of phototherapy and 
PUVA are temporary and treatment needs to be 
repeated yearly. A total of 59 of our patients had 
3 or more courses of successful yearly treatment, 
15 of whom had 5 or more treatment courses. 
There appears to be no loss of benefit with sub-
sequent courses. In our practice, patients who have 
had 3-4 years of successful desensitization are en-
couraged to try a year without treatment. The 
natural history of this condition is unknown but 
from our experience a proportion of patients do 
spontaneously improve with time. 
The concern with repeated yearly UVB photo-
therapy is the long-term skin cancer risk. A pre-
vious study by Lark0 & Diffey (20) suggests that 
the cumulative UVB qose, and therefore skin can-
cer risk, received by patients undergoing regular 
phototherapy for psoriasis, is approximately 2-3 
times that of a yearly three weeks' Mediterranean 
holiday. It is probable that PLE subjects, through 
their behavioural avoidance of sunlight and the 
lower cumulative dose used in desensitization com-
pared to a course for psoriasis, may in fact be at a 
lower risk than normal subjects and UVB-treated 
psoriatic patients. 
Desensitization adapted to individual patient's 
needs, such as dose incremental regimen, exposed-
site treatment with or without topical steroid use, 
can produce a successful outcome for the majority 
of PLE patients. 
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settled immediately on withdrawal of isotretinoin. The second 
patient was a 16-year-old boy who had mild asthma and who 
developed nocturnal symptoms and exercise-induced wheeze 
during the first month of treatment with isotretinoin. It 
improved on withdrawal of the drug and recurred when it 
was started again for a further flare of acne. 
Although uncommon. there have been 20 reports to the 
Committee on Safety of Medicines of isotretinoin causing 
asthma-related side-elTects. In one controlled study. a propor-
tion of patients with acne taking Isotretinoin showed a 
Significant reduction in their forced expiratory flow rate.3 The 
mechanism by which isotretinoin exacerbates asthma Is not 
known. but drying of the tracheobronchial tree leading to 
increased irritability has been proposed.1.2 
We wish to draw this rare side-effect of Isotretinoin to 
readers' attention and urge that a history of asthma is sought 
in patients starting the drug. If positive. a baseline peak flow 
measurement Is useful. and an appropriate warning should 
be given. 
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Photosensitizing drugs may lower the narrow-band 
ultraviolet B (TL-Ol) minimal erythema dose 
SIR, Does it matter if patients attending for narrow-band 
(TL-01. 311-313 nm) ultraviolet (UV) B phototherapy are 
on known phototoxic systemic therapy? Many patients 
attending for treatment of psoriasis. atopiC dermatitis and 
other conditions are taking potentially photoactive medi-
cation including non-steroidal anti-inflammatory drugs 
(NSAIDs). thiazide diuretics. quinine. phenothiazines and 
fluoroquinolones. Such age~ts are known to be photoactive 
within the UVA wavebands. with extension Into the UVB 
region in some. I - 4 Stern et al. have examined the use of these 
drugs during PUVA.5 and found a slightly increased risk of 
burning. resulting in the need for discontinuation of PUVA 
therapy. particularly in older patients. No work which 
examines the elTect of photoactive medication during UVB 
has been published. 
A prospective study was established to record current 
medication and minimal erythema dose (MED) in all patients 
starting UVB (TL-01). The MED was measured by irradiating 
CORRESPONDENCE 389 
eight 1· 5 xl, 5 em squares on the patient's back with a 
series of UVB TL-01 doses (25. 50. 70. 100. 140.200. 280 
and 390 mJ/cm2 in skin types I and II. and 50-550 mJ/cm2 
in skin types III and IV) using a unit consisting of eight TL-01 
tubes. the output of which was measured monthly with an 
IL1400A radiometer/photometer. Calibration Is traceable to 
the National Physical Laboratory. The MED was defined as the 
dose required to cause just perceptible erythema at 24 h. 
Patients with known abnormal photosensitivity were 
excluded. 
In total. 401 patients were studied between November 
1995 and June 1997. Ninety-five (24%) were receiving 
medication considered to be potentially photoactive. Of 
these. 31 (8%) were taking more than one potentially 
photoactive medication. One hundred and thirty-one (33%) 
were receiving other drugs and 175 (44%) were taking no 
medication. 
The MED values for patients either taking no -medication or 
taking drugs from 10 groups of suspected photosensitizers are 
shown in Figure 1. The Kruskal-Wallis equality of popu-
lations rank test was used to determine whether or not 
dilTerences in MEDs across the groups of patients on no drugs 
and on suspected photosensitizers could be explained by 
chance. When this showed a significant difference between 
the groups (P = 0'002). the Wilcoxon rank-sum test was 
applied to compare the MED values for individual drug groups 
with those on no medication. This showed Significant 
lowering of the MED for patients on NSAIDs. phenothiazines 
and calcium-channel blockers (Table 1). Similar results were 
found when patients on more than one suspected photo-
sensitizer were excluded (data available on request from 
authors). There was no significant dilTerence in distribution 
of skin phototypes between those taking and not taking 
potentially photoactive medication (P = 0'22). 
The numbers involved were small. but our findings suggest 
that some photoactive medications may influence the UVB 
TL-01 MED. In particular. NSAIDs. ealcium-channel blockers 
and. probably. phenothiazines are associated with a lower 
MED. Lowering of a patient's MED by photoactive medication 
should. on current knowledge. not contraindicate the use 
of TL-01 (narrow-band) UVB phototherapy. It is. however. 
Table 1. Minimal erythema dose (MED) values for patients on no 
medication and those on suspected photosensitizers (where there 
were 10 or more patients on individual medications) 
Medication 
No medication 
NSAIDs 
H2-blockers 
Phenothiazines 
Calcium-channel blockers 
Thiazides 
Tricyclic antidepressants 
No. Median MED 
patients (mJ/cm2) 
175 140 
36 100 
28 140 
23 140, 
19 100 
13 140 
10 140 
P-value8 
0'0027 
0'74 
0'0096 
0'0041 
0'36 
0'97 
NSAIDs. non-steroidal anti-inflammatory drugS; 8 Wilcoxon rank-sum 
test comparing those on medication with those on no medication. 
© 2000 British Association ofDermat~logiSts, British Journal of Dermatology, 142, 370-393 
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Figure 1. TIrOl minimal erythema dose values for patients on no 
medication and on drugs within groups of suspected photosensitizers. 
NSAIDs. non-steroidal anti-inflammatory drugs. 
another reason for performing MED testing prior to 
treatment. 
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Reactive perforating coUagenosis associated with 
underlying malignancy 
SIR, We were interested in the recent report by Chae et al. of a 
patient with reactive perforating collagenosis (RPC) and 
periampullary carcinoma. 1 The authors suggest RPC should 
be considered a paraneoplastic condition. We report a further 
case of RPC associated with underlying malignancy. 
A 75-year-old lady presented with a 6-month history of 
nausea, anorexia, 10 kg weight loss and an itchy rash on her 
back. There was a history of hysterectomy and bilateral 
salpingo-oophorectomy for endometrial carcinoma 20 years 
previously and also a 20-year history of non-insulin-
dependent diabetes. Her medications consisted of metformin, 
• 
Figure]. (a) Multiple dome shaped papules wilh sauccr-like rims and distinctive central dark brown crusts are evident on the back. (b) A 
photomicrograph of a lesion on lhe back shows hyperkeratosis. hypergranuloSiS, acanthosis and a plug of debris with necrotic collagen fibres 
suggestive of transepidermal elimination. 
© 2000 British Association of Dermatologists. British Journal oj Dermatology. ]42. 370-393 
Narrowband TL-Ol Phototherapy 
for Patch-Stage Mycosis Fungoides 
Colin Clark, MRCP; Robert S. Dawe, MRCP; Alan T. Evans, MRCPath; 
Graham Lowe, FRCP; James Ferguson, FRCP 
Background: Although patch-stage mycosis fungoi-
des (MF) has a generally good prognosis, and long-term 
survival rates with current therapies (UV -B, photoche-
motherapy, topical nitrogen mustards, electron-beam 
therapy) are similar, there is concern regarding their po-
tential adverse effects. Narrowband or TL-01 UV-B pho-
totherapy (311 nm), in use for more than 10 years, is more 
effective than broadband UV -B for the treatment of pso-
riasis, with an efficacy approaching that of psoralen UV-A. 
This open study assesses TL-O 1 as an allernative therapy 
for patch-stage MF. 
using a standard protocol. Complete clearance of MF was 
achieved in 6 cases in a mean of 9 weeks or 26 treat-
ments (range, 20-37 weeks) and 4 patients have had pro-
longed remissions. Mean duration of clinical improve-
ment has been 20 months (range, 11-40 months). Partial 
response to TL-01 or poor histologic improvement was 
associated with rapid relapse. 
Observations: Eight white patients (4 men, 4 women; 
age range, 66-83 years) with histologically proven patch-
stage MF received TL-01 phototherapy 3 times weekly 
Conclusions: TL-01 is an effective, convenient therapy 
that may have less risk of long-term adverse effects than 
current alternatives. Although larger prospective stud-
ies are necessary, for some patients intermittent courses 
of TL-O 1 may offer effective long-term therapy. 
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M YCOSIS fungoides (MF) is an uncommon T-cell lymphoma, ini-tially confined to the skin, that can evolve 
from limited to widespread cutaneous dis-
ease. Progression from patch, plaque, and 
tumor stages may, in a few cases, culmi-
nate in disseminated lymphoma with vis-
ceral and lymphatic involvement. In patch-
stage MF, the malignant clone of T helper 
cells demonstrates epidermotropism with 
abnormal cells evident in the epidermiS and 
superficial dermis. The accessibility of this 
site for local treatment in conjunction \vith 
the failure of studies to demonstrate pro-
longed survival with more aggressive sys-
temic therapy confirms topical therapeu-
tic modalities as the treatment of choice for 
patch-stage MF.l 
Commonly used treatments for early 
MF include photochemotherapy (psor-
alen UV-A [PUVA)) and topical nitrogen 
mustard (mechlorethamine) or carmus-
tine chemotherapy. Total-skin electron-
beam radiation therapy is also used in some 
centers.2 All have been reported to have 
equal efficacy in'stage 1 MF with a com-
plete response to treatment in more than 
70% of cases.) Although the median dura-
tion of disease-free remissions reported for 
these therapies is variable, the long-term 
survival rates are not Significantly differ-
ent.} Broadband UV-B has also been shown 
to have similar efficacy for skin clearance, 
with a 23% sustained disease-free remis-
sion on discontinuation of maintenance 
therapy in stage Ia disease (mainly patch-
stage disease)." Although several studies 
have suggested that narrowband TL-O 1 is 
more effective than broadband UV-B in the 
treatment of psoriasis.5•s there is only I re-
port of its use in MF.9 
, RESULTS 
Eight patients received a total of II TL-O I 
courses (Table 2). TL-OI was well toler-
ated. but toward the end of most courses 
dose increments were reduced to 10% 
when higher TL-O I doses were being used. 
All patients achieved a rapid and clini-
cally Significant improvement in their con-
dition with abolition or reduction of pru-
ritus. Six patients achieved complete 
clearance of the eruption (Figure 1), and 
the other 2 responded satisfactorily with 
partial clearance. For those patients who 
achieved complete clinical clearance (pa-
tients 1,2,3,6,7, and 8), a mean of 26 
treatments (9 weeks) was required. While 
some of the residual areas were in sanc-, 
tuary sites such as the gluteal cleft, oth-
ers were not. One 'patient has had re-
peated prolonged clinical remissions 
without maintenance therapy (patient 1). 
Patient 2 relapsed soon after initial TL-O I 
clearance but has achieved prolonged re-
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PATIENTS AND METHODS 
Eight whitc pa ti ents (age range, 66-82 years) with histologi-
cally provcn patch-stage MF recciq:ci n~lrrowba t1d TL-O l pho-
to th erapy. All histologic analyses were done in depende ntly 
by 2 o f us (J. G. L. and A.T.E.), and pat ients with preMF or 
doubtful histologic findings were excl uded. 1o Pretreatment 
and posttrea tment skin b iopsy specimens were taken from 
patches, residual areas, or trea tment-clearcd sites. All had nor-
mal fu ll hematologic and biochemical profil es ( full blood 
coun t, urea and elect rolyte, and Ii \·er fu nction tests) and uri-
nalys is and ches t radiogra ph fi ndings. None had palpable 
lymphadeno pathy or organomegaly, but 1 pa tien t (case 3) 
with an atypical acute prese ntation underwe nt bone mar-
row examination and an abdominal computed tomographic 
scan, both of w·hich produced normal results. Cutaneous in-
volvement was classified by recognized TNMB and clinical 
staging protocols I I (Table 1 and Table 2) . All of the pa-
tients had clinical stage 1 disease (n or T2 , NO, MO), with 
cutaneous in vo lve ment consisting of p~\lch-sLage disease o f 
limited extent in 4 cases (s tage l a) and more widespread in 
the others (s tage Ib) (Table 3 ) . Allhough a Sezary prepa-
ration was not ava ilable for all pat ients, the b classification 
does not affec t the cl inical staging. Patients were offered TL-Ol 
treatment when prior therapy (topical steroids, PUVA) had 
either failed or produced adverse effects or if they were re-
luctant to have sys temic medication. There was a minimum 
of 3 months between TL-O 1 treatment and previous photo-
therapy. Patien ts used emollients during treatment , and·topi-
cal steroids were limited to use at sanc tuary sites. 
Table 1. TNMB Classification for Mycosis Fungoides* 
Classification 
T (Skin) 
T1 
T2 
T3 
T4 
N (Nodes) 
NO 
N1 
N2 
N3 
M (Viscera) 
MO 
M1 
B (Blood) 
BO 
B1 
Description 
Limited patch/plaque « 10% of total skin surface) 
Generalized patch/plaque (~ 10% of total skin surface) 
Tumors 
Generalized erythroderma 
Lymph nodes clinica lly uninvolved 
Lymph nodes enlarged, histologically uninvolved 
(includes "reactive" and "dermatopathic" nodes) 
Lymph nodes clinica lly uninvolved, histologically 
involved 
Lymph nodes enlarged and histolog ically invo lved 
No visceral involvement 
Vi sceral involvement 
No circulating atypical (Sezary) cells « 5% of total 
lymphocytes) 
Circulating atypical (Sezary) cells ( ~5% of total 
lymphocytes) 
• Reprinted substantially from Kim et al. '2 
miss ion following a second course. I hree of our 8 pa-
tients remain in clinical remiss ion withou t maintenance 
therapy at this time. 
Pretherapy and posttherapy biopsy resul ts were avail-
able for s tudy except for patient 5, who relapsed rapidly 
All trea tm ents \\"C re carried out in a purpose-built CLl -
bicle constructed by the medical physics department of Nine-
wells Hospital, Du ndee , Sco tland, containing 50 lOO-\\' 
TL-O l flu orescent lam ps (Philips Elec tro nics , Ne\\· York, 
NY). The irrad iance withi n the cubicle changed from 3.53 
mW/cml to 2.22 mW/cml during the stud)' period . and ex-
posure times were adjusted accord ingly. lrrad iance was mea-
sured monthly, by a s tandard protocol, w ith an interna-
tional light meter (l L-4000; Able Ins tru me nts , Reading, 
England) calibrated using a spectroradiometer. 
Patients rece i\·ed TL-Ol pho totherapy by our stan-
dard protocol. D The minimum erythemal dose fo r each pa-
tient was determi ned prio r to start ing trea tm ent by irra-
d ia tion of a template of eigh t 1 X l -cm2 apertu res on the 
upper back with a TL-Ol source 20 cm from the patien t. 
Two standard ranges of doses were administered : 25 to 390 
mJlcm1 for phototypes 1 and 2 or 70 to 770 mJlcm1 for pho-
to types 3 and 4. 1-1 Therapy commenced with 70% of the 
minimum erythemal dose. Treatment was ad ministered 3 
times weekly with 20% increment at each exposure unless 
modified by the erythemal respo nse assessed at 48 hours 
after trea tmen t. Photo th erapy was con ti nued un til com-
plete clinical clearance o r minimal residual ac tivity was 
achieved. Minimal residual ac tivity and partial response were 
defined as a grea ter than 90% and 50% im provement, re-
spectively, with persistent sk in disease despite continuing 
trea tment (ie, sanclUary sites). Relapse was defined as clini-
cally significant disease requiring furth er therapy. A face 
shield and gloves were used to minimi ze UV-B exposure 
to a reas habitually exposed to sunlight but unaffec ted by 
MF (cases 2, 3, 5, and 7) . 
Table 2. Clinical Staging System for MycosiS Fungoides* 
Clinical 
Stages T 
TNMB Clas~ificationt 
N 
I 
M 
IA 
IB 
IIA 
liB 
IliA 
IIIB 
IVA 
IVB 
T1 
T2 
T1-2 
T3 
T4 
T4 
T1-4 
T1-4 
NO 
NO 
N1 
NO-1 
NO 
N1 
N2-3 
NO-3 
MO 
MO 
MO 
MO 
MO 
MO 
MO 
M1 
* Reprinted substantially from Kim et al. '2 
t B classification does not alter the clinical stage. 
and ex tenSively and on whom a pos ttherapy biopsy was 
\ not done. Diagnosis relied on the presence of typical his-
tologic features on hematoxylin-eosin-s tained sec tions. 
All pre therapy specimens demonstrated a superficial der-
mal mononuclea r cell inOammatory infiltrate contain-
ing phenotypically abnormal lymphocytes (Figure 2 ). 
All showed epidermotropism, Pautrier microabcesses, and 
variable acanthosis . I -cell marker studies were avail-
able in 4 cases , showing predominant I helper (CD4+) 
cell infiltrates (cases 2, 3, 4, and 6). I-cell receptor gene 
rearrangement studies were not routinely performed. 
Although no posttreatment biopsy findings showed 
entirely normal histologic charac teristics, most showed a 
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Table 3. Clinical Characteristics of Study Patients With Patch-Stage Mycosis Fungoides (MF)" 
Case No.1 Duration of Pre· 1I; F Duration 
Age ,y/Sex Phototype Skin Eruption. V of MF, y Stage , TNM Previous Treatment Complications 
1/67/M II 29 3 l a PUVA, topical steroid PUVA pain 
2177/M I 1'1 4 lb PUVA, topical steroid PUVA pain, basal cell carcinoma x 2 
3/82/M III ~ 3 lb PUVA. topical steroid 
4/7 1/F I 5 1 lb PUVA, topical steriod Basal cell carcinoma 
SI78/M II 1.S 1 la Topical/systemic steroid 
6/72/F II 70 1 l a PUVA, topical stero id Solar keratoses. lentigenes, basal cell carcinoma 
7/71/F I 10 2 lb Topical steroid 
8/66/M III 19 1 l a PUVA, topical steroid Psoralen-associated nausea 
" PUVA indicates psoralen-UV-A. The psoralen used in all previous treatments was oraIB-methoxsalen. 
Figure 1. Left, Patch-stage mycosis fungoides (case 2) with pruritic, superficial, scaly. erythema tOllS patches on the lower trunk. Right. Complete clinical 
remission in the same patient following narrowband TL -0 1 phototherapy. 
reduction of the inflammatory infiltrate (cases 1, 2, 3, 6 , 7, 
anel 8) . Marked reduction of the inllammatory infiltrate wi th 
loss of epidermotropism and Pautrier microabcesses was 
found in those who achieved a prolonged remission (pa-
tients 1 and2), but acanthosis and a mild chronic atypical 
dermal inllammatOlY infiltrate remained (Figure 2). 1n case 
3, despite appare nt clinical clearance, the atypicallympho-
cyti c infiltrate was only moderately reduced after trea t-
ment, and the subsequent remission was shon lived. Par-
tial response (case 4) was assoc ia ted with a pers istent, 
atypical lymphoid cell infiltrate, epidermotropism, Pau-
trier microabcesses, ancl acanthosis. 
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The mos t important prognosti c indica tors for MF are the. 
extent and type of sk in involvement and whether extra-
cutaneous spread has occurred . I ) Failure to achieve com-
plete remission following initial therapy is also a risk fac-
tor for progression .Il ·16 The outlook for mos t patients 
receivi ng treatment for limited patch MF (stage l a) is good, 
with a life expectancy similar to the normal population 
(cases 1,5 ,6, and 8).'1 More extensive patch/plaque dis-
ease (stage Ib) is associated with disease progression and 
mortality. One study reports disease progression in 24% 
W\\'\\'. A RCHDERMA TOL.COM 
Figure 2. Left, Patch-stage mycosis fungoides pretreatment histologic photomicrograph (case 2) showing acanthosis, a superficial dermal mononuclear cell 
inflammatory infiltrate containing phenotypically abnormal lymphocytes that demonstrate epidermotropism. Right, Marked reduction of the atypical lymphocytic 
infiltrate in the same patient following narrowband TL -O I phototherapy. (Hematoxylin-eosin; original magnification x 166 for both photographs.) 
Table 4. Resp onse to TI-01 Phototherapy in Patch-Stage Mycosis Fungoides* 
No.ol MED, PEAK TL-01 Histologic Time to 
Case TL -01 Courses Trea lments mJ/cm2 Dose , mJ/cm2 Clinical Response Improvemenlt Relapse , mOl 
May 1992 20 140 673 Clear 40 
May 1996 20 140 814 Clear 11 
November 1997 20 200 1192 Clear Marked 24 
2 August 1996 34 280 21 11 MRA < 3 
February 1997 37 200 1919 Clear Marked 18 
3 January 1996 33 280 1442 Clear Moderate 1 
4 May 1997 42 70 1083 Partial response Minimal 
5 June 1997 30 70 1919 Partial response 
6 June 1998 20 200 895 Clear Marked Remission 
7 July 1998 19 100 285 Clear Marked Remission 
8 August 1998 33 280 1442 Clear Moderate Remiss ion 
*MED indicates minimum erythem,?1 dose; ellipses, not available; MRA, minimal residual activity; and NA. not applicable. 
t Moderate improvement indicates residual mycosis fungoides; marked improvement is not diagnostic for mycocis fungoides. 
:j:Relapse is defined as return 01 clinically significant disease. 
of those with generalized patch/plaque IF, and 20% o f 
patients ultimatel y di ed of their disease. II> However, clini -
cal staging fails to differentiate between patch-stage MF 
and the more adva nccd plaque-stage disease. As a result, 
it is diffi cult to directl y compare outcome and treatment 
efficacy betwee n s tudies of s tage 1 MF and those w here 
only pa tch-stage disease has been included . Despite this, 
when controlled for the disease s tage, the efficacy of cur-
rently available topical therapies is similar in respect to com-
plete response and long- term survival rates, although the 
reported duration of d isease- free remission is variable. 
Although the ability of UV-B to clea r patch-s tage MF 
has been known since the 1950s, it seems to have been 
rarely sLUdied .17 Two reports of broadband UV-B pho-
totherap)' for "earl y" MF have shown similar effective-
ness. Most of these patients had limited patch-stage dis-
ease , and co mplete remission was ac hieved in more than 
80% in a median of 5 m onths to cl ea rance, results com -
parable with other top ical therapies:1.I8.19 Both studies used 
maintenance regimens foll OWing complete remission and 
noted high relapse rates when this treatment was s topped . 
Neve rtheless , 23% of patients in 1 study had a long-
term susta ined remission (>58 months).; Ultraviolet-13 
phototherapy was most effective with patch-stage or thin-
plaque disease, and the authors concl uded that this might 
be due to the limited ab ility ofUV-B to penetrate thicker 
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les ions. This may also be reOec ted in an Itali an retro-
spec tive s tudy where PUVA was repon ed to be more ef-
fec tive than broadband UV-B for s tage 1 MF. 2l1 
arrowba nd phototherapy uses the Philips TL-Ol 
lamp , which has an emiss ion spec trum (311-3l3 nm) 
w ithin the therape utiC ac tion spectrum for pso riasis. In 
many centers it has replaced tradi ti onal broadband UV-B 
phototherapy as the trea tment of choice for psoriasis and 
o ther dermatoses. 
In thi s s tudy, the response to TL-Ol was best when 
there was a long his tory of premyco tic eruption sugges-
tive of an indolent and less aggressive di sease more sus-
cep tible to this therapy. No correla ti on between skin pho-
to type and therapeutic response was found (Table 3 and 
Table 4 ). Although pers istent his tologic abnormaliti es 
were demonstrated in all cases, similar findings have been 
reported with PUVA .21 Without ma intenance therapy, 3 
patients relapsed rapidly and reqUired alternative therapy. 
One pati ent had ex tensive, indurated MF patches and her 
partial response to TL-Ol and subsequent relapse was, 
perhaps, predi ctable (case 4) . ' 
Although current topical therapies are effective, they 
can have clinically Signifi can t adverse effects . High cu-
mulative numbers of PUVA trea tments in patients wi th 
pso riasis have been assoc iated no t o nl y with an in-
creased incidence of nonmelanoma cutaneous carcino-
WWW.ARCHDERMATOl.COM 
mas,!! but also a small but important increase in malig-
nant melanomas.23 Topical nitrogen mustard causes a high 
incidence of allergic contact dermatitis, an increased in-
cidence of cutaneous and internal malignancies, and en-
vironmental contamination. 24 Carmustine is associated 
with marrow suppression, intertrigo, and telangecta-
sia.25 Total-skin electron-beam radiation therapy can pro-
duce serious adverse effects including erythema, edema, 
desquamation, total alopecia and nail loss, blistering, pig-
mentation, telangectasias, and chronic xerosis. 26 
When compared with PUV A, Tl-Ol phototherapy has 
several advantages. As systemic psoralen is not required, 
related acute adverse effects (nausea, headaches, and light-
headedness) and the need for protective glasses after treat-
ment are avoided. Tl-Ol phototherapy usually has shorter 
irradiation times, which aids compliance since patients with 
MF are often elderly and infirm. It can also be used in the 
rare instance where therapy is required during preg-
nancy. 
Although we have achieved sustained remissions in 
50% of our patients (mean, 20 months), others have re-
ported more transient remissions.9 Unlike PUVA, with 
which maintainance is effective, once-weekly treatment 
with Tl-Ol, attempted for 1 patient (case 3), proved dif-
ficult because painful posttreatment erythema devel-
oped despite UV-B dose reduction. 
Acute adverse effects from Tl-O 1 phototherapy can 
include erythema and pruritus. The major chronic ad-
verse effects are photoaging and photocarcinogenisis. De-
spite the absence of long-term prospective studies, the 
photocarcinogenic risk of Tl-Ol seems to be less than 
that associated with PUV A. 27.28 Of concern is the recent 
discovery of p53 tumor suppressor gene mutations in 
some MF tumors (40%).29 These mutations were pre-
dominantly in C:T and CC:TT transitions, which are char-
acteristic of UV-B-induced DNA damage and were not 
found in plaque-stage disease. This might suggest a role 
for UV radiation therapy in the progression of the later 
stages of MF. However, in the absence of epidemiologi-
cal evidence for the association of UV radiation and MF 
progression, further work is necessary to determine the 
Significance of these findings. 3o•31 
Narrowband phototherapy offers the potential for 
prolonged remission for some patients with patch-stage 
MF. Although our study cohort was small (8 patients), 
we believe Tl-Ol treatment should be included among 
the initial therapeutic options in view of its efficacy, con-
venience, and likelihood of fewer long-term adverse ef-
fects. Clearly, larger prospective, long-term follow-up 
studies are necessary to define the role of Tl-O 1 in patch-
stage MF. However, our experience has shown Tl-Ol to 
be effective when PUVA therapy has been unsatisfac-
tory or curtailed because of adverse effects. The opti-' 
mum therapeutic regimen for Tl-Ol therapy in MF is still 
to be determined, but a more prolonged induction'phase 
or the use of maintenance therapy may improve its effi-
cacy while retaining a favorable adverse-effect profile. 
Accepted for publication February 1, 2000. 
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